<SEC-DOCUMENT>0001104659-23-041529.txt : 20230404
<SEC-HEADER>0001104659-23-041529.hdr.sgml : 20230404
<ACCEPTANCE-DATETIME>20230404162526
ACCESSION NUMBER:		0001104659-23-041529
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20230404
DATE AS OF CHANGE:		20230404

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protagonist Therapeutics, Inc
		CENTRAL INDEX KEY:			0001377121
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				980505495
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-266595
		FILM NUMBER:		23798076

	BUSINESS ADDRESS:	
		STREET 1:		7707 GATEWAY BLVD., SUITE 140
		CITY:			NEWARK
		STATE:			CA
		ZIP:			94560-1160
		BUSINESS PHONE:		(510) 474-0170

	MAIL ADDRESS:	
		STREET 1:		7707 GATEWAY BLVD., SUITE 140
		CITY:			NEWARK
		STATE:			CA
		ZIP:			94560-1160

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Protagonist Therapeutics Inc
		DATE OF NAME CHANGE:	20130605

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Protagonist Inc
		DATE OF NAME CHANGE:	20061002
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>tm2311339-2_424b5.htm
<DESCRIPTION>424B5
<TEXT>
<html>
  <head>
    <title>tm2311339-2_424b5 - none - 5.92191s</title>
  </head>
  <body style="margin-left:auto;margin-right:auto;width:595.31pt;">
    <div style="position:relative;overflow-x:hidden;min-height:775.71pt;page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="position:absolute;top:738.83pt;left:48.66pt;height:30.02pt;width:706pt;transform-origin:0pt -0pt;transform:rotate(-90deg) translate(0%, 0%);">
        <div style="text-align:justify; width:706pt; line-height:9.5pt;font-weight:bold;color:#FC0014;font-family:Helvetica, Arial, sans-serif;font-size:8pt;">
          <font style="letter-spacing:-0.08pt;">This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, as amended, but is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus do not constitute an offer to sell these securities, and we are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted.</font><font style="color:#000000;letter-spacing:-0.08pt;"> </font>
          <br >
        </div>
      </div>
      <div style="margin-top:27.85pt;min-height:706pt;margin-left:87.66pt;width:456pt;">
        <div style="text-align:right; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#8202;Filed Pursuant to Rule&#160;424(b)(5)</font>&#8203;</div>
        <div style="margin-top:2pt; text-align:right; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#8202;Registration Statement No. 333-266595</font>&#8203;</div>
        <div style="margin-top:-1pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;color:#FC0014;">
          <font style="letter-spacing:-0.2pt;">Subject to Completion </font>
          <br >
          <font style="letter-spacing:-0.2pt;">Preliminary Prospectus Supplement dated April 4, 2023</font><font style="font-weight:normal;color:#000000;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">PROSPECTUS SUPPLEMENT</font><font style="letter-spacing:-0.2pt;"> </font> <br ><font style="letter-spacing:-0.2pt;">(To prospectus dated August&#160;16, 2022)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font></div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">$100,000,000</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="lg_protagonist-pn.jpg" alt="[MISSING IMAGE: lg_protagonist-pn.jpg]" height="69" width="277" >
        </div>
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Common stock</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are offering $100,000,000 of shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is listed on the Nasdaq Global Market, or Nasdaq, under the symbol &#8220;PTGX.&#8221; On April&#160;3, 2023, the last reported sale price of our common stock was $22.82 per share. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; on page <a href="#tsRIFA">S-10</a> of this prospectus supplement and in the accompanying prospectus, as well as those contained in the other documents that are incorporated by reference herein and therein and any related free writing prospectus. You should carefully read this entire prospectus supplement and the accompanying prospectus, including any information incorporated by reference, before deciding whether to purchase shares of our common stock.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:53.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:375.93pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Per share </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:375.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Public offering price </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.035pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:3.035pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:375.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Underwriting discounts and commissions</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.035pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:3.035pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:375.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Proceeds, before expenses, to Protagonist Therapeutics, Inc. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.035pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:3.035pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">See &#8220;Underwriting&#8221; for additional disclosure regarding underwriting compensation. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The underwriters may also purchase up to an additional $15,000,000 of shares of our common stock from us at the public offering price, less the underwriting discount, within 30&#160;days from the date of this prospectus supplement. See &#8220;Underwriting&#8221; for more information. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The underwriters expect to deliver the shares of common stock to purchasers against payment on or about &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2023 through the book-entry facilities of The Depository Trust Company. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Joint Book-Running Managers</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:14pt;">
          <tr style="line-height:13.97pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:14pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:144pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.28pt;">J.P. Morgan</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:144pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.28pt;">Jefferies</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:144pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.28pt;">Piper Sandler</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Lead Managers</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:11.99pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:12pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:222pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.24pt;">BTIG</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:222pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.24pt;">H.C. Wainwright &amp; Co.</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:8.01pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Prospectus Supplement dated &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2023</font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC">&#8203;</a><a name="TOC2">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:135pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TABLE OF CONTENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROSPECTUS SUPPLEMENT</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:175pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tsATPS"><font style="letter-spacing:0.2pt;">ABOUT THIS PROSPECTUS SUPPLEMENT </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tsATPS">S-1</a></font> <a href="#tsATPS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tsCSCF"><font style="letter-spacing:0.2pt;">CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tsCSCF">S-3</a></font> <a href="#tsCSCF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tsPSS"><font style="letter-spacing:0.2pt;">PROSPECTUS SUPPLEMENT SUMMARY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tsPSS">S-4</a></font> <a href="#tsPSS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tsTHOF"><font style="letter-spacing:0.2pt;">THE OFFERING </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tsTHOF">S-8</a></font> <a href="#tsTHOF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tsRIFA"><font style="letter-spacing:0.2pt;">RISK FACTORS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tsRIFA">S-10</a></font> <a href="#tsRIFA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tsUOP"><font style="letter-spacing:0.2pt;">USE OF PROCEEDS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tsUOP">S-12</a></font> <a href="#tsUOP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tsDIL"><font style="letter-spacing:0.2pt;">DILUTION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tsDIL">S-13</a></font> <a href="#tsDIL"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tsUND"><font style="letter-spacing:0.2pt;">UNDERWRITING </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tsUND">S-15</a></font> <a href="#tsUND"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tsLEMA"><font style="letter-spacing:0.2pt;">LEGAL MATTERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tsLEMA">S-23</a></font> <a href="#tsLEMA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tsEXP"><font style="letter-spacing:0.2pt;">EXPERTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tsEXP">S-23</a></font> <a href="#tsEXP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tsWYCF"><font style="letter-spacing:0.2pt;">WHERE YOU CAN FIND MORE INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tsWYCF">S-23</a></font> <a href="#tsWYCF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tsIOCI"><font style="letter-spacing:0.2pt;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tsIOCI">S-24</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:220pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tATP"><font style="letter-spacing:0.2pt;">ABOUT THIS PROSPECTUS</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tATP">1</a></font> <a href="#tATP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCSCFL"><font style="letter-spacing:0.2pt;">CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCSCFL">2</a></font> <a href="#tCSCFL"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tTHCO"><font style="letter-spacing:0.2pt;">THE COMPANY</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tTHCO">3</a></font> <a href="#tTHCO"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tRIFA"><font style="letter-spacing:0.2pt;">RISK FACTORS</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tRIFA">4</a></font> <a href="#tRIFA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUOP"><font style="letter-spacing:0.2pt;">USE OF PROCEEDS</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUOP">5</a></font> <a href="#tUOP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSWO"><font style="letter-spacing:0.2pt;">SECURITIES WE MAY OFFER </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSWO">6</a></font> <a href="#tSWO"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOCS"><font style="letter-spacing:0.2pt;">DESCRIPTION OF CAPITAL STOCK</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOCS">7</a></font> <a href="#tDOCS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDODS"><font style="letter-spacing:0.2pt;">DESCRIPTION OF DEBT SECURITIES </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDODS">11</a></font> <a href="#tDODS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOW"><font style="letter-spacing:0.2pt;">DESCRIPTION OF WARRANTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOW">22</a></font> <a href="#tDOW"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOU"><font style="letter-spacing:0.2pt;">DESCRIPTION OF UNITS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOU">23</a></font> <a href="#tDOU"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPOD"><font style="letter-spacing:0.2pt;">PLAN OF DISTRIBUTION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPOD">26</a></font> <a href="#tPOD"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLEMA"><font style="letter-spacing:0.2pt;">LEGAL MATTERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLEMA">28</a></font> <a href="#tLEMA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXP"><font style="letter-spacing:0.2pt;">EXPERTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEXP">28</a></font> <a href="#tEXP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tWCFM"><font style="letter-spacing:0.2pt;">WHERE YOU CAN FIND MORE INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tWCFM">29</a></font> <a href="#tWCFM"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tIOCIBR"><font style="letter-spacing:0.2pt;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tIOCIBR">30</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:10pt; text-align:center; width:446pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tsATPS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ABOUT THIS PROSPECTUS SUPPLEMENT</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus supplement and the accompanying prospectus form part of a registration statement on Form S-3 (File No. 333-266595) that we filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on August&#160;5, 2022, using a &#8220;shelf&#8221; registration process. Under this shelf registration, we may, from time to time, sell common stock and other securities, including in this offering. This document contains two parts. The first part consists of this prospectus supplement, which describes the specific terms of this offering of our common stock and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference herein. The second part, the accompanying prospectus, including the documents incorporated by reference therein, provides more general information. Generally, when we refer to this prospectus, we are referring to both parts of this document combined. This prospectus supplement may add, update or change information contained in the accompanying prospectus. To the extent there is a conflict between the information contained in this prospectus supplement and the information contained in the accompanying prospectus or any document incorporated by reference therein filed prior to the date of this prospectus supplement, you should rely on the information in this prospectus supplement; provided, that if any statement in one of these documents is inconsistent with a statement in another document having a later date&#8201;&#8212;&#8201;for example, a document incorporated by reference in the accompanying prospectus&#8201;&#8212;&#8201;the statement in the document having the later date modifies or supersedes the earlier statement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have not, and the underwriters have not, authorized anyone to provide any information other than that contained or incorporated by reference in this prospectus supplement, the accompanying prospectus or in any free writing prospectus that we have authorized for use in connection with this offering. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus supplement and the accompanying prospectus do not constitute an offer to sell, or a solicitation of an offer to purchase, the shares of our common stock offered by this prospectus supplement and the accompanying prospectus in any jurisdiction to or from any person to whom or from whom it is unlawful to make such offer or solicitation of an offer in such jurisdiction. The information contained in this prospectus supplement, the accompanying prospectus, any free writing prospectus that we have authorized for use in connection with this offering, including the documents incorporated by reference herein or therein is accurate only as of the respective dates thereof, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or of any sale of our common stock. It is important for you to read and consider all information contained in this prospectus supplement, the accompanying prospectus and any free writing prospectus that we have authorized for use in connection with this offering, including the documents incorporated by reference herein and therein, in making your investment decision. You should also read and consider the information in the documents to which we have referred you in the sections entitled &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Information by Reference&#8221; in this prospectus supplement and in the accompanying prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We and the underwriters are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement and the accompanying prospectus and the offering of our common stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement and the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering of our common stock and the distribution of this prospectus supplement and the accompanying prospectus outside the United States. This prospectus supplement and the accompanying prospectus do not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any shares of our common stock offered by this prospectus supplement and the accompanying prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:580pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">Except as otherwise indicated herein or as the context otherwise requires, references in this prospectus supplement, the accompanying prospectus and the information incorporated by referenced herein or therein to &#8220;Protagonist,&#8221; &#8220;the company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar references refer to Protagonist Therapeutics, Inc., a corporation under the laws of the State of Delaware. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">S-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tsCSCF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:112pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus supplement, the accompanying prospectus, the documents incorporated by reference and any free writing prospectus that we have authorized for use in connection with this offering contain forward-looking statements, including statements regarding our future financial condition, business strategy and plans and objectives of management for future operations. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify forward-looking statements by terminology such as &#8220;believe,&#8221; &#8220;will,&#8221; &#8220;may,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;might,&#8221; &#8220;approximately,&#8221; &#8220;expect,&#8221; &#8220;predict,&#8221; &#8220;could,&#8221; &#8220;potentially&#8221; or the negative of these terms or other similar expressions. Forward-looking statements appear in a number of places throughout this prospectus supplement, the accompanying prospectus, the documents incorporated by reference and any free writing prospectus that we have authorized for use in connection with this offering and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the potential for our programs, the timing of our clinical trials, the potential for eventual regulatory approval and commercialization of our product candidates and our potential receipt of milestone payments and royalties under our collaboration agreements; future operating results or the ability to generate sales, income or cash flow, and the impact of the ongoing COVID-19 pandemic, are forward-looking statements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Discussions containing these forward-looking statements may be found, among other places, in the section of this prospectus supplement under the heading &#8220;Risk Factors&#8221; and in the sections entitled &#8220;Business&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; incorporated by reference from our <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1377121/000155837023003906/ptgx-20221231x10k.htm">Annual Report on Form 10-K for the year ended December&#160;31, 2022</a>, as well as any amendments thereto, filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. We discuss in greater detail many of these risks under the heading &#8220;Risk Factors&#8221; in this prospectus supplement and in our <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1377121/000155837023003906/ptgx-20221231x10k.htm">Annual Report on Form 10-K for the year ended December&#160;31, 2022</a>, as well as any amendments thereto reflected in subsequent filings with the SEC and in the other documents incorporated by reference herein, and elsewhere in this prospectus supplement. Also, these forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable statement and, except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, statements such as &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus supplement, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tsPSS">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">PROSPECTUS SUPPLEMENT SUMMARY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">This summary highlights selected information contained elsewhere in this prospectus supplement or incorporated by reference herein and does not contain all of the information that you need to consider in making your investment decision. You should carefully read the entire prospectus supplement, the accompanying prospectus or any free writing prospectus that we have authorized for use in connection with this offering, including the risks of investing in our common stock discussed under the heading &#8220;Risk Factors&#8221; contained in this prospectus supplement, the accompanying prospectus or any free writing prospectus that we have authorized for use in connection with this offering, and under similar headings in the other documents that are incorporated by reference into this prospectus supplement. You should also carefully read the information incorporated by reference into this prospectus supplement, including our financial statements and related notes incorporated by reference into this prospectus supplement and the accompanying prospectus, before making your investment decision.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Protagonist Therapeutics, Inc.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Overview</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We are a biopharmaceutical company with peptide-based new chemical entities rusfertide and PN-235 in different stages of development, all derived from our proprietary discovery technology platform. Our clinical programs fall into two broad categories of diseases: (i)&#160;hematology and blood disorders; and (ii)&#160;inflammatory and immunomodulatory diseases. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">Our Product Pipeline</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="position:relative;margin-top:9.8pt; text-align:center; width:456pt;">
            <img src="tb_ourproductpipeline-4clr.jpg" alt="[MISSING IMAGE: tb_ourproductpipeline-4clr.jpg]" height="301" width="608" >
          </div>
          <div style="margin-top:16.6pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Recent Developments</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">Rusfertide</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our most advanced clinical asset, rusfertide (generic name for PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of erythrocytosis, iron overload and other blood disorders and is wholly owned. Hepcidin is a key hormone in regulating iron equilibrium and is critical to the proper development of red blood cells. Rusfertide mimics the effect of the natural hormone hepcidin, but with greater potency, solubility and stability. Data from our rusfertide Phase&#160;2 clinical trials presented at medical conferences in 2021 and 2022 provided evidence regarding the potential of rusfertide for managing hematocrit, reducing thrombotic risk and improving iron deficiency symptoms. Rusfertide has a unique mechanism of action in the potential treatment of the blood disorder polycythemia vera (&#8220;PV&#8221;), which </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">may enable it to specifically decrease and maintain hematocrit levels within the range of recommended clinical guidelines without causing the iron deficiency that can occur with frequent phlebotomy. Our rusfertide Phase&#160;2 clinical trials include the following: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">REVIVE, a Phase&#160;2 proof of concept (&#8220;POC&#8221;) trial, was initiated in the fourth quarter of 2019. We completed enrollment of patients in the first quarter of 2022 with a target of approximately 50 patients to be enrolled through the end of the randomization portion of the trial, which was completed during the first quarter of 2023, and will continue in open label extension. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">PACIFIC, another Phase&#160;2 trial for rusfertide patients diagnosed with PV and with routinely elevated hematocrit levels (&gt;48%), was initiated during the first quarter of 2021 and completion of the 52-week trial is expected during the second quarter of 2023. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">At the June&#160;2022 American Society of Clinical Oncology (&#8220;ASCO&#8221;) Annual Meeting, we presented updated interim results for REVIVE and PACIFIC demonstrating the effects of dosing interruption and resumption. Rusfertide dosing interruption led to loss of effect, including increased phlebotomy rate and increases in hematocrit and red blood cells. Rusfertide restart restored therapeutic benefits. Following the brief clinical hold described below, over 90% of patients in the REVIVE trial provided reconsent and returned to rusfertide treatment after dosing interruption and reinitiation. At the June&#160;2022 European Hematology Association Congress, we presented interim data as of May&#160;2022 showing that rusfertide treatment interruption reverses hematologic gains and re-initiation of treatment restores therapeutic benefits in patients with PV. At the December&#160;2022 American Society of Hematology (&#8220;ASH&#8221;) meeting, we presented data as of October&#160;2022 related to rusfertide, including a subgroup of analyses of the adverse event profile from the REVIVE trial. These preliminary results indicated that 84% of treatment-emergent adverse events (&#8220;TEAEs&#8221;) were Grade 2 or below. 16% of patients experienced Grade 3 TEAEs and there were no Grade 4 TEAEs. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">On March&#160;15, 2023, we announced positive topline results from the blinded, placebo-controlled, randomized withdrawal portion of the REVIVE trial. Subjects receiving rusfertide achieved statistically significant improvements versus placebo in the trial&#8217;s primary endpoint. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The double-blind, placebo-controlled, 12-week randomized withdrawal portion was included as Part&#160;2 of the REVIVE trial study to evaluate rusfertide in PV patients with frequent phlebotomy requirements. In the REVIVE trial, subjects were initially enrolled in the 28-week open label dose-titration and efficacy evaluation Part&#160;1 of the study, followed by 1:1 randomization of 53 subjects to placebo versus rusfertide therapy for a subsequent duration of 12 weeks. More subjects receiving rusfertide during the blinded randomized withdrawal portion of the REVIVE trial were responders compared with placebo (69.2% versus 18.5%, p=0.0003). A study subject was defined as a responder if the subject completed 12 weeks of double-blind treatment while maintaining hematocrit control without phlebotomy eligibility and without phlebotomy. During the 12 weeks of the blinded randomized withdrawal, only 2 of 26 subjects on rusfertide were phlebotomized. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">VERIFY, a global Phase&#160;3 clinical trial of rusfertide in PV for approximately 250 patients, was initiated in the first quarter of 2022. Significant efforts have been taken toward the goal of full enrollment and a high degree of interest has been observed from physicians and patient communities. We expect enrollment completion in the fourth quarter of 2023. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">On September&#160;16, 2021, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) placed a clinical hold on our then ongoing rusfertide clinical trials following our submission to the FDA of findings in a 26-week rasH2 transgenic mouse carcinogenicity study. In October&#160;2021, we submitted a Complete Response to the FDA related to the clinical hold, and the FDA removed the clinical hold on October&#160;8, 2021. In our Complete Response, we provided the individual patient clinical safety reports the FDA requested for human cancers observed in rusfertide clinical trials, updated the investigator brochure and patient informed consent forms for ongoing rusfertide trials, proposed new safety and stopping rules in trial protocols for our ongoing rusfertide clinical trials, and performed a comprehensive review of our rusfertide safety database. Dosing of patients and enrollment in ongoing clinical trials with rusfertide resumed in the fourth quarter of 2021. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The FDA granted orphan drug designation for rusfertide for the treatment of PV in June&#160;2020, and Fast Track designation for rusfertide for the treatment of PV in December&#160;2020. The EMA granted orphan </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">drug designation for rusfertide for treatment of PV in October&#160;2020. The FDA granted Breakthrough Therapy Designation for rusfertide for the treatment of PV in June&#160;2021. In April&#160;2022, we received a letter from the FDA indicating the FDA&#8217;s intent to rescind Breakthrough Therapy Designation for rusfertide in PV. In June&#160;2022, we voluntarily withdrew our Breakthrough Therapy Designation following correspondence with FDA and based on our internal analysis of the relative utility of Breakthrough Therapy Designation for Phase&#160;3 trials and beyond. The FDA correspondence relating to the Breakthrough Therapy designation does not address the rusfertide Fast Track Designation, which remains active. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">In keeping with our organizational prioritization of rusfertide in PV, plans to initiate trials of rusfertide in additional disease indications have been paused. This decision was influenced in part by the enactment of the Inflation Reduction Act (&#8220;IRA&#8221;) in the United States and includes previously planned trials of rusfertide in the subset of hereditary hemochromatosis patients with chronic arthropathy. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">JNJ-2113 (formerly known as PN-235)</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our partnered Interleukin-23 receptor (&#8220;IL-23R&#8221;) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways currently targeted by marketed injectable antibody drugs. Our orally stable peptide approach may offer a targeted therapeutic approach for gastrointestinal (&#8220;GI&#8221;) and systemic compartments as needed. We believe that, compared to antibody drugs, JNJ-2113 has the potential to provide clinical improvement in an oral medication with increased convenience and compliance and the opportunity for the earlier introduction of targeted oral therapy. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">In May&#160;2017, we entered into a worldwide license and collaboration agreement with Janssen Biotech, Inc. (&#8220;Janssen&#8221;), a Johnson &amp; Johnson company, to co-develop and co-detail our IL-23R antagonist compounds, including PTG-200 (JNJ-67864238) and certain related compounds for all indications, including inflammatory bowel disease (&#8220;IBD&#8221;). PTG-200 was a first-generation investigational, orally delivered, IL-23R antagonist for the treatment of IBD. The agreement with Janssen was amended in May&#160;2019 to expand the collaboration by supporting efforts towards second-generation IL-23R antagonists; and in July&#160;2021 to, among other things, enable Janssen to independently research and develop collaboration compounds for multiple indications in the IL-23 pathway and further align our financial interests. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">During the fourth quarter of 2021, following a pre-specified interim analysis criteria, a portfolio decision was made by Janssen to advance second-generation product candidate JNJ-2113 (JNJ-77242113) based on its superior potency and overall pharmacokinetic and pharmacodynamic profile. A JNJ-2113 Phase&#160;1 trial was completed in the fourth quarter of 2021. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">In February&#160;2022, Janssen initiated FRONTIER1, a 255-patient Phase&#160;2b clinical trial of JNJ-2113 in moderate-to-severe plaque psoriasis, which was completed in December&#160;2022. FRONTIER1 was a randomized, multicenter, double-blind, placebo-controlled study that evaluated three once-daily dosages and two twice-daily dosages of JNJ-2113 taken orally. The primary endpoint of the study is the proportion of patients achieving PASI-75 (a 75% improvement in skin lesions as measured by the Psoriasis Area and Severity Index) at 16 weeks. In March&#160;2023, we announced positive topline results from the trial. JNJ-2113 achieved the study&#8217;s primary efficacy endpoint, with a statistically significant greater proportion of patients who received JNJ-2113 achieving PASI-75 responses compared to placebo at Week 16 in all five of the study&#8217;s treatment groups. A clear dose response was observed across an eight-fold dose range. Treatment was well tolerated, with no meaningful difference in frequency of adverse events across treatment groups versus placebo. It is our expectation that JNJ-2113 will progress into a Phase&#160;3 registrational study in plaque psoriasis on the strength of the FRONTIER1 data. Advancement of JNJ-2113 into a Phase&#160;3 study and meeting the primary endpoint in that study would qualify us for milestone payments of $50&#160;million and $115&#160;million, respectively. Data will be presented from various pre-clinical and clinical studies on JNJ-2113 at medical conferences beginning in the second quarter of 2023. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Other Phase&#160;2 studies of JNJ-2113 that Janssen has initiated include the SUMMIT study of JNJ-2113 for the treatment of moderate-to-severe plaque psoriasis expected to be completed in the second quarter of 2023 and FRONTIER2, a long-term extension study. A Phase&#160;1 trial of an immediate release formulation of JNJ-2113 in healthy Chinese adult participants is currently recruiting. Following the completion of Phase&#160;2 studies of JNJ-2113 in plaque psoriasis, we expect Janssen to initiate a separate Phase&#160;2 trial of JNJ-2113 in a second indication. Additional indications may include any or all of psoriatic arthritis, UC and&#160;CD. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="text-indent:20pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">During the fourth quarter of 2021, we received a $7.5&#160;million milestone payment from Janssen triggered by the completion of data collection for JNJ-2113 Phase&#160;1 activities. In the second quarter of 2022, we received a $25.0&#160;million milestone payment in connection with the dosing of a third patient in FRONTIER1 during the first quarter of 2022. We will be eligible to receive a $10.0&#160;million milestone payment in connection with the dosing of a third patient in the second Phase&#160;2 trial of a second-generation candidate, a $50&#160;million milestone payment upon dosing of a third patient in a Phase&#160;3 trial for a second-generation compound for any indication, and a $115.0&#160;million milestone payment upon a Phase&#160;3 clinical trial for a second-generation compound for any indication meeting its primary clinical endpoint. We remain eligible for up to approximately $855.0&#160;million in future development and sales milestone payments, in addition to the $112.5&#160;million in nonrefundable payments from Janssen received to date. We also remain eligible to receive tiered royalties on net product sales at&#160;percentages ranging from mid-single digits to ten&#160;percent. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">PN-943</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">PN-943 is a wholly owned, investigational, orally delivered, gut-restricted alpha 4 beta 7 (&#8220;&alpha;4&beta;7&#8221;) specific integrin antagonist for IBD. During the second quarter of 2020, we initiated IDEAL, a 159 patient Phase&#160;2 trial evaluating the safety, tolerability and efficacy of PN-943 in patients with moderate to severe UC. Enrollment in IDEAL was completed during the first quarter of 2022. The trial includes a 12-week induction period, which has been completed, and a 40-week extended treatment period. With the exception of completing the 40-week extended treatment period for eligible patients in the IDEAL trial, which is expected to be completed in the first quarter of 2023, we do not intend to dedicate further internal resources to clinical development or contract manufacturing activities for our PN-943 clinical program. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">Discovery Platform</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our clinical assets are all derived from our proprietary discovery platform. Our platform enables us to engineer novel, structurally constrained peptides that are designed to retain key advantages of both orally delivered small molecules and injectable antibody drugs in an effort to overcome many of their limitations as therapeutic agents. Importantly, constrained peptides can be designed to potentially alleviate the fundamental instability inherent in traditional peptides to allow different delivery forms, such as oral, subcutaneous, intravenous, and rectal. We continue to use our peptide technology platform to discover product candidates against targets in disease areas with significant unmet medical needs. For example, we have a pre-clinical stage program to identify an orally active hepcidin mimetic, which we believe will be complementary to the injectable rusfertide for offering the best treatment options for PV, hereditary hemochromatosis and other potential erythropoietic and iron imbalance disorders. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Company Information</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our principal executive offices are located at 7707 Gateway Boulevard, Suite 140, Newark, California 94560. Our telephone number is (510) 474-0170. Our website address is www.protagonist-inc.com. The information contained in, or accessible through, our website does not constitute part of this prospectus supplement, and should not be relied on in determining whether to make an investment decision, and the inclusion of our website address in this prospectus supplement is an inactive textual reference only. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The Protagonist logo and other trademarks or service marks of Protagonist Therapeutics, Inc. appearing in this prospectus supplement are the property of Protagonist Therapeutics, Inc. Other trademarks, service marks or trade names appearing in this prospectus are the property of their respective owners. We do not intend our use or display of other companies&#8217; trademarks, service marks or trade names to imply a relationship with, or endorsement or sponsorship of us by, these other companies. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tsTHOF">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-bottom:24.8099999999999pt; margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">THE OFFERING</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="width:180pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Common stock offered by us </font>
            </div>
          </div>
          <div style="margin-left:204pt; margin-top:-12pt; width:252pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">$100,000,000 of shares of our common stock. </font>
          </div>
          <div style="width:180pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Common stock to be outstanding after this offering </font>
            </div>
          </div>
          <div style="margin-left:204pt; margin-top:-12pt; width:252pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares, or&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares if the underwriters exercise their option to purchase additional shares in full. </font>
          </div>
          <div style="width:180pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Option to purchase additional shares </font>
            </div>
          </div>
          <div style="margin-left:204pt; margin-top:-12pt; width:252pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The underwriters have a 30-day option to purchase up to $15,000,000 of additional shares of our common stock. </font>
          </div>
          <div style="width:180pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Use of proceeds </font>
            </div>
          </div>
          <div style="margin-left:204pt; margin-top:-12pt; width:252pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We currently intend to use the net proceeds from this offering to fund continued clinical development and pre-commercialization activities associated with rusfertide and for working capital and general corporate purposes. Pending these uses, we intend to invest the net proceeds of this offering in interest-bearing, investment-grade securities. See &#8220;Use of Proceeds&#8221; for additional information. </font>
          </div>
          <div style="width:180pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Risk factors </font>
            </div>
          </div>
          <div style="margin-left:204pt; margin-top:-12pt; width:252pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">You should read and consider the information set forth under the heading &#8220;Risk Factors&#8221; in this prospectus supplement and in the accompanying prospectus, together with the risk factors and cautionary statements described in our <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1377121/000155837023003906/ptgx-20221231x10k.htm">Annual Report on Form 10-K for the year ended December&#160;31, 2022</a>, as incorporated by reference herein, before deciding to invest in shares of our common stock. </font>
          </div>
          <div style="width:180pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Nasdaq Global Market Symbol </font>
            </div>
          </div>
          <div style="margin-left:204pt; margin-top:-12pt; width:252pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#8220;PTGX.&#8221;</font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The number of shares of our common stock to be outstanding after this offering is based on 49,339,252 shares of our common stock outstanding as of December&#160;31, 2022 and excludes: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">5,123,464 shares of common stock issuable upon the exercise of stock options issued and outstanding under our 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;), as of December&#160;31, 2022, having a weighted average exercise price of $19.20 per share; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">591,186 shares of common stock issuable upon the vesting of outstanding restricted stock&#160;units, under the 2016 Plan, as of December&#160;31, 2022; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">199,500 shares of common stock issuable upon the vesting of outstanding performance stock&#160;units, under the 2016 Plan, as of December&#160;31, 2022; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">an aggregate of 1,350,793 shares of common stock, subject to increase on an annual basis, reserved for future issuance under the 2016 Plan, as of December&#160;31, 2022; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">949,217 shares of common stock issuable upon the exercise of stock options issued and outstanding under our Amended and Restated 2018 Inducement Plan, as amended (the &#8220;Inducement Plan&#8221;), as of December&#160;31, 2022, having a weighted average exercise price of $20.85 per share; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">46,250 shares of common stock issuable upon the vesting of outstanding restricted stock&#160;units, under the Inducement Plan, as of December&#160;31, 2022; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">an aggregate of 574,772 shares of common stock reserved for future issuance under the Inducement Plan, as of December&#160;31, 2022; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">167,828 shares of common stock issuable upon the exercise of stock options issued and outstanding under our 2007 Equity Incentive Plan, as of December&#160;31, 2022, having a weighted average exercise price of $3.78 per share; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">1,255,290 shares of our common stock reserved for future issuance under our 2016 Employee Stock Purchase Plan, as of December&#160;31, 2022; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">2,750,000 shares of common stock issuable upon the exercise of warrants outstanding as of December&#160;31, 2022, at a weighted average exercise price of $12.50 per share; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">1,749,199 shares of common stock sold in &#8220;at-the-market&#8221; offerings (the &#8220;ATM Offerings&#8221;) since December&#160;31, 2022. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Unless otherwise indicated, all information in this prospectus supplement assumes no exercise of outstanding stock options or warrants or vesting of restricted stock&#160;units or performance stock&#160;units after December&#160;31, 2022 and no exercise by the underwriters of their option to purchase additional shares of our common stock.</font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tsRIFA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RISK FACTORS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Investing in our securities involves a high degree of risk. Before deciding whether to invest in our common stock, you should consider carefully the risks and uncertainties described below and under the heading &#8220;Risk Factors&#8221; in the accompanying prospectus and under the heading &#8220;Risk Factors&#8221; contained in our <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1377121/000155837023003906/ptgx-20221231x10k.htm">Annual Report on Form 10-K for the year ended December&#160;31, 2022</a>, which is incorporated by reference into this prospectus supplement and the accompanying prospectus in their entirety, together with the other information in this prospectus supplement and the accompanying prospectus, the documents incorporated by reference herein and therein and any free writing prospectus that we may authorize for use in connection with this offering. The risks described in these documents are not the only ones we face, but those that we consider to be material. There may be other unknown or unpredictable economic, business, competitive, regulatory or other factors that could have a material adverse effect on our future results. Past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. If any of these risks actually occur, our business, financial condition, results of operations, cash flow or prospects could be seriously harmed. This could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment. Please also read carefully the section below titled &#8220;Forward-Looking Statements.&#8221;</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Relating to this Offering</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Management will have broad discretion as to the use of the net proceeds from this offering, and may not use the proceeds effectively.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Our management will have broad discretion as to the use of the net proceeds from this offering and could use them for purposes other than those contemplated at the time of the offering. Our management may use the net proceeds for corporate purposes that may not improve our financial condition or market value and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">You will experience immediate and substantial dilution.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The offering price per share in this offering will exceed the net tangible book value per share of our common stock outstanding prior to this offering. Assuming that shares of our common stock are sold at a price of $22.82 per share (the last reported sale price of our common stock on the Nasdaq Global Market on April&#160;3, 2023) for aggregate gross proceeds of $100.0&#160;million, and after deducting commissions and estimated offering expenses payable by us, you would experience immediate dilution of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, representing the difference between our as adjusted net tangible book value per share as of December&#160;31, 2022 after giving effect to this offering. The exercise of outstanding stock options and warrants and the vesting of additional restricted stock&#160;units and performance&#160;units may result in further dilution of your investment. See the section titled &#8220;Dilution&#8221; below for a more detailed illustration of the dilution you may incur if you participate in this offering. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Future sales of our common stock in the public market could cause our common stock price to fall.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our common stock price could decline as a result of sales of a large number of shares of common stock after this offering or the perception that these sales could occur. These sales, or the possibility that these sales may occur, might also make it more difficult for us to sell equity securities in the future at a time and price that we deem appropriate. Assuming that shares of our common stock are sold at a price of $22.82 per share (the last reported sale price of our common stock on the Nasdaq Global Market on April&#160;3, 2023), upon the completion of this offering,&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of our common stock would be outstanding (or&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of our common stock if the underwriters exercise their option to purchase additional shares from us in full), based on the number of shares outstanding as of December&#160;31, 2022, of which &#8199;&#8199;&#8199;&#8199; will be freely tradable without restriction in the public market immediately following this offering. If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after the lock-up lapse, the trading price of our common stock could decline. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:22pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The price of our common stock may be volatile and can fluctuate substantially, which could result in substantial losses for purchasers of our common stock in this offering.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If you purchase shares of our common stock in this offering, you may not be able to resell those shares at or above the public offering price. The trading price of our shares of common stock has fluctuated, and is likely to continue to fluctuate substantially. The trading price of our shares of common stock depends on a number of factors, including those described or incorporated by reference in this &#8220;Risk Factors&#8221; section, many of which are beyond our control and may not be related to our operating performance. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Since January&#160;1, 2023, our common stock has traded at prices as low as $10.62 per share and as high as $25.69 per share through April&#160;3, 2023. The stock market in general and the market for smaller biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your common stock at or above the public offering price. The market price for our common stock may be influenced by many factors, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the degree of success of competitive products or technologies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">results of clinical trials and preclinical studies, of our drug candidates or those of our competitors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">regulatory or legal developments in the United States and other countries; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">receipt of, or failure to obtain, regulatory approvals; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">developments or disputes concerning patent applications, issued patents or other proprietary rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the recruitment or departure of key personnel; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the level of expenses related to any of our drug candidates or clinical development programs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the results of our efforts to discover, develop, acquire or in-license additional technologies or drug candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">variations in our financial results or those of companies that are perceived to be similar to us; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">rumors or announcements regarding transactions involving our company or drug candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">changes in the structure of healthcare payment systems; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">market conditions in the pharmaceutical and biotechnology sectors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">general economic, industry and market conditions; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the other factors described or incorporated by reference in this &#8220;Risk Factors&#8221; section. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If securities or industry analysts either do not publish research about us or publish inaccurate or unfavorable research about us, our business or our market, or if they change their recommendations regarding our common stock adversely, the trading price or trading volume of our common stock could decline.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The trading market for our common stock will be influenced in part by the research and reports that securities or industry analysts may publish about us, our business, our market, or our competitors. If one or more of these analysts initiate research with an unfavorable rating or downgrade our common stock, provide a more favorable recommendation about our competitors or publish inaccurate or unfavorable research about our business, our common stock price would likely decline. If any analyst who may cover us were to cease coverage of us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause the trading price or trading volume of our common stock to decline. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tsUOP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:376pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">USE OF PROCEEDS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We estimate that the net proceeds to us from our issuance and sale of $100.0&#160;million of shares of common stock in this offering will be approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, or approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million if the underwriters exercise their option to purchase additional shares of our common stock in full, in each case, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We currently intend to use the net proceeds from this offering, together with our cash, cash equivalents and investments, to fund continued clinical development and pre-commercialization activities associated with rusfertide and for working capital and general corporate purposes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve. The amounts and timing of our actual expenditures depend on numerous factors, including the progress of our preclinical development efforts, the ongoing status of and results of our clinical trials and other studies and any unforeseen cash needs. As a result, our management will have broad discretion in the application of the net proceeds, and investors will be relying on the judgment of our management regarding the application of the net proceeds of this offering. Although we may use a portion of the net proceeds from the offering for the acquisition or licensing, as the case may be, of product candidates, technologies, compounds, other assets or complementary businesses, we have no current understandings, agreements or commitments to do so. Pending these uses, we intend to invest the net proceeds from this offering in interest-bearing, investment-grade securities. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tsDIL">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DILUTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If you invest in our securities, your interest will be diluted to the extent of the difference between the public offering price per share and the as adjusted net tangible book value per share of our common stock after this offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our net tangible book value as of December&#160;31, 2022 was approximately $215.6&#160;million, or $4.37 per share. Net tangible book value per share is determined by dividing our total tangible assets, less total liabilities, by the number of shares of our common stock outstanding as of December&#160;31, 2022. Dilution with respect to net tangible book value per share represents the difference between the amount per share paid by purchasers of shares of common stock in this offering and the net tangible book value per share of our common stock immediately after this offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">After giving effect to the assumed issuance and sale of $100,000,000 of shares of our common stock at an assumed public offering price of $22.82 per share of common stock (the last reported sale price of our common stock on the Nasdaq Global Market on April&#160;3, 2023), and after deducting underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted net tangible book value as of December&#160;31, 2022 would have been approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, or $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share. This represents an immediate increase in net tangible book value of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share to existing stockholders and immediate dilution of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share to investors purchasing our common stock in this offering at the public offering price. The following table illustrates this dilution on a per share basis: </font>
        </div>
        <table style="width:456pt;height:83pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:381.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Assumed public offering price per share </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">22.82 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:381.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net tangible book value per share of common stock as of December&#160;31, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.37</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:381.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Increase in net tangible book value per share attributable to this offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:1.917pt 0pt 1.833pt 0pt; width:381.59pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">As adjusted net tangible book value per share as of December&#160;31, 2022, after giving effect to this offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:381.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Dilution per share to new investors purchasing our common stock in this offering </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.1pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If the underwriters&#8217; option to purchase additional shares is exercised in full, the as adjusted net tangible book value per share after giving effect to this offering would be $&#8199;&#8199;&#8199;&#8199; per share, and the dilution in net tangible book value per share to investors purchasing common stock in this offering would be $&#8199;&#8199;&#8199;&#8199; per share. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The above discussion and table are based on 49,339,252 shares of our common stock outstanding as of December&#160;31, 2022 and excludes: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">5,123,464 shares of common stock issuable upon the exercise of stock options issued and outstanding under the 2016 Plan, as of December&#160;31, 2022, having a weighted average exercise price of $19.20 per share; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">591,186 shares of common stock issuable upon the vesting of outstanding restricted stock&#160;units, under the 2016 Plan, as of December&#160;31, 2022; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">199,500 shares of common stock issuable upon the vesting of outstanding performance stock&#160;units, under the 2016 Plan, as of December&#160;31, 2022; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">an aggregate of 1,350,793 shares of common stock, subject to increase on an annual basis, reserved for future issuance under the 2016 Plan, as of December&#160;31, 2022; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">949,217 shares of common stock issuable upon the exercise of stock options issued and outstanding under the Inducement Plan, as of December&#160;31, 2022, having a weighted average exercise price of $20.85 per share; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">46,250 shares of common stock issuable upon the vesting of outstanding restricted stock&#160;units, under the Inducement Plan, as of December&#160;31, 2022; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">an aggregate of 574,772 shares of common stock reserved for future issuance under the Inducement Plan, as of December&#160;31, 2022; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:422pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">167,828 shares of common stock issuable upon the exercise of stock options issued and outstanding under our 2007 Equity Incentive Plan, as of December&#160;31, 2022, having a weighted average exercise price of $3.78 per share; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">1,255,290 shares of our common stock reserved for future issuance under our 2016 Employee Stock Purchase Plan, as of December&#160;31, 2022; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">2,750,000 shares of common stock issuable upon the exercise of warrants outstanding as of December&#160;31, 2022, at a weighted average exercise price of $12.50 per share; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">1,749,199 shares of common stock sold in the ATM Offerings since December&#160;31, 2022. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To the extent that options or warrants outstanding as of December&#160;31, 2022 have been or may be exercised, restricted stock&#160;units or performance&#160;units outstanding as of December&#160;31, 2022 continue to vest, or other shares are issued, investors purchasing our common stock in this offering may experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tsUND">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">UNDERWRITING</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are offering the shares of common stock described in this prospectus through a number of underwriters. J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler &amp; Co. are acting as joint book-running managers of the offering and as representatives of the underwriters. We have entered into an underwriting agreement with the underwriters. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to the underwriters, and each underwriter has severally agreed to purchase, at the public offering price less the underwriting discounts and commissions set forth on the cover page of this prospectus, the number of shares of common stock listed next to its name in the following table: </font>
        </div>
        <table style="width:456pt;height:98.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:383.53pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:60.47pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:383.53pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">J.P. Morgan Securities LLC </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:60.47pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:383.53pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Jefferies LLC </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60.47pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:383.53pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Piper Sandler &amp; Co. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60.47pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:383.53pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">BTIG, LLC</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60.47pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:383.53pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">H.C. Wainwright &amp; Co., LLC</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60.47pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 3.25pt 0pt; width:383.53pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3pt double #000000;padding:0pt 0pt 2.5pt 0pt; width:60.47pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The underwriters are committed to purchase all of the shares of common stock offered by us if they purchase any shares. The underwriting agreement also provides that if an underwriter defaults, the purchase commitments of non-defaulting underwriters may also be increased or the offering may be terminated. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The underwriters propose to offer the shares directly to the public at the initial public offering price set forth on the cover page of this prospectus and to certain dealers at that price less a concession not in excess of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share. After the initial offering of the shares to the public, if all of the shares are not sold at the initial public offering price, the underwriters may change the offering price and the other selling terms. Sales of any shares made outside of the United States may be made by affiliates of the underwriters. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The underwriters have an option to buy up to $15,000,000 of additional shares of common stock from us. The underwriters have 30&#160;days from the date of this prospectus to exercise this option to purchase additional shares. If any shares are purchased with this option to purchase additional shares, the underwriters will purchase shares in approximately the same proportion as shown in the table above. If any additional shares of common stock are purchased, the underwriters will offer the additional shares on the same terms as those on which the shares are being offered. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The underwriting fee is equal to the public offering price per share of common stock less the amount paid by the underwriters to us per share of common stock. The underwriting fee for the common stock is $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share. The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters assuming both no exercise and full exercise of the underwriters&#8217; option to purchase additional shares. </font>
        </div>
        <table style="width:456pt;height:74.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:362.17pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Without</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Option to</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Purchase</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Additional</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">With</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Option to</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Purchase</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Additional</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:362.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Per Share </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.955pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:4.955pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.955pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:4.955pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:362.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.955pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:4.955pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.955pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.955pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have agreed to reimburse the underwriters for certain of their expenses in an amount up to $25,000. The underwriters have agreed to reimburse us for certain of our expenses. We estimate that the total expenses of this offering, including filing and listing fees, printing fees and legal and accounting expenses, but excluding the underwriting discounts and commissions, will be approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A prospectus in electronic format may be made available on the web sites maintained by one or more underwriters, or selling group members, if any, participating in the offering. The underwriters may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">account holders. Internet distributions will be allocated by the representatives to underwriters and selling group members that may make Internet distributions on the same basis as other allocations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We, our executive officers, and directors have agreed, subject to specified exceptions, not to directly or indirectly: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">sell, offer, contract or grant any option to sell (including any short sale), pledge, transfer, establish an open &#8220;put equivalent position&#8221; within the meaning of Rule&#160;16a-l(h) under the Securities Exchange Act of 1934, as amended; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">otherwise dispose of any shares of common stock, options or warrants to acquire shares of common stock, or securities exchangeable or exercisable for or convertible into shares of common stock currently or hereafter owned either of record or beneficially; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">publicly announce an intention to do any of the foregoing for a period of 60&#160;days after the date of this prospectus supplement without the prior written consent of J.P. Morgan Securities LLC (and, solely with respect to us, without the additional prior consent of Jefferies LLC and Piper Sandler &amp; Co.). </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This restriction terminates after the close of trading of the common stock on and including the 60th day after the date of this prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">J.P. Morgan Securities LLC may, in its sole discretion (and solely with respect to our securities, J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler &amp; Co. may, in their sole discretion) and at any time or from time to time before the termination of the 60-day period release all or any portion of the securities subject to lock-up agreements. Except for customary lock-up exceptions, there are no existing agreements between the underwriters and any of our shareholders who will execute a lock-up agreement, providing consent to the sale of shares prior to the expiration of the lock-up period. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Record holders of our securities are typically the parties to the lock-up agreements with the underwriters referred to above, while holders of beneficial interests in our shares who are not also record holders in respect of such shares are not typically subject to any such agreements or other similar restrictions. Accordingly, we believe that certain holders of beneficial interests who are not record holders and are not bound by lock-up agreements could enter into transactions with respect to those beneficial interests that negatively impact our stock price. In addition, a shareholder who is not subject to a lock-up agreement with the underwriters may be able to sell, short sell, transfer, hedge, pledge, lend or otherwise dispose of or attempt to sell short sell, transfer, hedge, pledge, lend or otherwise dispose of, their equity interests at any time after the closing of this offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our common stock is listed on the Nasdaq Global Market under the symbol &#8220;PTGX.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with this offering, the underwriters may engage in stabilizing transactions, which involves making bids for, purchasing and selling shares of our common stock in the open market for the purpose of preventing or retarding a decline in the market price of the common stock while this offering is in progress. These stabilizing transactions may include making short sales of common stock, which involves the sale by the underwriters of a greater number of shares of common stock than they are required to purchase in this offering, and purchasing shares of common stock on the open market to cover positions created by short sales. Short sales may be &#8220;covered&#8221; shorts, which are short positions in an amount not greater than the underwriters&#8217; option to purchase additional shares referred to above, or may be &#8220;naked&#8221; shorts, which are short positions in excess of that amount. The underwriters may close out any covered short position either by exercising their option to purchase additional shares, in whole or in part, or by purchasing shares in the open market. In making this determination, the underwriters will consider, among other things, the price of shares available for purchase in the open market compared to the price at which the underwriters may purchase shares through the option to purchase additional shares. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">common stock in the open market that could adversely affect investors who purchase in this offering. To the extent that the underwriters create a naked short position, they will purchase shares in the open market to cover the position. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The underwriters have advised us that, pursuant to Regulation&#160;M of the Securities Act of 1933, they may also engage in other activities that stabilize, maintain or otherwise affect the price of the common stock, including the imposition of penalty bids. This means that if the representatives of the underwriters purchase common stock in the open market in stabilizing transactions or to cover short sales, the representatives can require the underwriters that sold those shares as part of this offering to repay the underwriting discount received by them. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">These activities may have the effect of raising or maintaining the market price of the common stock or preventing or retarding a decline in the market price of the common stock, and, as a result, the price of the common stock may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities, they may discontinue them at any time. The underwriters may carry out these transactions on the Nasdaq Global Market, in the over-the-counter market or otherwise. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Certain of the underwriters and their affiliates have provided in the past to us and our affiliates and may provide from time to time in the future certain commercial banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have received and may continue to receive customary fees and commissions. For example, Jefferies LLC is our sales agent under our Open Market Sale Agreement, pursuant to which we may offer and sell, from time to time, up to an additional $100&#160;million of shares of common stock through an &#8220;at the market offering&#8221; as defined in Rule&#160;415(a)(4) promulgated under the Securities Act. In addition, from time to time, certain of the underwriters and their affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves or their customers, long or short positions in our debt or equity securities or loans, and may do so in the future. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notice to prospective investors in the European Economic Area and the United Kingdom</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">None of this prospectus supplement, the accompanying prospectus and any related free writing prospectus is a prospectus for the purposes of Regulation (EU) 2017/1129 (the &#8220;Prospectus Regulation&#8221;). This prospectus supplement, the accompanying prospectus and any related free writing prospectus have been prepared on the basis that any offer of shares of our common stock in any Member State of the European Economic Area will be made pursuant to an exemption under the Prospectus Regulation from the requirement to publish a prospectus for offers of shares of our common stock. Accordingly any person making or intending to make an offer in that Member State of shares of our common stock which are the subject of the offering contemplated in this prospectus supplement, the accompanying prospectus and any related free writing prospectus may only do so in circumstances in which no obligation arises for the Company or any of the underwriters to publish a prospectus pursuant to Article&#160;3 of the Prospectus Regulation in relation to such offer. Neither the Company nor the underwriters have authorized, nor do they authorize, the making of any offer of shares of our common stock in circumstances in which an obligation arises for the Company or the underwriters to publish a prospectus for such offer. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In relation to each Member State of the European Economic Area (each a &#8220;Relevant State&#8221;), no securities have been offered or will be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the securities which has been approved by the competent </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that offers of securities may be made to the public in that Relevant State at any time: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.29pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">A.</font>
          <br >
        </div>
        <div style=" margin-top:8.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to any legal entity which is a qualified investor as defined under Article&#160;2 of the Prospectus Regulation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">B.</font>
          <br >
        </div>
        <div style=" margin-top:8.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article&#160;2 of the Prospectus Regulation), subject to obtaining the prior consent of the underwriters; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">C.</font>
          <br >
        </div>
        <div style=" margin-top:8.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">in any other circumstances falling within Article&#160;1(4) of the Prospectus Regulation, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">provided that no such offer of securities shall require us or any underwriter to publish a prospectus pursuant to Article&#160;3 of the Prospectus Regulation or supplement a prospectus pursuant to Article&#160;23 of the Prospectus Regulation and each person who initially acquires any securities or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with us and each of the underwriters that it is a &#8220;qualified investor&#8221; within the meaning of Article&#160;2(e) of the Prospectus Regulation. In the case of any securities being offered to a financial intermediary as that term is used in the Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the securities acquired by it in the offer have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any securities to the public other than their offer or resale in a Relevant State to qualified investors as so defined or in circumstances in which the prior consent of the underwriters has been obtained to each such proposed offer or resale. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase or subscribe for any securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This European Economic Area selling restriction is in addition to any other selling restrictions set out below. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notice to prospective investors in the United Kingdom</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the United Kingdom, none of this prospectus supplement, the accompanying prospectus and any related free writing prospectus is a prospectus for the purposes of Regulation (EU) 2017/1129 as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018, as amended by the European Union (Withdrawal Agreement) Act 2020 (the &#8220;EUWA&#8221;) (the &#8220;UK Prospectus Regulation&#8221;). This prospectus supplement, the accompanying prospectus and any related free writing prospectus have been prepared on the basis that any offer of shares of our common stock in the United Kingdom will be made pursuant to an exemption under the UK Prospectus Regulation from the requirement to publish a prospectus for offers of shares of our common stock. Accordingly any person making or intending to make an offer in the United Kingdom of shares of our common stock which are the subject of the offering contemplated in this prospectus supplement, the accompanying prospectus and any related free writing prospectus may only do so in circumstances in which no obligation arises for the Company or any of the underwriters to publish a prospectus pursuant to Section&#160;85 of the United Kingdom&#8217;s Financial Services and Markets Act 2000, as amended (the &#8220;FSMA&#8221;) in relation to such offer. Neither the Company nor the underwriters have authorized, nor do they authorize, the making of any offer of shares of our common stock in circumstances in which an obligation arises for the Company or the underwriters to publish a prospectus for such offer. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">No securities have been offered or will be offered pursuant to the offering to the public in the United Kingdom prior to the publication of a prospectus in relation to such securities which has been approved by the Financial Conduct Authority, except that the securities may be offered to the public in the United Kingdom at any time: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">A.</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to any legal entity which is a qualified investor as defined under Article&#160;2 of the U.K. Prospectus Regulation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">B.</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article&#160;2 of the U.K. Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">C.</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">in any other circumstances falling within Section&#160;86 of the FMSA. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">provided that no such offer of such securities shall require us or any underwriter to publish a prospectus pursuant to Section&#160;85 of the FSMA and each person who initially acquires any shares of our common stock or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of the representatives and the Company that it is a &#8220;qualified investor&#8221; within the meaning of Article&#160;2(e) of the UK Prospectus Regulation. In the case of any shares of our common stock being offered to a financial intermediary as that term is used in Article&#160;5 of the UK Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares of our common stock acquired by it in the offer have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares of our common stock to the public other than their offer or resale in the United Kingdom to qualified investors as so defined or in circumstances in which the prior consent of the representatives have been obtained to each such proposed offer or resale. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to the securities in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase or subscribe for any securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">he communication of this prospectus supplement, the accompanying prospectus, any related free writing prospectus and any other document or materials relating to the issue of the shares of our common stock offered hereby is not being made, and such documents and/or materials have not been approved, by an authorized person for the purposes of section 21 of the FSMA. Accordingly, such documents and/or materials are not being distributed to, and must not be passed on to, the general public in the United Kingdom This document and such other documents and/or materials are for distribution only to persons who (i)&#160;have professional experience in matters relating to investments and who fall within the definition of investment professionals (as defined in Article&#160;19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#8220;Financial Promotion Order&#8221;)), (ii)&#160;fall within Article&#160;49(2)(a) to (d)&#160;of the Financial Promotion Order, (iii)&#160;are outside the United Kingdom or (iv)&#160;are any other persons to whom it may otherwise lawfully be made under the Financial Promotion Order (all such persons together being referred to as &#8220;relevant persons&#8221;) investment or investment activity to which this prospectus supplement, the accompanying prospectus and any related free writing prospectus relates will be engaged in only with, relevant persons. Any person in the United Kingdom that is not a relevant person should not act or rely on this prospectus supplement, the accompanying prospectus or any related free writing prospectus or any of their contents. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any invitation or inducement to engage in investment activity (within the meaning of Section&#160;21 of the FSMA) in connection with the issue or sale of the shares of our common stock may only be communicated or caused to be communicated in circumstances in which Section&#160;21(1) of the FSMA does not apply to the Company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All applicable provisions of the FSMA must be complied with in respect to anything done by any person in relation to the shares of our common stock in, from or otherwise involving the United Kingdom. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notice to prospective investors in Canada</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The securities may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the securities </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#8217;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory for particulars of these rights or consult with a legal advisor. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notice to prospective investors in Switzerland</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (&#8220;SIX&#8221;) or on any other stock exchange or regulated trading facility in Switzerland. This document does not constitute a prospectus within the meaning of, and has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the securities or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Neither this document nor any other offering or marketing material relating to the offering, us, or the securities have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA (FINMA), and the offer of securities has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (&#8220;CISA&#8221;). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of securities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notice to prospective investors in Australia</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus supplement: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">does not constitute a disclosure document or a prospectus under Chapter 6D.2 of the Corporations Act 2001 (Cth) (the &#8220;Corporations Act&#8221;); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">has not been, and will not be, lodged with the Australian Securities and Investments Commission (&#8220;ASIC&#8221;), as a disclosure document for the purposes of the Corporations Act and does not purport to include the information required of a disclosure document for the purposes of the Corporations Act; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">may only be provided in Australia to select investors who are able to demonstrate that they fall within one or more of the categories of investors available under section 708 of the Corporations Act (&#8220;Exempt Investors&#8221;). </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The securities may not be directly or indirectly offered for subscription or purchased or sold, and no invitations to subscribe for or buy the securities may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating to any securities may be distributed in Australia, except where disclosure to investors is not required under Chapter 6D of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the securities, you represent and warrant to us that you are an Exempt Investor. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As any offer of securities under this document will be made without disclosure in Australia under Chapter 6D.2 of the Corporations Act, the offer of those securities for resale in Australia within 12&#160;months may, under section 707 of the Corporations Act, require disclosure to investors under Chapter 6D.2 if none of the exemptions in section 708 applies to that resale. By applying for the securities you undertake to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">us that you will not, for a period of 12&#160;months from the date of issue of the securities, offer, transfer, assign or otherwise alienate those securities to investors in Australia except in circumstances where disclosure to investors is not required under Chapter 6D.2 of the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notice to prospective investors in Japan</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The securities have not been and will not be registered pursuant to Article&#160;4, Paragraph 1 of the Financial Instruments and Exchange Act. Accordingly, none of the securities nor any interest therein may be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any &#8220;resident&#8221; of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect at the relevant time. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notice to prospective investors in Hong Kong</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The securities have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&#160;to &#8220;professional investors&#8221; as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the &#8220;SFO&#8221;) of Hong Kong and any rules made thereunder; or (b)&#160;in other circumstances which do not result in the document being a &#8220;prospectus&#8221; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong (the &#8220;CO&#8221;) or which do not constitute an offer to the public within the meaning of the CO. No advertisement, invitation or document relating to the securities has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons outside Hong Kong or only to &#8220;professional investors&#8221; as defined in the SFO and any rules made thereunder. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notice to prospective investors in Singapore</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each joint book-running manager has acknowledged that this prospectus supplement has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, each joint book-running manager has represented and agreed that it has not offered or sold any securities or caused the securities to be made the subject of an invitation for subscription or purchase and will not offer or sell any shares or cause the securities to be made the subject of an invitation for subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, this prospectus supplement or any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the securities, whether directly or indirectly, to any person in Singapore other than (i)&#160;to an institutional investor (as defined in Section&#160;4A of the Securities and Futures Act (Chapter 289) of Singapore, as modified or amended from time to time (the &#8220;SFA&#8221;)) pursuant to Section&#160;274 of the SFA; (ii)&#160;to a relevant person (as defined in Section&#160;275(2) of the SFA) pursuant to Section&#160;275(1) of the SFA, or any person pursuant to Section&#160;275(1A) of the SFA, and in accordance with the conditions specified in Section&#160;275 of the SFA, or (iii)&#160;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. Where the securities are subscribed or purchased under Section&#160;275 of the SFA by a relevant person which is: (a)&#160;a corporation (which is not an accredited investor (as defined in Section&#160;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or (b)&#160;a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, securities or securities-based derivatives contracts (each term as defined in Section&#160;2(1) of the SFA) of that corporation or the beneficiaries&#8217; rights and interest (howsoever described) in that trust shall not be transferred within six&#160;months after that corporation or that trust has acquired the shares pursuant to an offer made under Section&#160;275 of the SFA except: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(a)</font>
          <br >
        </div>
        <div style=" margin-top:7.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to an institutional investor or to a relevant person, or to any person arising from an offer referred to in Section&#160;275(1A) or Section&#160;276(4)(i)(B) of the SFA; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:164pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(b)</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">where no consideration is or will be given for the transfer; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(c)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">where the transfer is by operation of law; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(d)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">as specified in Section&#160;276(7) of the SFA; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(e)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">as specified in Regulation&#160;37A of the Securities and Futures (Offers of Investments) Securities and Securities-based Derivatives Contracts Regulations&#160;2018. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Singapore SFA Product Classification-In connection with Section&#160;309B of the SFA and the CMP Regulations&#160;2018, unless otherwise specified before an offer of the securities, the Issuer has determined, and hereby notifies all relevant persons (as defined in Section&#160;309A(1) of the SFA), that the securities are &#8220;prescribed capital markets products&#8221; &#8203;(as defined in the CMP Regulations&#160;2018) and Excluded Investment Products (as defined in MAS Notice SFA 04-N12: Notice on the Sale of Investment Products and MAS Notice FAA-N16: Notice on Recommendations on Investment Products). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notice to prospective investors in China</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus supplement will not be circulated or distributed in the PRC and the securities will not be offered or sold, and will not be offered or sold to any person for re-offering or resale directly or indirectly to any residents of the PRC except pursuant to any applicable laws and regulations of the PRC. Neither this prospectus supplement nor any advertisement or other offering material may be distributed or published in the PRC, except under circumstances that will result in compliance with applicable laws and regulations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notice to prospective investors in the Dubai International Financial Centre</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus supplement relates to an Exempt Offer in accordance with the Markets Rules 2012 of the Dubai Financial Services Authority (&#8220;DFSA&#8221;). This prospectus supplement is intended for distribution only to persons of a type specified in the Markets Rules 2012 of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus supplement nor taken steps to verify the information set forth herein and has no responsibility for the prospectus supplement. The securities to which this prospectus supplement relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not understand the contents of this prospectus supplement you should consult an authorized financial advisor. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In relation to its use in the DIFC, this document is strictly private and confidential and is being distributed to a limited number of investors and must not be provided to any person other than the original recipient, and may not be reproduced or used for any other purpose. The interests in the securities may not be offered or sold directly or indirectly to the public in the DIFC. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tsLEMA">&#8203;</a><a name="tsEXP">&#8203;</a><a name="tsWYCF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:284pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LEGAL MATTERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Gibson, Dunn &amp; Crutcher LLP, San Francisco, California will pass upon the validity of the common stock offered hereby. The underwriters are being represented by Latham &amp; Watkins LLP, San Diego, California, in connection with the offering. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXPERTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Ernst &amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements as of December&#160;31, 2022 and 2021, and for each of the three&#160;years in the period ended December&#160;31, 2022, included in our <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1377121/000155837023003906/ptgx-20221231x10k.htm">Annual Report on Form 10-K for the year ended December&#160;31, 2022</a>, as set forth in their report, which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst &amp; Young LLP&#8217;s report, given on their authority as experts in accounting and auditing. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">WHERE YOU CAN FIND MORE INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We file annual, quarterly and special reports, proxy statements and other information with the SEC, and we have filed with the SEC a registration statement on Form S-3 under the Securities Act with respect to the securities offered by this prospectus. This prospectus, which forms part of the registration statement, does not contain all of the information included in the registration statement, including its exhibits and schedules. For further information about us and the securities described in this prospectus, you should refer to the registration statement, its exhibits and schedules and our reports, proxies, information statements and other information filed with the SEC. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our filings are available to the public on the Internet, through a database maintained by the SEC at http://www.sec.gov. We also maintain a website at www.protagonist-inc.com. We have included our website address for the information of prospective investors and do not intend it to be an active link to our website. Information contained on our website does not constitute a part of this prospectus (or any document incorporated by reference herein). </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tsIOCI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:120pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The SEC allows us to incorporate by reference the information and reports we file with it, which means that we can disclose important information to you by referring you to these documents. The information incorporated by reference is an important part of this prospectus, and information that we file after the date hereof with the SEC will automatically update and supersede the information already incorporated by reference. We are incorporating by reference the documents listed below: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1377121/000155837023003906/ptgx-20221231x10k.htm">our Annual Report on Form 10-K for the year ended December&#160;31, 2022 filed with the SEC on March&#160;15, 2023; </a></font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The sections included in our <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1377121/000110465922045545/tm223475-1_def14a.htm">definitive proxy statement on Schedule&#160;14A, filed with the SEC on April&#160;13, 2022</a> that are incorporated by reference into our <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1377121/000155837022002385/ptgx-20211231x10k.htm">Annual Report on Form 10-K for the year ended December&#160;31, 2021; </a></font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our Current Reports on Form 8-K filed with the SEC on <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1377121/000110465923001872/tm232306d1_8k.htm">January&#160;6, 2023</a> and <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1377121/000110465923031135/tm239184d1_8k.htm">March&#160;10, 2023</a>; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the description of our common stock set forth in our registration statement on <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1377121/000119312516675653/d223095d8a12ba.htm">Form 8-A, filed with the SEC on August&#160;9, 2016</a>, including any amendments thereto or reports filed for the purposes of updating this description, including <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1377121/000155837022002385/ptgx-20211231xex4d7.htm">Exhibit&#160;4.7 to our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, filed with the SEC on February&#160;28, 2022. </a></font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All documents we file with the SEC pursuant to Sections&#160;13(a), 13(c), 14 or 15(d) of the Exchange Act shall be deemed incorporated by reference in this prospectus and to be a part of this prospectus from the date of filing of those documents, with the exception of any portion of any report or document that is not deemed &#8220;filed&#8221; under such provisions on or after the date of this prospectus, until the earlier of the date on which: (1)&#160;all of the securities registered hereunder have been sold; or (2)&#160;the registration statement of which this prospectus is a part has been withdrawn. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under no circumstances will any information filed under Items&#160;2.02 or 7.01 of Current Report on Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon written or oral request, we will provide without charge to each person to whom a copy of the prospectus is delivered a copy of the documents incorporated by reference herein (other than exhibits to such documents unless such exhibits are specifically incorporated by reference herein). You may request a copy of these filings, at no cost, by writing, calling or emailing us at the contact information set forth below. We have authorized no one to provide you with any information that differs from that contained in this prospectus. Accordingly, we take no responsibility for any other information that others may give you. You should not assume that the information in this prospectus is accurate as of any date other than the date of the front cover of this prospectus. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Protagonist Therapeutics, Inc. </font>
          <br >
          <font style="letter-spacing:0.2pt;">7707 Gateway Boulevard, Suite 140 </font>
          <br >
          <font style="letter-spacing:0.2pt;">Newark, California 94560 </font>
          <br >
          <font style="letter-spacing:0.2pt;">(510) 474-0170</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="lg_protagonist-pn.jpg" alt="[MISSING IMAGE: lg_protagonist-pn.jpg]" height="81" width="325" >
        </div>
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">COMMON STOCK </font>
          <br >
          <font style="letter-spacing:-0.28pt;">PREFERRED STOCK </font>
          <br >
          <font style="letter-spacing:-0.28pt;">DEBT SECURITIES </font>
          <br >
          <font style="letter-spacing:-0.28pt;">WARRANTS </font>
          <br >
          <font style="letter-spacing:-0.28pt;">UNITS</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:10.167pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">From time to time, we may issue, in one or more series or classes, up to an aggregate of $300,000,000 of our common stock, preferred stock, debt securities, warrants and/or&#160;units, at prices and on terms that we will determine at the time of the offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus provides you with a general description of the securities we may offer. Each time we offer securities, we will provide specific terms of the securities offered in a supplement to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. We may not sell any securities under this prospectus without delivery of the applicable prospectus supplement. If information in any prospectus supplement is inconsistent with the information in this prospectus, then the information in that prospectus supplement will apply and will supersede the information in this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should read this prospectus, the applicable prospectus supplement and any related free writing prospectus carefully, as well as any documents incorporated by reference, before you invest in any of the securities being offered. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our shares of common stock are listed on The Nasdaq Global Market under the symbol &#8220;PTGX.&#8221; The last reported sale price of our common stock on The Nasdaq Global Market on August&#160;2, 2022 was $10.63 per share. We recommend that you obtain current market quotations for our common stock prior to making an investment decision. </font>
        </div>
        <div style="margin-top:18.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; contained in this prospectus beginning on page <a href="#tRIFA">4</a> and any applicable prospectus supplement, and under similar headings in the other documents that are incorporated by reference into this prospectus.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:100pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Prospectus dated August 16, 2022</font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC3">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TABLE OF CONTENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:220pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tATP"><font style="letter-spacing:0.2pt;">ABOUT THIS PROSPECTUS</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tATP">1</a></font> <a href="#tATP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCSCFL"><font style="letter-spacing:0.2pt;">CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCSCFL">2</a></font> <a href="#tCSCFL"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tTHCO"><font style="letter-spacing:0.2pt;">THE COMPANY</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tTHCO">3</a></font> <a href="#tTHCO"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tRIFA"><font style="letter-spacing:0.2pt;">RISK FACTORS</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tRIFA">4</a></font> <a href="#tRIFA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUOP"><font style="letter-spacing:0.2pt;">USE OF PROCEEDS</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUOP">5</a></font> <a href="#tUOP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSWO"><font style="letter-spacing:0.2pt;">SECURITIES WE MAY OFFER </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSWO">6</a></font> <a href="#tSWO"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOCS"><font style="letter-spacing:0.2pt;">DESCRIPTION OF CAPITAL STOCK</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOCS">7</a></font> <a href="#tDOCS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDODS"><font style="letter-spacing:0.2pt;">DESCRIPTION OF DEBT SECURITIES </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDODS">11</a></font> <a href="#tDODS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOW"><font style="letter-spacing:0.2pt;">DESCRIPTION OF WARRANTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOW">22</a></font> <a href="#tDOW"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOU"><font style="letter-spacing:0.2pt;">DESCRIPTION OF UNITS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOU">23</a></font> <a href="#tDOU"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPOD"><font style="letter-spacing:0.2pt;">PLAN OF DISTRIBUTION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPOD">26</a></font> <a href="#tPOD"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLEMA"><font style="letter-spacing:0.2pt;">LEGAL MATTERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLEMA">28</a></font> <a href="#tLEMA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXP"><font style="letter-spacing:0.2pt;">EXPERTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEXP">28</a></font> <a href="#tEXP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tWCFM"><font style="letter-spacing:0.2pt;">WHERE YOU CAN FIND MORE INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tWCFM">29</a></font> <a href="#tWCFM"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tIOCIBR"><font style="letter-spacing:0.2pt;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tIOCIBR">30</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tATP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:192pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ABOUT THIS PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus is a part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission (the &#8220;SEC&#8221; or the &#8220;Commission&#8221;) utilizing a &#8220;shelf&#8221; registration process. Under this shelf registration process, we may sell any combination of the securities described in this prospectus in one or more offerings up to a total dollar amount of $300,000,000. This prospectus provides you with a general description of the securities we may offer. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each time we sell securities under this prospectus, we will provide a prospectus supplement that will contain specific information about the terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in any documents that we have incorporated by reference into this prospectus. You should carefully read both this prospectus and any prospectus supplement together with additional information under the headings &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Information by Reference.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have not authorized anyone to provide you with any information other than that contained or incorporated by reference in this prospectus and any applicable prospectus supplement, along with the information contained in any free writing prospectuses we have authorized for use in connection with a specific offering. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. This prospectus, any applicable supplement to this prospectus or any related free writing prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus, any applicable supplement to this prospectus or any related free writing prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should not assume that the information contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus, any applicable prospectus supplement or any related free writing prospectus is delivered, or securities are sold, on a later date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless the context otherwise requires, we use the terms &#8220;Protagonist,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; in this prospectus to refer to Protagonist Therapeutics, Inc. and, where appropriate, our subsidiaries. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCSCFL">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:136pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus and the documents that we have filed with the SEC that are incorporated by reference herein contain forward-looking statements, including statements regarding our future financial condition, business strategy and plans and objectives of management for future operations. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify forward-looking statements by terminology such as &#8220;believe,&#8221; &#8220;will,&#8221; &#8220;may,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;might,&#8221; &#8220;approximately,&#8221; &#8220;expect,&#8221; &#8220;predict,&#8221; &#8220;could,&#8221; &#8220;potentially&#8221; or the negative of these terms or other similar expressions. Forward-looking statements appear in a number of places throughout this prospectus, the documents incorporated by reference and any free writing prospectus that we have authorized for use in connection with this offering and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the potential for our programs, the timing of our clinical trials, the potential for eventual regulatory approval and commercialization of our product candidates and our potential receipt of milestone payments and royalties under our collaboration agreements; future operating results or the ability to generate sales, income or cash flow, and the impact of the ongoing COVID-19 pandemic, are forward-looking statements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Discussions containing these forward-looking statements may be found, among other places, in the section of this prospectus under the heading &#8220;Risk Factors&#8221; and in the sections entitled &#8220;Business&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; incorporated by reference from our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, as well as any amendments thereto, filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. We discuss in greater detail many of these risks under the heading &#8220;Risk Factors&#8221; and elsewhere in this prospectus and in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, as well as any amendments thereto reflected in subsequent filings with the SEC and in the other documents incorporated by reference herein. Also, these forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable statement and, except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, statements such as &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tTHCO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:468pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">THE COMPANY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are a biopharmaceutical company with peptide-based new chemical entities rusfertide, PN-943 and PN-235 in different stages of development, all derived from the Company&#8217;s proprietary discovery technology platform. Our clinical programs fall into two broad categories of diseases; (i)&#160;hematology and blood disorders, and (ii)&#160;inflammatory and immunomodulatory diseases. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Corporate Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our principal executive offices are located at 7707 Gateway Boulevard, Suite 140, Newark, California&#160;94560. Our telephone number is (510) 474-0170. Our website address is www.protagonist-inc.com. References to our website address do not constitute incorporation by reference of the information contained on the website, and the information contained on the website is not part of this document. We have included our website in this prospectus solely as an inactive textual reference. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tRIFA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:468pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RISK FACTORS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Investing in our securities involves risks. You should carefully consider the risks, uncertainties and other factors described in our most recent Annual Report on Form 10-K, as supplemented and updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that we have filed or will file with the SEC, and in other documents which are incorporated by reference into this prospectus, as well as the risk factors and other information contained in or incorporated by reference into any accompanying prospectus supplement before investing in any of our securities. Our business, financial condition, results of operations, cash flows or prospects could be materially and adversely affected by any of these risks. The risks and uncertainties described in the documents incorporated by reference herein are not the only risks and uncertainties that you may face. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For more information about our SEC filings, please see &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Information by Reference.&#8221; </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tUOP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:444pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">USE OF PROCEEDS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Except as described in any applicable prospectus supplement or in any free writing prospectuses we have authorized for use in connection with a specific offering, we currently intend to use the net proceeds from the sale of the securities offered by us hereunder for working capital and general corporate purposes, which may include, among other things, funding research and development, clinical trials, vendor payables, potential regulatory submissions, hiring additional personnel and capital expenditures. Our expected use of proceeds from the sale of the securities offered hereby represents our current intentions based on our present plans and business condition. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the proceeds to be received from the sale of the securities offered hereby or the amounts that we will actually spend on the uses set forth above. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pending the use of the net proceeds, we may invest the proceeds in interest-bearing, investment-grade securities, certificates of deposit or government securities. When we offer and sell the securities to which this prospectus relates, the prospectus supplement related to such offering will set forth our intended use of the proceeds, if any, received from the sale of such securities. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tSWO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:572pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">SECURITIES WE MAY OFFER</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">This prospectus contains summary descriptions of the securities we may offer from time to time. These summary descriptions are not meant to be complete descriptions of each security. The particular terms of any security will be described in the applicable prospectus supplement.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tDOCS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF CAPITAL STOCK</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The description below of our capital stock and provisions of our amended and restated certificate of incorporation (our &#8220;certificate of incorporation&#8221;) and amended and restated bylaws (our &#8220;bylaws&#8221;) are summaries and are qualified by reference to our certificate of incorporation and our bylaws which are filed as exhibits to the registration statement of which this prospectus is part, and by the applicable provisions of Delaware law. For more information on how you can obtain our certificate of incorporation and our bylaws, see the heading &#8220;Where You Can Find More Information.&#8221;</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of the date of this prospectus, our certificate of incorporation, authorizes us to issue up to 90,000,000 shares of common stock, $0.00001 par value per share, and 10,000,000 shares of preferred stock, $0.00001 par value per share. As of June&#160;30, 2022, 48,683,931 shares of common stock were outstanding and no shares of preferred stock were outstanding. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Common Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Voting Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, including the election of directors, and do not have cumulative voting rights. Accordingly, the holders of a majority of the outstanding shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they so choose, other than any directors that holders of any preferred stock we may issue may be entitled to elect. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Dividend Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to preferences that may be applicable to any then outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared by the board of directors out of legally available funds. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Liquidation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the event of our liquidation, dissolution or winding up, the holders of common stock will be entitled to share ratably in the assets legally available for distribution to stockholders after the payment of or provision for all of our debts and other liabilities, subject to the prior rights of any preferred stock then outstanding. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Rights and Preferences</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Holders of common stock have no preemptive or conversion rights or other subscription rights and there are no redemption or sinking funds provisions applicable to the common stock. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Anti-Takeover Effects of Delaware Law and our Certificate of Incorporation and Bylaws</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Some provisions of Delaware law, our certificate of incorporation and our bylaws contain provisions that could make the following transactions more difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or otherwise; or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions which provide for payment of a premium over the market price for our shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Undesignated Preferred Stock</font><font style="letter-spacing:0.2pt;">&#8201;&#8212;&#8201;The ability to authorize undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change control of us. These and other provisions may have the effect of deterring hostile takeovers or delaying changes in control or management of our company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Stockholder Meetings</font><font style="letter-spacing:0.2pt;">&#8201;&#8212;&#8201;Our bylaws provide that a special meeting of stockholders may be called only by our chairman of the board, chief executive officer or president, or by a resolution adopted by a majority of our board of directors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Requirements for Advance Notification of Stockholder Nominations and Proposals</font><font style="letter-spacing:0.2pt;">&#8201;&#8212;&#8201;Our bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Elimination of Stockholder Action by Written Consent</font><font style="letter-spacing:0.2pt;">&#8201;&#8212;&#8201;Our certificate of incorporation and our bylaws eliminate the right of stockholders to act by written consent without a meeting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Staggered Board</font><font style="letter-spacing:0.2pt;">&#8201;&#8212;&#8201;Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected each year by our stockholders. This system of electing and removing directors may tend to discourage a third-party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Removal of Directors</font><font style="letter-spacing:0.2pt;">&#8201;&#8212;&#8201;Our certificate of incorporation provides that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two thirds of the total voting power of all of our outstanding voting stock then entitled to vote in the election of directors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Stockholders Not Entitled to Cumulative Voting</font><font style="letter-spacing:0.2pt;">&#8201;&#8212;&#8201;Our certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our preferred stock may be entitled to elect. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Delaware Anti-Takeover Statute</font><font style="letter-spacing:0.2pt;">&#8201;&#8212;&#8201;We are subject to Section&#160;203 of the Delaware General Corporation Law, which prohibits persons deemed to be &#8220;interested stockholders&#8221; from engaging in a &#8220;business combination&#8221; with a publicly held Delaware corporation for three&#160;years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three&#160;years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#8217;s voting stock. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Choice of Forum</font><font style="letter-spacing:0.2pt;">&#8201;&#8212;&#8201;Our certificate of incorporation provides that, unless we consent in writing to the selection of an alternative form, the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (1)&#160;any derivative action or proceeding brought on our behalf; (2)&#160;any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders; (3)&#160;any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware or our certificate of incorporation or bylaws; (4)&#160;any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws; or (5)&#160;any action asserting a claim governed by the internal affairs doctrine. This provision does not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction. Our certificate of incorporation also provides that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">to this choice of forum provision. It is possible that a court of law could rule that the choice of forum provision contained in our certificate of incorporation is inapplicable or unenforceable if it is challenged in a proceeding or otherwise. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Amendment of Charter Provisions</font><font style="letter-spacing:0.2pt;">&#8201;&#8212;&#8201;The amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue preferred stock, would require approval by holders of at least two thirds of the total voting power of all of our outstanding voting stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The provisions of Delaware law, our certificate of incorporation and our bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our board and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Transfer Agent and Registrar</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The transfer agent and registrar for our common stock is American Stock Transfer &amp; Trust Company,&#160;LLC. The transfer agent&#8217;s address is 6201 15th Avenue, Brooklyn, New York 11219. The transfer agent for any series of preferred stock that we may offer under this prospectus will be named and described in the prospectus supplement for that series. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Listing</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our common stock is listed on The Nasdaq Global Market under the symbol &#8220;PTGX.&#8221; The applicable prospectus supplement will contain information, where applicable, as to any other listing, if any, on the Nasdaq Global Market or any securities market or other exchange of the preferred stock covered by such prospectus supplement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Preferred Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors may, without further action by our stockholders, fix the rights, preferences, privileges and restrictions of up to an aggregate of 10,000,000 shares of preferred stock in one or more series and authorize their issuance. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of our common stock. The issuance of our preferred stock could adversely affect the voting power of holders of our common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change of control or other corporate action. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following summary of terms of our preferred stock is not complete. You should refer to the provisions of our certificate of incorporation and bylaws and the resolutions containing the terms of each class or series of the preferred stock which have been or will be filed with the SEC at or prior to the time of issuance of such class or series of preferred stock and described in the applicable prospectus supplement. The applicable prospectus supplement may also state that any of the terms set forth herein are inapplicable to such series of preferred stock, provided that the information set forth in such prospectus supplement does not constitute material changes to the information herein such that it alters the nature of the offering or the securities offered. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will fix the designations, voting powers, preferences and rights of the preferred stock of each series we issue under this prospectus, as well as the qualifications, limitations or restrictions thereof, in the certificate of designation relating to that series. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation that describes the terms of the series of preferred stock we are offering. We will describe in the applicable prospectus supplement the terms of the series of preferred stock being offered, including, to the extent applicable: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:78pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the title and stated value; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the number of shares we are offering; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the liquidation preference per share; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the purchase price; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the dividend rate, period and payment date and method of calculation for dividends; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the procedures for any auction and remarketing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the provisions for a sinking fund; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any listing of the preferred stock on any securities exchange or market; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether the preferred stock will be convertible into our common stock, and, if applicable, the conversion price, or how it will be calculated, and the conversion period; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price, or how it will be calculated, and the exchange period; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">voting rights of the preferred stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">preemptive rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">restrictions on transfer, sale or other assignment; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether interests in the preferred stock will be represented by depositary shares; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a discussion of material United States federal income tax considerations applicable to the preferred stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any limitations on the issuance of any class or series of preferred stock ranking senior to or on a parity with the series of preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any other specific terms, preferences, rights or limitations of, or restrictions on, the preferred stock. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If we issue shares of preferred stock under this prospectus, the shares will be fully paid and non-assessable. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The issuance of preferred stock could adversely affect the voting power of holders of common stock and reduce the likelihood that common stockholders will receive dividend payments and payments upon liquidation. The issuance could have the effect of decreasing the market price of the common stock. The issuance of preferred stock also could have the effect of delaying, deterring or preventing a change in control of us. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tDODS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF DEBT SECURITIES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The paragraphs below describe the general terms and provisions of the debt securities we may issue. When we offer to sell a particular series of debt securities, we will describe the specific terms of the securities in a supplement to this prospectus, including any additional covenants or changes to existing covenants relating to such series. The prospectus supplement also will indicate whether the general terms and provisions described in this prospectus apply to a particular series of debt securities. You should read the actual indenture if you do not fully understand a term or the way we use it in this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may offer senior or subordinated debt securities. Each series of debt securities may have different terms. The senior debt securities will be issued under one or more senior indentures, dated as of a date prior to such issuance, between us and the trustee identified in the applicable prospectus supplement, as amended or supplemented from time to time. We will refer to any such indenture throughout this prospectus as the &#8220;senior indenture.&#8221; Any subordinated debt securities will be issued under one or more separate indentures, dated as of a date prior to such issuance, between us and the trustee identified in the applicable prospectus supplement, as amended or supplemented from time to time. We will refer to any such indenture throughout this prospectus as the &#8220;subordinated indenture&#8221; and to the trustee under the senior or subordinated indenture as the &#8220;trustee.&#8221; The senior indenture and the subordinated indenture are sometimes collectively referred to in this prospectus as the &#8220;indentures.&#8221; The indentures will be subject to and governed by the Trust Indenture Act of 1939, as amended (the &#8220;Trust Indenture Act&#8221;). We included copies of the forms of the indentures as exhibits to our registration statement and they are incorporated into this prospectus by reference. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we issue debt securities at a discount from their principal amount, then, for purposes of calculating the aggregate initial offering price of the offered securities issued under this prospectus, we will include only the initial offering price of the debt securities and not the principal amount of the debt securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have summarized below the material provisions of the indentures and the debt securities, or indicated which material provisions will be described in the related prospectus supplement. The prospectus supplement relating to any particular securities offered will describe the specific terms of the securities, which may be in addition to or different from the general terms summarized in this prospectus. Because the summary in this prospectus and in any prospectus supplement does not contain all of the information that you may find useful, you should read the documents relating to the securities that are described in this prospectus or in any applicable prospectus supplement. Please read &#8220;Where You Can Find More Information&#8221; to find out how you can obtain a copy of those documents. Except as otherwise indicated, the terms of the indentures are identical. As used under this caption, the term &#8220;debt securities&#8221; includes the debt securities being offered by this prospectus and all other debt securities issued by us under the indentures. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The indentures: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">do not limit the amount of debt securities that we may issue; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">allow us to issue debt securities in one or more series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">do not require us to issue all of the debt securities of a series at the same time; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">allow us to reopen a series to issue additional debt securities without the consent of the holders of the debt securities of such series. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless we give you different information in the applicable prospectus supplement, the senior debt securities will be unsubordinated obligations and will rank equally with all of our other senior unsecured and unsubordinated indebtedness. Payments on the subordinated debt securities will be subordinated to the prior payment in full of all of our senior indebtedness, as described under &#8220;Description of Debt Securities&#8201;&#8212;&#8201;Subordination&#8221; and in the applicable prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each indenture provides that we may, but need not, designate more than one trustee under an indenture. Any trustee under an indenture may resign or be removed and a successor trustee may be appointed to act with respect to the series of debt securities administered by the resigning or removed trustee. If two or more persons are acting as trustee with respect to different series of debt securities, each trustee shall be a </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">trustee of a trust under the applicable indenture separate and apart from the trust administered by any other trustee. Except as otherwise indicated in this prospectus, any action described in this prospectus to be taken by each trustee may be taken by each trustee with respect to, and only with respect to, the one or more series of debt securities for which it is trustee under the applicable indenture. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The prospectus supplement for each offering will provide the following terms, where applicable: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the title of the debt securities and whether they are senior or subordinated; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the aggregate principal amount of the debt securities being offered, the aggregate principal amount of the debt securities outstanding as of the most recent practicable date and any limit on their aggregate principal amount, including the aggregate principal amount of debt securities authorized; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the price at which the debt securities will be issued, expressed as a&#160;percentage of the principal and, if other than the principal amount thereof, the portion of the principal amount thereof payable&#160;upon declaration of acceleration of the maturity thereof or, if applicable, the portion of the principal amount of such debt securities that is convertible into common stock or other securities of ours or the method by which any such portion shall be determined; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if convertible, the terms on which such debt securities are convertible, including the initial conversion price or rate and the conversion period and any applicable limitations on the ownership or transferability of common stock or other securities of ours received on conversion; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the date or dates, or the method for determining the date or dates, on which the principal of the debt securities will be payable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the fixed or variable interest rate or rates of the debt securities, or the method by which the interest rate or rates is determined; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the date or dates, or the method for determining the date or dates, from which interest will accrue; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the dates on which interest will be payable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the record dates for interest payment dates, or the method by which such dates will be determined; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the persons to whom interest will be payable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the basis upon which interest will be calculated if other than that of a 360-day year of twelve 30-day months; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any make-whole amount, which is the amount in addition to principal and interest that is required to be paid to the holder of a debt security as a result of any optional redemption or accelerated payment of such debt security, or the method for determining the make-whole amount; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the place or places where the principal of, and any premium or make-whole amount, and interest on, the debt securities will be payable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">where the debt securities may be surrendered for registration of transfer or conversion or exchange; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">where notices or demands to or upon us in respect of the debt securities and the applicable indenture may be served; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the times, prices and other terms and conditions upon which we may redeem the debt securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any obligation we have to redeem, repay or purchase the debt securities pursuant to any sinking fund or analogous provision or at the option of holders of the debt securities, and the times and prices at which we must redeem, repay or purchase the debt securities as a result of such obligation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the currency or currencies in which the debt securities are denominated and payable if other than United States dollars, which may be a foreign currency or&#160;units of two or more foreign currencies or a composite currency or currencies and the terms and conditions relating thereto, and the manner of determining the equivalent of such foreign currency in United States dollars; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether the principal of, and any premium or make-whole amount, or interest on, the debt securities of the series are to be payable, at our election or at the election of a holder, in a currency or currencies other than that in which the debt securities are denominated or stated to be payable, and other related terms and conditions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether the amount of payments of principal of, and any premium or make-whole amount, or interest on, the debt securities may be determined according to an index, formula or other method and how such amounts will be determined; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether the debt securities will be in registered form, bearer form, or both, and (i)&#160;if in registered form, the person to whom any interest shall be payable, if other than the person in whose name the security is registered at the close of business on the regular record date for such interest, or (ii)&#160;if in bearer form, the manner in which, or the person to whom, any interest on the security shall be payable if otherwise than upon presentation and surrender upon maturity; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any restrictions applicable to the offer, sale or delivery of securities in bearer form and the terms upon which securities in bearer form of the series may be exchanged for securities in registered form of the series and vice versa, if permitted by applicable laws and regulations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether any debt securities of the series are to be issuable initially in temporary global form and whether any debt securities of the series are to be issuable in permanent global form with or without coupons and, if so, whether beneficial owners of interests in any such permanent global security may, or shall be required to, exchange their interests for other debt securities of the series, and the manner in which interest shall be paid; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the identity of the depositary for securities in registered form, if such series are to be issuable as a global security; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the date as of which any debt securities in bearer form or in temporary global form shall be dated if other than the original issuance date of the first security of the series to be issued; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the applicability, if any, of the defeasance and covenant defeasance provisions described in this prospectus or in the applicable indenture; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether and under what circumstances we will pay any additional amounts on the debt securities in respect of any tax, assessment or governmental charge and, if so, whether we will have the option to redeem the debt securities in lieu of making such a payment; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether and under what circumstances the debt securities being offered are convertible into common stock or other securities of ours, as the case may be, including the conversion price or rate and the manner or calculation thereof; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the circumstances, if any, specified in the applicable prospectus supplement, under which beneficial owners of interests in the global security may obtain definitive debt securities and the manner in which payments on a permanent global debt security will be made if any debt securities are issuable in temporary or permanent global form; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any provisions granting special rights to holders of securities upon the occurrence of such events as specified in the applicable prospectus supplement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if the debt securities of such series are to be issuable in definitive form only upon receipt of certain certificates or other documents or satisfaction of other conditions, then the form and/or terms of such certificates, documents or conditions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the name of the applicable trustee and the nature of any material relationship with us or any of our affiliates, and the&#160;percentage of debt securities of the class necessary to require the trustee to take action; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any deletions from, modifications of or additions to our events of default or covenants with regard to such debt securities and any change in the right of any trustee or any of the holders to declare the principal amount of any of such debt securities due and payable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">applicable CUSIP numbers; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any other terms of such debt securities not inconsistent with the provisions of the applicable indenture. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may issue debt securities that provide for less than the entire principal amount thereof to be payable upon declaration of acceleration of the maturity of the debt securities. We refer to any such debt </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">securities throughout this prospectus as &#8220;original issue discount securities.&#8221; The applicable prospectus supplement will describe the United States federal income tax consequences and other relevant considerations applicable to original issue discount securities, including the portion of the principal amount thereof to be payable upon declaration of acceleration of the maturity of the debt securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Except as described in the indentures under &#8220;Compliance with Consolidation Provisions&#8221; and &#8220;Successor Entity&#8221; or as may be set forth in any prospectus supplement, the debt securities will not contain any provisions that (i)&#160;would limit our ability to incur indebtedness or (ii)&#160;would afford holders of debt securities protection in the event of (a)&#160;a highly leveraged or similar transaction involving us, or (b)&#160;a change of control or reorganization, restructuring, merger or similar transaction involving us that may adversely affect the holders of the debt securities. In the future, we may enter into transactions, such as the sale of all or substantially all of our assets or a merger or consolidation, that may have an adverse effect on our ability to service our indebtedness, including the debt securities, by, among other things, substantially reducing or eliminating our assets. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our governing instruments do not define the term &#8220;substantially all&#8221; as it relates to the sale of assets. Additionally, Delaware cases interpreting the term &#8220;substantially all&#8221; rely upon the facts and circumstances of each particular case. Consequently, to determine whether a sale of &#8220;substantially all&#8221; of our assets has occurred, a holder of debt securities must review the financial and other information that we have disclosed to the public. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will provide you with more information in the applicable prospectus supplement regarding any deletions, modifications, or additions to the events of default or covenants that are described below, including any addition of a covenant or other provision providing event risk or similar protection. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Payment</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless we give you different information in the applicable prospectus supplement, the principal of, and any premium or make-whole amount, and interest on, any series of the debt securities will be payable at the corporate trust office of the trustee. We will provide you with the address of the trustee in the applicable prospectus supplement. We may also pay interest by mailing a check to the address of the person entitled to it as it appears in the applicable register for the debt securities or by wire transfer of funds to that person at an account maintained within the United States. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">All monies that we pay to a paying agent or a trustee for the payment of the principal of, and any premium or make-whole amount, or interest on, any debt security will be repaid to us if unclaimed at the end of two&#160;years after the obligation underlying payment becomes due and payable. After funds have been returned to us, the holder of the debt security may look only to us for payment, without payment of interest for the period which we hold the funds. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Denomination, Interest, Registration and Transfer</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise described in the applicable prospectus supplement, the debt securities of any series will be issuable in denominations of $1,000 and integral multiples of $1,000. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to the limitations imposed upon debt securities that are evidenced by a computerized entry in the records of a depository company rather than by physical delivery of a note, a holder of debt securities of any series may: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">exchange them for any authorized denomination of other debt securities of the same series and of a like aggregate principal amount and kind upon surrender of such debt securities at the corporate trust office of the applicable trustee or at the office of any transfer agent that we designate for such purpose; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">surrender them for registration of transfer or exchange at the corporate trust office of the applicable trustee or at the office of any transfer agent that we designate for such purpose. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Every debt security surrendered for registration of transfer or exchange must be duly endorsed or accompanied by a written instrument of transfer satisfactory to the applicable trustee or transfer agent. Payment of a service charge will not be required for any registration of transfer or exchange of any debt </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">securities, but we or the trustee may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith. If in addition to the applicable trustee, the applicable prospectus supplement refers to any transfer agent initially designated by us for any series of debt securities, we may at any time rescind the designation of any such transfer agent or approve a change in the location through which any such transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for such series. We may at any time designate additional transfer agents for any series of debt securities. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Neither we, nor any trustee, will be required to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">issue, register the transfer of or exchange debt securities of any series during a period beginning at the opening of business 15&#160;days before the day that a notice of redemption of less than all the outstanding debt securities of the same series is mailed and ending at the close of business on the day of such mailing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">register the transfer of or exchange any debt security, or portion thereof, so selected for redemption, in whole or in part, except the unredeemed portion of any debt security being redeemed in part; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">issue, register the transfer of or exchange any debt security that has been surrendered for repayment at the option of the holder, except the portion, if any, of such debt security not to be so repaid. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Merger, Consolidation or Sale of Assets</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The indentures provide that we may, without the consent of the holders of any outstanding debt securities, (i)&#160;consolidate with, (ii)&#160;sell, lease or convey all or substantially all of our assets to, or (iii)&#160;merge with or into, any other entity provided that: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">either we are the continuing entity, or the successor entity, if other than us, assumes the obligations (a)&#160;to pay the principal of, and any premium or make-whole amount, and interest on, all of the debt securities and (b)&#160;to duly perform and observe all of the covenants and conditions contained in each indenture; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the holders of any outstanding debt securities shall be entitled to receive upon conversion or exchange of such debt securities the number of securities or property to which a holder of the number of shares of common stock or other securities of the Company deliverable upon conversion or exchange of such debt securities would have been entitled had such conversion or exchange occurred immediately prior to the transaction; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">an officers&#8217; certificate and legal opinion covering such conditions are delivered to each applicable trustee. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Covenants</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Existence</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Except as described therein under &#8220;Company May Consolidate, Etc.,&#8221; the indentures require us to do or cause to be done all things necessary to preserve and keep in full force and effect our existence, rights and franchises. However, the indentures do not require us to preserve any right or franchise if we determine that any right or franchise is no longer desirable in the conduct of our business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Provision of financial information</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The indentures require us to (i)&#160;within 30&#160;days of each of the respective dates by which we are required to file our annual reports, quarterly reports and other documents with the SEC, file with the trustee copies of the annual report, quarterly report and other documents that we file with the SEC under Section&#160;13 or 15(d) of the Exchange Act and (ii)&#160;file with the trustee and the SEC any additional information, documents and reports regarding compliance by us with the conditions and covenants of the indentures, as required. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Additional covenants</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The applicable prospectus supplement will set forth any of our additional covenants relating to any series of debt securities. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Events of Default, Notice and Waiver</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless the applicable prospectus supplement states otherwise, when we refer to &#8220;events of default&#8221; as defined in the indentures with respect to any series of debt securities, we mean: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">default in the payment of any installment of interest on any debt security of such series continuing for 90&#160;days; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">default in the payment of principal of, or any premium or make-whole amount on, any debt security of such series as and when the same shall become due and payable, whether at maturity, upon redemption, by declaration or otherwise; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">default in making any sinking fund payment as required for any debt security of such series as and when due and payable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">default in the performance or breach of any covenant or warranty in the debt securities or in the indenture by us continuing for 90&#160;days after written notice as provided in the applicable indenture, but not of a covenant added to the indenture solely for the benefit of a series of debt securities issued thereunder other than such series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">bankruptcy, insolvency or reorganization, or court appointment of a receiver, liquidator or trustee of us; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any other event of default provided with respect to a particular series of debt securities. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Notice of any such default shall be given to us by the trustee, or to us and the trustee by the holders of at least 25% in principal amount of the outstanding debt securities of that series. The written notice shall specify such default and require us to cause such indebtedness to be discharged or cause such acceleration to be rescinded or annulled and shall state that such notice is a &#8220;Notice of Default&#8221; under such indenture. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If an event of default occurs and is continuing with respect to debt securities of any series outstanding, then the applicable trustee or the holders of 25% or more in principal amount of the debt securities of that series will have the right to declare the principal amount of all the debt securities of that series to be due and payable. However, at any time after such a declaration of acceleration has been made, but before a judgment or decree for payment of the money due has been obtained by the applicable trustee, the holders of at least a majority in principal amount of outstanding debt securities of such series or of all debt securities then outstanding under the applicable indenture may rescind and annul such declaration and its consequences if: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">we have deposited with the applicable trustee all matured installments of interest upon and the principal of (and premium, if any, on) all the outstanding debt securities of such series that shall have become other than by acceleration (with interest upon such principal and premium, if any, and upon overdue installments of interest), plus applicable fees, expenses, disbursements and advances of the applicable trustee; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">all events of default, other than the non-payment of accelerated principal (and premium, if any) and accrued and unpaid interest on debt securities of such series, have been cured or waived. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The indentures require each trustee to give notice to the holders of debt securities within the later of 90&#160;days after of a default occurs and 30&#160;days after it is actually known to a trustee or written notice of it is received by the trustee, unless such default has been cured or waived. However, the trustee may withhold notice if specified persons of such trustee consider such withholding to be in the interest of the holders of debt securities. The trustee may not withhold notice of a default in the payment of principal, any premium or interest on any debt security of such series or in the payment of any sinking fund installment in respect of any debt security of such series. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The indentures provide that holders of debt securities of any series may not institute any proceedings, judicial or otherwise, with respect to such indenture or for any remedy under the indenture, unless the trustee fails to act for a period of 90&#160;days after the trustee has received a written request to institute proceedings in respect of an event of default from the holders of 25% or more in principal amount of the outstanding debt securities of such series, as well as an offer of indemnity reasonably satisfactory to the trustee. However, this provision will not prevent any holder of debt securities from instituting suit for the enforcement of </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">payment of the principal of, and any premium or make-whole amount, and interest on, such debt securities at the respective due dates thereof. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The indentures provide that, subject to provisions in each indenture relating to its duties in the case of a default, a trustee has no obligation to exercise any of its rights or powers at the request or direction of any holders of any series of debt securities then outstanding under the indenture, unless the holders have offered to the trustee reasonable security or indemnity. The holders of at least a majority in principal amount of the outstanding debt securities of any series or of all debt securities then outstanding under an indenture shall have the right to direct the time, method and place of conducting any proceeding for any remedy available to the applicable trustee, or of exercising any trust or power conferred upon such trustee. However, a trustee may refuse to follow any direction which: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">is in conflict with any law or the applicable indenture; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">may involve the trustee in personal liability; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">may be unduly prejudicial to the holders of debt securities of the series not joining the proceeding. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Within 120&#160;days after the close of each fiscal year, we will be required to deliver to each trustee a certificate, signed by one of our several specified officers, stating whether or not that officer has knowledge of any default under the applicable indenture. If the officer has knowledge of any default, the notice must specify the nature and status of the default. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Modification of the Indentures</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The indentures provide that no modifications or amendments may, without the consent of each affected holder, impair the right of any holder of any debt security to (i)&#160;receive payment of the principal of (and premium, if any) and interest on the debt securities, as provided in the debt securities or indentures, on or after the respective due dates expressed in the debt securities or the indentures (or in the case of redemption, on the redemption date) or (ii)&#160;institute suit for the enforcement of any such payment on or after such respective dates or redemption date. Furthermore, no modification or amendment may, without the consent of the holders of all of the debt securities affected by the modification or amendment: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">change the stated maturity of the principal of, or any premium or make-whole amount on, or any installment of principal of or interest on, any such debt security, or reduce the amount of interest payable thereon or principal thereof; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">reduce the&#160;percentage in principal amount of any outstanding debt securities necessary to modify or amend the applicable indenture with respect to such debt securities. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The holders of a majority in aggregate principal amount of the outstanding debt securities of each affected series may, on behalf of all holders of debt securities of that series, waive, insofar as that series is concerned, our compliance with material restrictive covenants of the applicable indenture. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We and our respective trustee may make modifications and amendments of an indenture without the consent of any holder of debt securities, including for any of the following purposes: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to evidence the succession of another person to us as obligor under such indenture in compliance with the Trust Indenture Act; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to add to our covenants for the benefit of the holders of all or any series of debt securities or to surrender any right or power conferred upon us in such indenture; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to add events of default for the benefit of the holders of all or any series of debt securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to add or change any provisions of an indenture (i)&#160;to change or eliminate restrictions on the payment of principal of, or premium or make-whole amount, or interest on, debt securities in bearer form, (ii)&#160;to permit or facilitate the issuance of debt securities in uncertificated form, or (iii)&#160;that otherwise does not adversely affect the interests of the holders of the debt securities of any series in any material respect; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to establish the form or terms of debt securities of any series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to provide for the acceptance of appointment by a successor trustee or facilitate the administration of the trusts under an indenture by more than one trustee; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to cure any ambiguity, defect or inconsistency in an indenture. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Subordination</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise provided in the applicable prospectus supplement, subordinated debt securities will be subject to the following subordination provisions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Upon any distribution to our creditors in a liquidation, dissolution or reorganization, the payment of the principal of and interest on any subordinated debt securities will be subordinated to the extent provided in the applicable indenture in right of payment to the prior payment in full of all senior debt. However, our obligation to make payments of the principal of and interest on such subordinated debt securities otherwise will not be affected. No payment of principal or interest will be permitted to be made on subordinated debt securities at any time if a default on senior debt exists that permits the holders of such senior debt to accelerate its maturity and the default is the subject of judicial proceedings or we receive notice of the default. After all senior debt is paid in full and until the subordinated debt securities are paid in full, holders of subordinated debt securities will be subrogated to the rights of holders of senior debt to the extent that distributions otherwise payable to holders of subordinated debt securities have been applied to the payment of senior debt. The subordinated indenture will not restrict the amount of senior debt or other indebtedness of ours. As a result of these subordination provisions, in the event of a distribution of assets upon insolvency, holders of subordinated debt securities may recover less, ratably, than our general creditors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The term &#8220;senior debt&#8221; will be defined in the applicable indenture as the principal of and interest on, or substantially similar payments to be made by us in respect of, other outstanding indebtedness, whether outstanding at the date of execution of the applicable indenture or subsequently incurred, created or assumed. The prospectus supplement may include a description of additional terms implementing the subordination feature. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">No restrictions will be included in any indenture relating to subordinated debt securities upon the creation of additional senior debt. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If this prospectus is being delivered in connection with the offering of a series of subordinated debt securities, the accompanying prospectus supplement or the information incorporated in this prospectus by reference will set forth the approximate amount of senior debt outstanding as of the end of our most recent fiscal quarter. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Discharge, Defeasance and Covenant Defeasance</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise indicated in the applicable prospectus supplement, the indentures allow us to discharge our obligations to holders of any series of debt securities issued under any indenture when: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">either (i)&#160;all securities of such series have already been delivered to the applicable trustee for cancellation; or (ii)&#160;all securities of such series have not already been delivered to the applicable trustee for cancellation but (a)&#160;have become due and payable, (b)&#160;will become due and payable within one year, or (c)&#160;if redeemable at our option, are to be redeemed within one year, and we have irrevocably deposited with the applicable trustee, in trust, funds in such currency or currencies, currency unit or&#160;units or composite currency or currencies in which such debt securities are payable, an amount sufficient to pay the entire indebtedness on such debt securities in respect of principal and any premium or make-whole amount, and interest to the date of such deposit if such debt securities have become due and payable or, if they have not, to the stated maturity or redemption date; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">we have paid or caused to be paid all other sums payable; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">an officers&#8217; certificate and an opinion of counsel stating the conditions to discharging the debt securities have been satisfied has been delivered to the trustee. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise indicated in the applicable prospectus supplement, the indentures provide that, upon our irrevocable deposit with the applicable trustee, in trust, of an amount, in such currency or currencies, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">currency unit or&#160;units or composite currency or currencies in which such debt securities are payable at stated maturity, or government obligations, or both, applicable to such debt securities, which through the scheduled payment of principal and interest in accordance with their terms will provide money in an amount sufficient to pay the principal of, and any premium or make-whole amount, and interest on, such debt securities, and any mandatory sinking fund or analogous payments thereon, on the scheduled due dates therefor, the we may elect either: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to defease and be discharged from any and all obligations with respect to such debt securities; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to be released from our obligations with respect to such debt securities under the applicable indenture or, if provided in the applicable prospectus supplement, our obligations with respect to any other covenant, and any omission to comply with such obligations shall not constitute an event of default with respect to such debt securities. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">When we use the term &#8220;government obligations,&#8221; we mean securities that are: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">direct obligations of the United States or the government that issued the foreign currency in which the debt securities of a particular series are payable, for the payment of which its full faith and credit is pledged; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">obligations of a person controlled or supervised by and acting as an agency or instrumentality of the United States or other government that issued the foreign currency in which the debt securities of such series are payable, the payment of which is unconditionally guaranteed as a full faith and credit obligation by the United States or such other government, which are not callable or redeemable at the option of the issuer thereof and shall also include a depository receipt issued by a bank or trust company as custodian with respect to any such government obligation or a specific payment of interest on or principal of any such government obligation held by such custodian for the account of the holder of a depository receipt. However, except as required by law, such custodian is not authorized to make any deduction from the amount payable to the holder of such depository receipt from any amount received by the custodian in respect of the government obligation or the specific payment of interest on or principal of the government obligation evidenced by such depository receipt. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise provided in the applicable prospectus supplement, if after we have deposited funds and/or government obligations to effect defeasance or covenant defeasance with respect to debt securities of any series, (i)&#160;the holder of a debt security of such series is entitled to, and does, elect under the terms of the applicable indenture or the terms of such debt security to receive payment in a currency, currency unit or composite currency other than that in which such deposit has been made in respect of such debt security, or (ii)&#160;a conversion event occurs in respect of the currency, currency unit or composite currency in which such deposit has been made, the indebtedness represented by such debt security will be deemed to have been, and will be, fully discharged and satisfied through the payment of the principal of, and premium or make-whole amount, and interest on, such debt security as they become due out of the proceeds yielded by converting the amount so deposited in respect of such debt security into the currency, currency unit or composite currency in which such debt security becomes payable as a result of such election or such cessation of usage based on the applicable market exchange rate. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">When we use the term &#8220;conversion event,&#8221; we mean the cessation of use of: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a currency, currency unit or composite currency both by the government of the country that issued such currency and for the settlement of transactions by a central bank or other public institutions of or within the international banking community; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the European Currency Unit both within the European Monetary System and for the settlement of transactions by public institutions of or within the European Communities; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any currency unit or composite currency other than the European Currency Unit for the purposes for which it was established. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise provided in the applicable prospectus supplement, all payments of principal of, and any premium or make-whole amount, and interest on, any debt security that is payable in a foreign currency that ceases to be used by its government of issuance shall be made in United States dollars. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The applicable prospectus supplement may further describe the provisions, if any, permitting such defeasance or covenant defeasance, including any modifications to the provisions described above, with respect to the debt securities of or within a particular series. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Conversion Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The terms and conditions, if any, upon which the debt securities are convertible into common stock or other securities of ours will be set forth in the applicable prospectus supplement. The terms will include whether the debt securities are convertible into shares of common stock or other securities of ours, the conversion price, or manner of calculation thereof, the conversion period, provisions as to whether conversion will be at the issuing company&#8217;s option or the option of the holders, the events requiring an adjustment of the conversion price and provisions affecting conversion in the event of the redemption of the debt securities and any restrictions on conversion. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Global Securities</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The debt securities of a series may be issued in whole or in part in the form of one or more global securities that will be deposited with, or on behalf of, a depository identified in the applicable prospectus supplement relating to such series. Global securities, if any, issued in the United States are expected to be deposited with The Depository Trust Company (&#8220;DTC&#8221;), as depository. We may issue global securities in either registered or bearer form and in either temporary or permanent form. We will describe the specific terms of the depository arrangement with respect to a series of debt securities in the applicable prospectus supplement relating to such series. We expect that unless the applicable prospectus supplement provides otherwise, the following provisions will apply to depository arrangements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Once a global security is issued, the depository for such global security or its nominee will credit on its book-entry registration and transfer system the respective principal amounts of the individual debt securities represented by such global security to the accounts of participants that have accounts with such depository. Such accounts shall be designated by the underwriters, dealers or agents with respect to such debt securities or by us if we offer such debt securities directly. Ownership of beneficial interests in such global security will be limited to participants with the depository or persons that may hold interests through those participants. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We expect that, under procedures established by DTC, ownership of beneficial interests in any global security for which DTC is the depository will be shown on, and the transfer of that ownership will be effected only through, records maintained by DTC or its nominee, with respect to beneficial interests of participants with the depository, and records of participants, with respect to beneficial interests of persons who hold through participants with the depository. Neither we nor the trustee will have any responsibility or liability for any aspect of the records of DTC or for maintaining, supervising or reviewing any records of DTC or any of its participants relating to beneficial ownership interests in the debt securities. The laws of some states require that certain purchasers of securities take physical delivery of such securities in definitive form. Such limits and laws may impair the ability to own, pledge or transfer beneficial interest in a global security. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">So long as the depository for a global security or its nominee is the registered owner of such global security, such depository or such nominee, as the case may be, will be considered the sole owner or holder of the debt securities represented by the global security for all purposes under the applicable indenture. Except as described below or in the applicable prospectus supplement, owners of beneficial interest in a global security will not be entitled to have any of the individual debt securities represented by such global security registered in their names, will not receive or be entitled to receive physical delivery of any such debt securities in definitive form and will not be considered the owners or holders thereof under the applicable indenture. Beneficial owners of debt securities evidenced by a global security will not be considered the owners or holders thereof under the applicable indenture for any purpose, including with respect to the giving of any direction, instructions or approvals to the trustee under the indenture. Accordingly, each person owning a beneficial interest in a global security with respect to which DTC is the depository must rely on the procedures of DTC and, if such person is not a participant with the depository, on the procedures of the participant through which such person owns its interests, to exercise any rights of a holder under the applicable indenture. We understand that, under existing industry practice, if DTC requests any action of holders or if an owner of a beneficial interest in a global security desires to give or take any action which a holder is entitled to give or take under the applicable indenture, DTC would authorize the participants holding the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:24pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">relevant beneficial interest to give or take such action, and such participants would authorize beneficial owners through such participants to give or take such actions or would otherwise act upon the instructions of beneficial owners holding through them. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Payments of principal of, and any premium or make-whole amount, and interest on, individual debt securities represented by a global security registered in the name of a depository or its nominee will be made to or at the direction of the depository or its nominee, as the case may be, as the registered owner of the global security under the applicable indenture. Under the terms of the applicable indenture, we and the trustee may treat the persons in whose name debt securities, including a global security, are registered as the owners thereof for the purpose of receiving such payments. Consequently, neither we nor the trustee have or will have any responsibility or liability for the payment of such amounts to beneficial owners of debt securities including principal, any premium or make-whole amount, or interest. We believe, however, that it is currently the policy of DTC to immediately credit the accounts of relevant participants with such payments, in amounts proportionate to their respective holdings of beneficial interests in the relevant global security as shown on the records of DTC or its nominee. We also expect that payments by participants to owners of beneficial interests in such global security held through such participants will be governed by standing instructions and customary practices, as is the case with securities held for the account of customers in bearer form or registered in street name, and will be the responsibility of such participants. Redemption notices with respect to any debt securities represented by a global security will be sent to the depository or its nominee. If less than all of the debt securities of any series are to be redeemed, we expect the depository to determine the amount of the interest of each participant in such debt securities to be redeemed to be determined by lot. Neither we, the trustee, any paying agent nor the security registrar for such debt securities will have any responsibility or liability for any aspect of the records relating to or payments made on account of beneficial ownership interests in the global security for such debt securities or for maintaining any records with respect thereto. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Neither we nor the trustee will be liable for any delay by the holders of a global security or the depository in identifying the beneficial owners of debt securities, and we and the trustee may conclusively rely on, and will be protected in relying on, instructions from the holder of a global security or the depository for all purposes. The rules applicable to DTC and its participants are on file with the SEC. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If a depository for any debt securities is at any time unwilling, unable or ineligible to continue as depository and we do not appoint a successor depository within 90&#160;days, we will issue individual debt securities in exchange for the global security representing such debt securities. In addition, we may at any time and at our sole discretion, subject to any limitations described in the applicable prospectus supplement relating to such debt securities, determine not to have any of such debt securities represented by one or more global securities and in such event will issue individual debt securities in exchange for the global security or securities representing such debt securities. Individual debt securities so issued will be issued in denominations of $1,000 and integral multiples of $1,000. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The debt securities of a series may also be issued in whole or in part in the form of one or more bearer global securities that will be deposited with a depository, or with a nominee for such depository, identified in the applicable prospectus supplement. Any such bearer global securities may be issued in temporary or permanent form. The specific terms and procedures, including the specific terms of the depositary arrangement, with respect to any portion of a series of debt securities to be represented by one or more bearer global securities will be described in the applicable prospectus supplement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">No Recourse</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There is no recourse under any obligation, covenant or agreement in the applicable indenture or with respect to any security against any of our or our successor&#8217;s past, present or future shareholders, employees, officers or directors.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tDOW">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF WARRANTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following description, together with the additional information we may include in any applicable prospectus supplements, summarizes the material terms and provisions of the warrants that we may offer under this prospectus and the related warrant agreements and warrant certificates. While the terms summarized below will apply generally to any warrants that we may offer, we will describe the particular terms of any series of warrants in more detail in the applicable prospectus supplement. If we indicate in the prospectus supplement, the terms of any warrants offered under that prospectus supplement may differ from the terms described below. Specific warrant agreements will contain additional important terms and provisions and will be incorporated by reference as an exhibit to the registration statement, which includes this prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may issue warrants for the purchase of common stock, preferred stock and/or debt securities in one or more series. We may issue warrants independently or together with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from these securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will evidence each series of warrants by warrant certificates that we will issue under a separate warrant agreement. We will enter into the warrant agreement with a warrant agent. We will indicate the name and address of the warrant agent in the applicable prospectus supplement relating to a particular series of warrants. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will describe in the applicable prospectus supplement the terms of the series of warrants, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the offering price and aggregate number of warrants offered; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the currency for which the warrants may be purchased; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if applicable, the date on and after which the warrants and the related securities will be separately transferable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may be purchased upon such exercise; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreement and the warrants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the terms of any rights to redeem or call the warrants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the periods during which, and places at which, the warrants are exercisable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the manner of exercise; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the dates on which the right to exercise the warrants will commence and expire; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the manner in which the warrant agreement and warrants may be modified; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">federal income tax consequences of holding or exercising the warrants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the terms of the securities issuable upon exercise of the warrants; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any other specific terms, preferences, rights or limitations of or restrictions on the warrants. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tDOU">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF UNITS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may issue&#160;units comprised of shares of common stock, shares of preferred stock, debt securities and warrants in any combination. We may issue&#160;units in such amounts and in as many distinct series as we wish. This section outlines certain provisions of the&#160;units that we may issue. If we issue&#160;units, they will be issued under one or more unit agreements to be entered into between us and a bank or other financial institution, as unit agent. The information described in this section may not be complete in all respects and is qualified entirely by reference to the unit agreement with respect to the&#160;units of any particular series. The specific terms of any series of&#160;units offered will be described in the applicable prospectus supplement. If so described in a particular supplement, the specific terms of any series of&#160;units may differ from the general description of terms presented below. We urge you to read any prospectus supplement related to any series of&#160;units we may offer, as well as the complete unit agreement and unit certificate that contain the terms of the&#160;units. If we issue&#160;units, forms of unit agreements and unit certificates relating to such&#160;units will be incorporated by reference as exhibits to the registration statement, which includes this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each unit that we may issue will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date. The applicable prospectus supplement may describe: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the designation and terms of the&#160;units and of the securities comprising the&#160;units, including whether and under what circumstances those securities may be held or transferred separately; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any provisions of the governing unit agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the price or prices at which such&#160;units will be issued; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the applicable United States federal income tax considerations relating to the&#160;units; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any provisions for the issuance, payment, settlement, transfer or exchange of the&#160;units or of the securities comprising the&#160;units; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any other terms of the&#160;units and of the securities comprising the&#160;units. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The provisions described in this section, as well as those described under &#8220;Description of Capital Stock,&#8221; &#8220;Description of Debt Securities&#8221; and &#8220;Description of Warrants&#8221; will apply to the securities included in each unit, to the extent relevant and as may be updated in any prospectus supplements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Issuance in Series</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may issue&#160;units in such amounts and in as many distinct series as we wish. This section summarizes terms of the&#160;units that apply generally to all series. Most of the financial and other specific terms of your series will be described in the applicable prospectus supplement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Unit Agreements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will issue the&#160;units under one or more unit agreements to be entered into between us and a bank or other financial institution, as unit agent. We may add, replace or terminate unit agents from time to time. We will identify the unit agreement under which each series of&#160;units will be issued and the unit agent under that agreement in the applicable prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following provisions will generally apply to all unit agreements unless otherwise stated in the applicable prospectus supplement: </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Modification without Consent</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We and the applicable unit agent may amend any unit or unit agreement without the consent of any holder: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to cure any ambiguity, including modifying any provisions of the governing unit agreement that differ from those described below; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to correct or supplement any defective or inconsistent provision; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to make any other change that we believe is necessary or desirable and will not adversely affect the interests of the affected holders in any material respect. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We do not need any approval to make changes that affect only&#160;units to be issued after the changes take effect. We may also make changes that do not adversely affect a particular unit in any material respect, even if they adversely affect other&#160;units in a material respect. In those cases, we do not need to obtain the approval of the holder of the unaffected unit; we need only obtain any required approvals from the holders of the affected&#160;units. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Modification with Consent</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may not amend any particular unit or a unit agreement with respect to any particular unit unless we obtain the consent of the holder of that unit, if the amendment would: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">impair any right of the holder to exercise or enforce any right under a security included in the unit if the terms of that security require the consent of the holder to any changes that would impair the exercise or enforcement of that right; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">reduce the&#160;percentage of outstanding&#160;units or any series or class the consent of whose holders is required to amend that series or class, or the applicable unit agreement with respect to that series or class, as described below. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any other change to a particular unit agreement and the&#160;units issued under that agreement would require the following approval: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if the change affects only the&#160;units of a particular series issued under that agreement, the change must be approved by the holders of a majority of the outstanding&#160;units of that series; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.39pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if the change affects the&#160;units of more than one series issued under that agreement, it must be approved by the holders of a majority of all outstanding&#160;units of all series affected by the change, with the&#160;units of all the affected series voting together as one class for this purpose. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These provisions regarding changes with majority approval also apply to changes affecting any securities issued under a unit agreement, as the governing document. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In each case, the required approval must be given by written consent. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Unit Agreements Will Not Be Qualified under Trust Indenture Act</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">No unit agreement will be qualified as an indenture, and no unit agent will be required to qualify as a trustee, under the Trust Indenture Act. Therefore, holders of&#160;units issued under unit agreements will not have the protections of the Trust Indenture Act with respect to their&#160;units. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Mergers and Similar Transactions Permitted; No Restrictive Covenants or Events of Default</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The unit agreements will not restrict our ability to merge or consolidate with, or sell our assets to, another corporation or other entity or to engage in any other transactions. If at any time we merge or consolidate with, or sell our assets substantially as an entirety to, another corporation or other entity, the successor entity will succeed to and assume our obligations under the unit agreements. We will then be relieved of any further obligation under these agreements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The unit agreements will not include any restrictions on our ability to put liens on our assets, nor will they restrict our ability to sell our assets. The unit agreements also will not provide for any events of default or remedies upon the occurrence of any events of default. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Governing Law</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The unit agreements and the&#160;units will be governed by Delaware law. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:130pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Form, Exchange and Transfer</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless the accompanying prospectus supplement states otherwise, we will issue each unit in global&#8201;&#8212;&#8201;i.e., book-entry&#8201;&#8212;&#8201;form only. Units in book-entry form will be represented by a global security registered in the name of a depositary, which will be the holder of all the&#160;units represented by the global security. Those who own beneficial interests in a unit will do so through participants in the depositary&#8217;s system, and the rights of these indirect owners will be governed solely by the applicable procedures of the depositary and its participants. We will describe book-entry securities, and other terms regarding the issuance and registration of the&#160;units in the applicable prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless the accompanying prospectus supplement states otherwise, each unit and all securities comprising the unit will be issued in the same form. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If we issue any&#160;units in registered, non-global form, the following will apply to them. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The&#160;units will be issued in the denominations stated in the applicable prospectus supplement. Holders may exchange their&#160;units for&#160;units of smaller denominations or combined into fewer&#160;units of larger denominations, as long as the total amount is not changed. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Holders may exchange or transfer their&#160;units at the office of the unit agent. Holders may also replace lost, stolen, destroyed or mutilated&#160;units at that office. We may appoint another entity to perform these functions or perform them ourselves. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Holders will not be required to pay a service charge to transfer or exchange their&#160;units, but they may be required to pay for any tax or other governmental charge associated with the transfer or exchange. The transfer or exchange, and any replacement, will be made only if our transfer agent is satisfied with the holder&#8217;s proof of legal ownership. The transfer agent may also require an indemnity before replacing any&#160;units. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">If we have the right to redeem, accelerate or settle any&#160;units before their maturity, and we exercise our right as to less than all those&#160;units or other securities, we may block the exchange or transfer of those&#160;units during the period beginning 15&#160;days before the day we mail the notice of exercise and ending on the day of that mailing, in order to freeze the list of holders to prepare the mailing. We may also refuse to register transfers of or exchange any unit selected for early settlement, except that we will continue to permit transfers and exchanges of the unsettled portion of any unit being partially settled. We may also block the transfer or exchange of any unit in this manner if the unit includes securities that are or may be selected for early settlement. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Only the depositary will be entitled to transfer or exchange a unit in global form, since it will be the sole holder of the unit. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Payments and Notices</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In making payments and giving notices with respect to our&#160;units, we will follow the procedures as described in the applicable prospectus supplement. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tPOD">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PLAN OF DISTRIBUTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may sell the securities from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination of these methods. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">at a fixed price or prices, which may be changed; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">at market prices prevailing at the time of sale; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">at prices related to such prevailing market prices; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">at negotiated prices. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may also sell equity securities covered by this registration statement in an &#8220;at the market offering&#8221; as defined in Rule&#160;415 under the Securities Act. Such offering may be made into an existing trading market for such securities in transactions at other than a fixed price, either: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">on or through the facilities of The Nasdaq Global Market or any other securities exchange or quotation or trading service on which such securities may be listed, quoted or traded at the time of sale; and/or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to or through a market maker otherwise than on The Nasdaq Global Market or such other securities exchanges or quotation or trading services. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Such at the market offerings, if any, may be conducted by underwriters acting as principal or agent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A prospectus supplement or supplements (and any related free writing prospectus that we may authorize to be provided to you) will describe the terms of the offering of the securities, including, to the extent applicable: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the name or names of any underwriters, dealers or agents, if any; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the purchase price of the securities and the proceeds we will receive from the sale; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any options under which underwriters may purchase additional securities from us; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any agency fees or underwriting discounts and other items constituting agents&#8217; or underwriters&#8217; compensation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any public offering price; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any discounts or concessions allowed or re-allowed or paid to dealers; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any securities exchange or market on which the securities may be listed. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Only underwriters named in the prospectus supplement are underwriters of the securities offered by the prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be&#160;subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters will be obligated to purchase all of the securities offered by the prospectus supplement. Any public offering price and any discounts or concessions allowed or re-allowed or paid to dealers may change from time to time. We may use underwriters with whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may sell securities directly or through agents we designate from time to time. We will name any agent involved in the offering and sale of securities, and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis for the period of its appointment. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:200pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may authorize agents or underwriters to solicit offers by certain types of institutional investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may provide agents and underwriters with indemnification against civil liabilities related to offerings pursuant to this prospectus, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to these liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All securities we offer, other than our shares of common stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids in accordance with Regulation&#160;M under the Exchange Act. Overallotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. These transactions may be effected on any exchange or over-the-counter market or otherwise. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any underwriters who are qualified market makers on The Nasdaq Global Market may engage in passive market making transactions in the securities on The Nasdaq Global Market in accordance with Rule&#160;103 of Regulation&#160;M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market maker&#8217;s bid, however, the passive market maker&#8217;s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">27</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tLEMA">&#8203;</a><a name="tEXP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:388pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LEGAL MATTERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Certain legal matters, including the legality of the securities offered, will be passed upon for us by Gibson, Dunn &amp; Crutcher LLP, San Francisco, California. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXPERTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Ernst &amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements as of December&#160;31, 2021 and 2020 and for each of the&#160;years then ended, included in our <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1377121/000155837022002385/ptgx-20211231x10k.htm">Annual Report on Form 10-K for the year ended December&#160;31, 2021</a>, and the effectiveness of our internal control over financial reporting as of December&#160;31, 2021, as set forth in their reports, which are incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst &amp; Young LLP&#8217;s report, given on their authority as experts in accounting and auditing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The financial statements for the year ended December&#160;31, 2019 incorporated in this prospectus by reference to the Annual Report on Form 10-K for the year ended December&#160;31, 2021 have been so incorporated in reliance on the report of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">28</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tWCFM">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:432pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">WHERE YOU CAN FIND MORE INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We file annual, quarterly and other reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&#8217;s website at www.sec.gov. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, including any amendments to those reports, and other information that we file with or furnish to the SEC pursuant to Section&#160;13(a) or 15(d) of the Exchange Act can also be accessed free of charge through the Internet. These filings will be available as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus is part of a registration statement that we filed with the SEC. This prospectus omits some information contained in the registration statement in accordance with SEC rules and regulations. You should review the information and exhibits in the registration statement for further information about us and our subsidiaries and the securities we are offering. Statements in this prospectus concerning any document we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to these filings. You should review the complete document to evaluate these statements. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">29</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tIOCIBR">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:96pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The SEC allows us to incorporate by reference the information and reports we file with it, which means that we can disclose important information to you by referring you to these documents. The information incorporated by reference is an important part of this prospectus, and information that we file after the date hereof with the SEC will automatically update and supersede the information already incorporated by reference. We are incorporating by reference the documents listed below: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1377121/000155837022002385/ptgx-20211231x10k.htm">Annual Report on Form 10-K for the year ended December&#160;31, 2021 filed with the SEC on February&#160;28, 2022</a> (and any portions of our <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1377121/000110465922045545/tm223475-1_def14a.htm">Definitive Proxy Statement on Schedule&#160;14A filed on April&#160;13, 2022</a> that are incorporated by reference into our <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1377121/000155837022002385/ptgx-20211231x10k.htm">Annual Report on Form 10-K for the year ended December&#160;31, 2021); </a></font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our Quarterly Reports on Form 10-Q for the quarters ended March&#160;31, 2022, filed with the SEC on <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1377121/000155837022007438/ptgx-20220331x10q.htm">May&#160;5, 2022</a>, and June&#160;30, 2022, filed with the SEC on <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1377121/000155837022012277/ptgx-20220630x10q.htm">August&#160;4, 2022</a>; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our Current Reports on Form 8-K filed with the SEC on <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1377121/000110465922025661/tm227311d1_8k.htm">February&#160;22, 2022</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1377121/000110465922037018/tm2210222d1_8k.htm">March&#160;23, 2022</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1377121/000110465922041035/tm2210916d1_8k.htm">March&#160;31, 2022</a> and <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1377121/000110465922067589/tm2217556d1_8k.htm">June&#160;2, 2022</a>; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the description of our common stock set forth in our registration statement on <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1377121/000119312516675653/d223095d8a12ba.htm">Form 8-A, filed with the SEC on August&#160;9, 2016</a>, including any amendments thereto or reports filed for the purposes of updating this description, including <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1377121/000155837022002385/ptgx-20211231xex4d7.htm">Exhibit&#160;4.7 to our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, filed with the SEC on February&#160;28, 2022. </a></font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All documents we file with the SEC pursuant to Sections&#160;13(a), 13(c), 14 or 15(d) of the Exchange Act shall be deemed incorporated by reference in this prospectus and to be a part of this prospectus from the date of filing of those documents, with the exception of any portion of any report or document that is not deemed &#8220;filed&#8221; under such provisions on or after the date of this prospectus, until the earlier of the date on which: (1)&#160;all of the securities registered hereunder have been sold; or (2)&#160;the registration statement of which this prospectus is a part has been withdrawn. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under no circumstances will any information filed under Items&#160;2.02 or 7.01 of Current Report on Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon written or oral request, we will provide without charge to each person to whom a copy of the prospectus is delivered a copy of the documents incorporated by reference herein (other than exhibits to such documents unless such exhibits are specifically incorporated by reference herein). You may request a copy of these filings, at no cost, by writing, calling or emailing us at the contact information set forth below. We have authorized no one to provide you with any information that differs from that contained in this prospectus. Accordingly, we take no responsibility for any other information that others may give you. You should not assume that the information in this prospectus is accurate as of any date other than the date of the front cover of this prospectus. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Protagonist Therapeutics, Inc. </font>
          <br >
          <font style="letter-spacing:0.2pt;">7707 Gateway Boulevard, Suite 140 </font>
          <br >
          <font style="letter-spacing:0.2pt;">Newark, CA 94560-1160 </font>
          <br >
          <font style="letter-spacing:0.2pt;">(510) 474-0170</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">30</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style=" width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;min-height:706pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 3pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:50pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">$100,000,000</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="position:relative;margin-top:62pt; text-align:center; width:456pt;">
          <img src="lg_protagonist-pn.jpg" alt="[MISSING IMAGE: lg_protagonist-pn.jpg]" height="69" width="277" >
        </div>
        <div style="margin-top:65pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Common stock</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:71.167pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 71.1666666666667pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Prospectus Supplement</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 18.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:76pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Joint Book-Running Managers</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:14pt;">
          <tr style="line-height:13.97pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:14pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:144pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.28pt;">J.P. Morgan</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:144pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.28pt;">Jefferies</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:144pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.28pt;">Piper Sandler</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:36pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Lead Managers</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:11.99pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:12pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:222pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.24pt;">BTIG</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:222pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.24pt;">H.C. Wainwright &amp; Co.</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:100.51pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 3pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>lg_protagonist-pn.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_protagonist-pn.jpg
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M .$  0 " P$! 0$            '" 4&"00# @$! 0 " P$!
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M" @(" @(" @(" @(" @(*Z9^S,L)S.HR"GK9Q3UTSY:*K!+HBQQYNX>TZM]
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M;E_D$GZ*,X2?EM;$_P".W+_()/T4,)/RVMB?\=N7^02?HH82?EM;$_X[<O\
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M:=E'1R-9I$Q@T#I'GHUXHC*P2," @(" @(" @(" @(" @(" @(" @(" @("
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M)<@Y$(^CHMX!OH>O?\Y:K[PH$0E:=&! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$&LNVZV^>XO?B=F<]Q)<XVZE))/
M22>[0>FW83AEHK([C:<=ME!<(>;N:NEHJ>"9G.TL=RO8P.&K20=#T%!G4! 0
M$! 0$! 0$!!S;\=7TUT_X#HOCJA$H0[LQ],.WW\Y;-]_PHS+L,B @(" @("
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M;74F5YK7YY>(!-;L4$8M\;QJQURJ>;D?IT'N6-+O(YS3U(C+HDB(@(" @("
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MI/  G@A,KB8M^;^Q^.FC?FV6UE36.&LL%FBBIHF'L;)4-F+O.8V^9$<6=J_
M)M6^(B@R'(()^I\\M%.S^M;21'^R0Q17F?@(S>V,?4X1D%'?XVZD4=8QUNJ2
M.H-/-+&X_;/8C.*LF6X1EV!W,V?,+-56:X:$LCJHRULC1IJZ-XU9(WCZS'$(
MSBL7X'MN;Y?L[J,^;55-#C6/-,,IIY71-K:R9GHT[^4CGC8T][(T]?(.M&)=
M [[0276QW.UPN:R:MI)Z:-[]>4.FC<P$Z:G0$HBH5^0!N'_*BR_4JO\ !(EB
M@;>':>[[-Y8S$;U74UPK'T<5<)Z/O!%R3/>P-^Z-:=1W9ZD9B6KXIC]1EF46
M3%:.5D%7?*^EMD$\NO=LDK9F0M<_E!/*"_4Z!&5H?R -P_Y467ZE5_@D1Q/R
M -P_Y467ZE5_@D,3\@#</^5%E^I5?X)#%?6Q4$EJL=LM<SFOFHJ2"FD>S7E+
MH8VL)&NAT)"(L@@(" @(*3>/;;BIJ(K%NE;X>>&D9\S7IS1Q8QTADI9#Y.9\
MC">TM",PHVB8@MMX$]R*3'\PNVWUTG$-/DT<<]J+] WV^D#M8P>V6-QTUZV
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M:^Q7:AO=KE,%RMM1%5T<[>EDT#P]CO<(").RN&9+39EB5CRNC ;3WJAIZ]C
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MGS2N#8HVE[W'H#6C4E&'&7.LGJ,TS._Y95.)EO-?45H#NEK)I"YC/,UNC1Y
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MG'X,CW!#!;3\WO\ PQGGR:V_&5",2O5+%%41/@G8V6"5I9+$\!S',<-"UP/
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MN7^7R?H(SC*1=K-DL$V<^=OXE05,/SU[/[=[5.ZHU]C[WN^7F T_7GZHPD5
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MC=7/IV];67='RES?;CT8QU8)DLN]U_M4$5'+;J&6BA ;'%#&:4M:.AK1&>0
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M[_3E8?5U/I(C,K2(P(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M[.CB32""-1Q!5P4@0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0:;E^TVVN>ZOR[%[?=*APT]LDA:RJ [!41\L
MH'F>@A>^>!;9BYN=):Y[Q97$ZMCI:MD\0X]!%5%*\\.CTT9Q:?-^;ZQIS]:?
M-JZ./3U9**&0Z^<2,_J(8OI2?F^\38_6NS.XS1ZCT8*6"%VG7Q<Z7I\R&+?L
M9\%6Q^/OCFKZ*NR&>/CK=*L]V7>6.E; TCR.U]U#%.E@QO'L5M[+3C5KI;1;
M8_5I:&%E/'KIIJ6Q@:D]9/$HPRB @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(*_>*[?"3:;#&6JP3]WFV1B2&W2MTYJ
M2G9H)JGR.',&Q_".OV)1F(<QI999Y7SSO=+/*XODD>2Y[GN.I<XGB23TE$WX
M0$$I;';'9)O9DAMMM)H<>H2U][O;V\T=/&[71C!J.>5^AY&:^4Z (Q,NG6W&
MU^&;56)E@PZWLI(3H:NK=H^JJI -.>>735Q[!T-Z@ B#<4! 0$! 0$! 0$'C
MNEIMU[HI+==:=E51R^O%(-1KU$'I!'41Q7QO6:+M/=KC&'WL7Z[-<5T3A,*W
M[C;;U6'5'MU#SU./S.TCF/%\+CT,DT_L7=?G7/M3TRK*SWJ=M$^KDETS2=7I
MS=/=JV7(X./ECL:"M(L @()WV7SJ6M9_%&ZRE]1"POMDKSJYT;!JZ(D]/*.+
M?@Z]@5UT/4)J_@USMCP]B@^8=-BC^/1&R?%S\?IX>5,:MJE" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @P^57W^+-@K;Y[/[5[&UKNXY^[Y
MN9[6>MRNT];7H7DS>8_ M57,,>[P/;DLM_<WJ;6/=[W#OX$5?E!_^G/^6_\
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M;P'-<T]((/ A8F(F,)W)4U33.,;)1_?-F<.NQ?+1QR6JI=J=:5WW+F/;&_4
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MYBF.5*^*;'5]4Z.LRJ;V.FX.]@@(=.X=CGC5K/<U/F5GR>@5U?%>GNQQ1O\
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M,T&CZ:8<NO1J7-X+P_V>8JG#N5=$MC_?Y6F,?Q*/_*&[XMLE?+C*RHR1PME
M#JZ!I:^I>.P::M;KVDZ^1;C*:%=KG&[\,>OW-%G?,=FW&%GXZN/@]_VVIYM5
MJH++006RV0-IZ*G;RQQM^N2>DDGB2>E7>S9HM4111&$0Y]?OUWJYKKG&9>Q?
M9\7RJ::GK*>6EJHFS4TS2R6)X#FN:X:$$'I!4:J8JB8F,8E.BN:)BJF<)A!N
M7['UL4TE;B+VSTSB7?-TSPV5FO4Q[CHX?;$'SJEYW0:HGO6=L?=G?TKYD/,E
M$Q%-_9/WHW>F.Q'LF+YK:)"TVJXTSSP+XHI>4Z=CF#0_56AG*9FW/AJCT2L<
M9S*78\=$^F/:^]#@.<7B8=W9ZOFDT/?53'0-(/7SS<H(4[>G9F[.RBKT[.M\
M[FJ92S&VNGT;>I+^";/4M@GBN^02,K;I$0^"G8":>)PZ''F +W#JX:#ZZM>G
MZ+39F*[GQ5<7!':INIZ_5?B;=J.[3.^>&>R$IJS*F_CFM>TM< YKAHYIX@@]
M16)C%F)P03F^RU='52W'$&MGI)27NMKG!DD1/$B,N(#F]@)U'1Q5*S^A5Q5-
M5G;'W>+F7[3O,-$TQ1?V3'ZW'SHYDP[,*:4,=8[@V771A;33'5PX^B6M(/N*
MOSDLQ3/@JZ)66,_EJH_F48?-#/8_M+F%[G8*FC=:Z(G[I45@[MP'7I$?3)[.
M 'E7NRVCYB[.V.Y''/9O:_-:[E;,;*N_/%3V[FP9UM3<J6>VT>)6V2KHX*4-
MJJD.8'R5!D<7.?S.'$C3HX <%[M0TBNF::;-,S$1MGEQ:_3=;MU175?KBF9J
MV1MV1@D/:2QW7'\6DH;Q3.I*LU<LHB>6D\CF1@'T21U%;_1K%RS8FFN,)[T^
MQ6]=S-N_F(JMSWH[L>UOBW:OM7SS#*;-;*:!\@@KH'=]15)&H;)IH6NZ^5PX
M'3R'J6MU#(QFK?=W3&Z6UTS4*LG=[V&-,[)C[<,*\7/;?-K5.Z&6S5%0&GT9
M:-AJ6.':#&"?J@%4*[I>9MSA-$SS;>ITBSJ^4NQC%<1\VSK?JU[:9O=96QQV
M>>F:3Z4M8TTS&CM/>:'Z@*6M+S-R<(HF.?9UL7M8REJ,9KB?EV]2UJZ>Y&B[
M>;&;[DE/9V62B?6.IWSF8,+6\H>(^7UB.G0JM:YE;M^*/PZ>]AC[%K\OYRSE
MZJ_Q*N[CAAZS9G&;[C=/>&7NB?1NJ'P&$/+7<P8).;U2>C4)H>5NV(K_ !*>
M[CA[3S!G+.8JH_#J[V&./J2BK*JCSUU#1W.CFH*^%M11U#2R:%XU:YI_^.!Z
ME\[ENFY3--48Q+Z6[E5NJ*J9PF$$Y7L?=:2:2JQ9XKJ(DD4<KFLJ&#L#G:->
M!YP?.J5G-!N4SC9^*.+A]Z_Y'S';JB*;_P ,\<;NV&@2XKE]O>626BX0./#5
ML$NCM.PM&AZ>I:*K*9BB=M%4>B5AISN6N1C%=,^F'NMFW&;WB4-BM%1"'<73
M5C33, /7K+RD^X"OO:TS,W9V43'/LZWPO:OE+4;:XGY=O4FO MJ;=B;V7.XO
M;7WT<62 $0P$C0]V#Q)^&?< 5PT_2*,O\=7Q5^J.;M4;4];KS4=RCX:/7//V
M)!FABJ(9*>=C98)6EDL;P'-<QPT((/2"%OJJ8JC"=TJ[35-,Q,;)A#V5[&4]
M3))68I4-I7.U<;?4%QBU^!(-2/,X'SA5+.:!%4]ZS.')/LE<\CYDJIB*;\=[
M_%&_TPC6MVZSNTR^G9JI[F^K)2#VCIX:@PEQ5>N:9FK<^"?1MZEGMZMD[L>.
MG]K9UODW#<]NDS8Y+/<I).AKJJ*6-HU^%-R@?548R.:N3A-%7IB?:G.H9.U&
M,5T1S3'L2KMYM!)9ZR&^Y.6/K8")*2@C(>R.0=#Y'=!<.EH;P!XZJS:;HLVJ
MHN7=\;H[52U77HO4S:L[IWU<?,EY6M31 0$! 0$! 0?.HIX*J%]/51,GIY!R
MR12M#V.'86NU!""*,T\/>PU_@GK\BQ6VV\:<TU?1DVH@^^<ZF=$TD_"!U4*[
ME-$=ZJ8B.5]+=NJNKNTQ,SQ0JEG?AZV997:8/=KT8^8=ZV=T$E, .D1.=$V3
M^NU\Y5;S.OVJ-EN.]/'NCM6O*>7+U<8W9[D<6^>R'UL&W6'XWROM]LC?5LXB
MKJ?N\W-IIJ'/UY>'O %6<QJN8O;ZL(XHV>];,MH^5L;J>]/'5M]W1#:V1OD<
MV.-I>]W!K&C4D^0!:N(F9;>9B(VL+?LKQW%Y7T]_N,5#5,',^FD),X'[$T%_
M]BMA:TW,W-M-$^G9UX-9=U7*VIPJN1Z-O5BTJX[ZX31D-I!5W G7TH81&P:=
MO?.C/'R-*V=OR_?J\4TT^O[=+4W?,F7I\,55>J/MZ'IP??S;FMO!I<^H;G:K
M2YP$-=;W15/+Y9F%@<!^QAY\BV5OR[;CQUS/-&':U5WS/<GP41'/./8NA@6-
M;.Y':XK[B#J3(J%VG[K,QJP'>]DB<>5CAUM=&#VA;6UH^5M_JX\^WW-->UO-
MW/U^['^'9[_6DBFI:6CB$%'!'3P-]6*)K8V#S!H 6THHIIC"F,(:>NNJN<:I
MF9Y7V4T! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 00EX@__ "Y_QW_FZIWF
M3^G^U_I7KRK_ %?V?]3V; ?P5>?E$7Z@KZ^7/!7SP^'FC^9;YIZTPJV*8("
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*$! 0$! 0$'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tb_ourproductpipeline-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tb_ourproductpipeline-4clr.jpg
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M -P  0 !!0$!               ! @,%!@<$" $! 0$! 0$! 0
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M]O>>T'KO^K>++]:ITW%XG6,_A[>]/M!Z[_JWBR_6ITW%XG6,_A[>\]H/7?\
M5O%E^M3IN+Q.L9_#V]Y[0>N^NV\67ZU.FXCK&?P]O>>T'KO^K>++]:G3<7B=
M8S^'M[SV@]=_U;Q)?K4Z;B\3K&?P]O>>T%KOKMO$E^M3IN+Q.LY_#V]Y[0>N
MQ]F\27ZU.FXO$ZQG\/;WGM!Z[_JWB2_6ITW%XG6,_A[>]'M!Z[Z[;Q9?K4Z;
MB\3K&?P]O>>T'KKKMO%E^M3IN+Q.L9_#V]Y[0>NNNV\67ZU.FXO$ZQG\/;WG
MM!Z[_JWBR_6ITW%XG6,WA[>][\)SXUM?9C'V4_F_97-S##)1LM>%\@::5E/0
M5C)Z?CBV9=,7JV:Z^(FFV61UMSLUA@M4Y'$V7F_FUL]C8^)LA=1T;7'=(.D]
M2Y\/P&._'$R[<5ZIEQY9MBE(:_[0>NZ[[;Q9?K5WZ;B\7EZQG\/;WI]H/7?]
M6\27ZU.FXO$ZQF\/;WGM!Z[_ *MXDOUJ=-Q'6,WA[>\]H/777;>++]:G3<7B
M=8S^'M[T>T'KO^K>)+]:G3<7B=8S^'M[SVA-=U_V;Q)?K4Z;B\3K&?P]O>>T
M'KO^K>++]:KTW%XG6,_A[>\]H/7?]6\67ZU.FXO$ZQG\/;WGM!Z[Z[;Q9?K4
MZ;B\3K&?P]O>GV@M=]=MXDOUJG3<7BG6,_A[>\]H/77]6\27ZU7IN+Q7K&?P
M]O>>T'KKKMO$E^M3IN+Q.L9_#V]Y[0>NNNV\27ZU.FXO$ZQG\/;WGM!Z[Z[;
MQ)?K4Z;B\4ZQG\/;WGM!Z[Z[;Q)?K4Z;B\5ZQG\/;WH]H/7?7;>++]:G3<1U
MC/X>WO3[0>N^NV\67ZU.FXO$ZQG\/;WGM!ZZZ[;Q)?K5.FXO$ZQG\/;WGM!Z
MZZ[;Q)?K4Z;B\3K&?P]O>CV@]=_U;Q9?K4Z;B\3K&?P]O>GV@]===MXLOUJ=
M-Q>)UC/X>WO/:#UUUVWBR_6ITW%XG6,_A[>\]H/7?7;>++]:G3L1UC/X>WO/
M:#UWUVWBR_6ITW$=8S^'M[T>T'KOKMO%E^M3IN(ZQG\/;WGM!ZZZ[;Q9?K4Z
M;B\3K&?P]O>>T'KO^K>)+]:G3<7B=8S^'M[SV@]=]=MXLOUJ=-Q>)UC/X>WO
M3[0>NOZMXDOUJO3<7B=8S^'M[T>T'KK^K>++]:G3<7B=8S^'M[SV@]=?U;Q)
M?K5.FXO$ZQG\/;WMCT-SIU?G]1VV,O?-_-Y6S.=PMD!K'$]XWR'I"\_$<#CL
MLF8>SA/4\N3)%LTIM^YA,AS\UO;W]U;Q^;<$,LD;:ME^*QQ _P +[B[V^G8I
MB)VO+?ZQFBZ8V>WO>?V@]=?U;Q)?K5>FXO%GK&?P]O>GV@]=_P!6\27ZU.FX
MO$ZQG\/;WGM!Z[Z[;Q9?K4Z=B.L9_#V]Y[0>N_ZMXDOUJ=-Q>)UC/X>WO1[0
M>NOZMXDOUJ=-Q>)UC/X>WO3[0>NOZMXLOUJ=-Q>)UC/X>WO/:#UW_5O%E^M3
MIN+Q.L9_#V]Z/:#UU_5O%E^M5Z;B\3K&?P]O>>T)KK^K>++]:G3<7BG6<WA[
M>\]H/777;>)+]:G3<7BO6,_A[>\]H/777;>)+]:G3<7B=9S^'M[SV@]=]=MX
MDOUJG3<7B=8S^'M[T^T'KO\ JWBR_6J]-Q>)UC/X>WO/:#UW_5O$E^M3IN+Q
M.L9_#V]Y[0>NOZMXDOUJ=-Q>)UC/X>WO/:#UW_5O$E^M4Z;B\3K&?P]O>>T'
MKOKMO%E^M3IN+Q.L9_#V]Z/:#UW_ %;Q)?K4Z;B\3K&?P]O>GVA-===KXLOU
MJO3<7B=8S^'M[T>T'KKKMO%E^M4Z;B\3K&?P]O>>T'KKKMO$E^M3IN+Q.L9_
M#V]Y[0>NNNV\67ZU.FXO$ZQF\/;WMJY?<Y-6ZDU!Z.R'8>;^:W4XX6R \4%N
M^1N^0]+5YN)X''996-8>[@O4LN7)NW4I2?N:[?<_-<07US#'YMV<4KV-JV6M
M&N('^%7HM].Q3$/'?ZOFBZ8V>WO6/:#UU_5O$E^M6NFXO%GK&?P]O>>T'KK^
MK>)+]:G3<7B=8S^'M[T>T'KK^K>)+]:G3<7B=8S^'M[SV@]=_P!6\27ZU3IN
M+Q.L9O#V]Y[0>N^NV\27ZU.FXO$ZQG\/;WGM!Z[_ *MXDOUJ=-Q>)UC-X>WO
M/:#UW_5O$E^M5Z;B\3K.?P]O>GV@]===MXDOUJ=-Q>)UC/X>WO/:#UUUVWB2
M_6ITW%XG6,_A[>]'M!Z[_JWBR_6J=-Q>)UC/X>WO/:#UWUVWB2_6ITW%XG6,
M_A[>\/Y@]=[O]&\27ZU.FXO$ZQG\/;WGM!Z[W?Z-XDOUJ=-Q>)UC/X>WO/:#
MUW_5O%E^M3IN+Q.L9_#V]Z?:#UW_ %;Q)?K4Z;B\3K&?P]O>CV@]=_U;Q)?K
M4Z;B\3K&?P]O>GV@]=_U;Q9?K4Z;B\3K&?P]O>'\P>N_ZMXDOUJ=-Q>)UC/X
M>WO1[0FN_P"K>)+]:G3<7B=8S>'M[T^T'KOKMO%E^M3IN(ZQG\/;WH/Y@]=C
M[-XDOUJ=-Q>)UG/X>WO!^8/75*_Z-XDOUJ=-Q>)UC/X>WO/:#UW_ %;Q)?K4
MZ;B\3K&?P]O>>T'KO^K>)+]:G3<7B=8S^'M[SV@]=_U;Q)?K4Z;B\3K&?P]O
M>>T'KO\ JWBR_6ITW%XG6,_A[>]/M!:[Z[;Q)?K4Z;B\3K.?P]O>>T%KOKMO
M$E^M5Z;B\3K&?P]O>CV@]=]=MXLOUJ=-Q>)UC/X>WO/:#UW_ %;Q)?K5.FXO
M$ZQG\/;WGM!Z[_JWB2_6J]-Q>)UC/X>WO/:#UW_5O%E^M3IN+Q.L9_#V]Y[0
M>N^NV\67ZU3IN+Q.L9_#V]Y[0>N^NV\27ZU.FXO$ZQG\/;WI]H/77]6\27ZU
M.FXO$ZQG\/;WGM!Z[Z[;Q9?K4Z;B.L9_#V]Y[0>N_P"K>++]:G3<7B=8S^'M
M[T>T'KO^K>++]:G3<7B=8S^'M[SV@]=_U;Q)?K5>FXCK&?P]O>>T'KO^K>++
M]:G3<7B=8S^'M[SV@]=_U;Q9?K4Z;B\3K&?P]O>>T)KK^K>)+]:G3<7BG6<W
MA[>\]H/777;>)+]:G3<7B=9S^'M[SV@]=]=MXLOUJ=-Q>*]8S^'M[SV@]=_U
M;Q9?K5.FXO$ZQG\/;WGM!Z[_ *MXLOUJ=-Q>)UC/X>WO/:#UW_5O%E^M5Z;B
M\3K&?P]O>>T'KKKMO%E^M3IN+Q.L9_#V]Z?:#UUUVWB2_6ITW$=8S^'M[SV@
M]=]=MXDOUJG3<7B=8S^'M[SV@M=]=MXLOUJ=-Q>)UC/X>WO1[0>N_P"K>)+]
M:G3<7B=8S>'M[SV@]===MXDOUJO3<7B=8S^'M[T^T%KOKMO$E^M4Z;B\4ZQG
M\/;WH]H/7?\ 5O%E^M3IN+Q7K&?P]O>>T'KO^K>)+]:G3<7B=8S^'M[SV@]=
M]=MXLOUJO3<1UC/X>WO3[0>N^NV\67ZU3IN+Q.L9_#V]Y[0>N^NV\27ZU.FX
MO$ZQG\/;WH]H/7=/]F\27ZU.FXO$ZQG\/;WGM":Z_JWB2_6J]-Q'6<WA[>]/
MM!ZZZ[;Q)?K5.FXO$ZQG\/;WGM!ZZZ[;Q)?K4Z;B\3K&?P]O>CV@]=_U;Q9?
MK5>FXO$ZQG\/;WI]H/7?]6\67ZU3IN(ZQG\/;WGM!Z[Z[;Q9?K5>FXCK&?P]
MO>CV@]===MXLOUJ=-Q>)UC-X>WO3[0>N^NV\67ZU.FXO$ZQG\/;WGM!Z[Z[;
MQ9?K5.FXO$ZQG\/;WGM!Z[Z[;Q9?K4Z;B\3K&?P]O>CV@]=]=MXLOUJ=-Q>)
MUC/X>WO/:#UUUVWBR_6ITW%XG6,_A[>]L6A^=>L,]JC'8J^\W\VN9."0,;(#
M3A)Z9#U=2X9^!QV63,/5PGJ>7)EBV:4E],K\Z_7/E7\RFS6=@.CT='_V\Z_3
M>E_TY^W^$/Q?K?\ 6C_M_C+BZ^N_/L_A]%:IS]L;S#XJXO+8.+#)#&][0X $
MBK0>@A<,F?'9-+IH]6+A,N6*VVS,+N3T#J_#VSKS)8>ZM[5FUTLD3VM &W>0
M%+.)QW32)AO)P>:R*W6S$-;W>^O0\14(%?<0-GP(HJAU"F]11 _EZD$HB-NY
M"A5%@%"@FB(C<@5]Q"J51!4"ON(52BU$007[+_7+<_\ 6,_O@I=V2Z8_W1]K
M=N<5/OO=?Y.+^1>+@OZ4/H>I_P!;W-!7O?+>_%8;*9NY;:8FTDN[AVZ.)I>[
MKW %<[\EMD5F:.N/%?DFEL5EE,IH/5^&MC>9/#W5M;#899(GM:#OWD#J7*SB
M,=TTB8=\G!YK(K=;,0US9\*]#QE?<14^YTH(J-W2@OVMI/?7,5I:1NEN)W".
M*-@)+G.V  !2Z8B*RU;;-TQ$=LLP-%:H.6."&+N/2X9VOFG9O[3@V;>&E:>$
M%QYC'N[U8H]'*9=_<W9WM&&N[6XL;F6SNXC#<PN+)(G@AP<.@@KM;=%T5AY[
M[)MFD]K(8K3.=S=M<W>*L);JVM #<R1,<]L=02.(@&FXKG?EMLF(NFE77'P]
M^2)FV*Q#%.!:2#L<-A'NKJX2A5%;XGQAKGM+0\5;4;QN4JLQ,*-B!LZD0V()
M11$051T#E'_S#<_[G=?]WD7@XW]D?;'WOJ^F_P!2?LG[FE9/;DKS_+R_WY7L
ML_;#YV3]T_:\FX+3F5/4BU2B(.Q%1Q(*D [$&;PVC]3:@C,V'Q=Q>1-V%\,;
MGC_W0>I<;\]EG[IH].+A<N2*VVS+SYC3N;T_(V+,V,UF]XJT3,<RHV_. ZEJ
MS+;?^V:L9<%^.?U1,,;P/X!)PGLSL#NA='&G>IJA!_8$%R""6ZF9;V["^60\
M+&-VDD] 29I%96V)NFD/;F,#E]/W(M,S:2V=P1Q".9KF.H=FYP"YV9+;XK;-
M73+AOQ32Z*2QWN4VKHXFQ%$2I7W$!!* BU15$*H.E<TC_P"'::']2'_;2KYW
M"?NN^U]CU#]MGV?BYKU^XOHOD,YA-'ZEU'!)<X7&7%[!$[@?)!&Y[0Z@-"6@
M]:XY,]EDTNFCTX>%RY8K9;,O5D.7NM,7;/O+_"7<%M&"Y\DD,C6@-%2:D#H6
M+>)QW32+H;OX+-9%;K9B&/MM-9V[QDN9M[&:3&0FDMRUCC&TUX=K@*;]BZ3E
MMB[=F=KC;P^2ZW>B-C$U[JZN!\*">C8BHV="(5"!L[R*5[J#*8O3F;S4$]SC
M+&6Y@M1Q3R1L<YK&[=I(!IN7._+;9-)FCMCP7Y(F;8K1C""TEKA0C81[RZ.-
M$(!1!!%4$C:@E%17W$2H$*I0J(515%15$3MI6J+4%>E"IOW()1$40*()09;2
M^S4N'_WVW_[5JY9?V3]CO@_J6_;#+\T#_P#?F9_RD?\ V+%RX3^E:]/J']>[
MW?<U'J7J>!LV.Y?:SRUG%?XW#75S9S5,4T<3W,=PDM-"&D;PO-=Q..V:3=%7
MLLX+-?%;;9H\V9T=J?3T39\SC+BSA>:-?-&Y@)_Z0"WCSV7S2V8EC+PN7'%;
MK9A8R&F<YB\?;Y7(6,UOC[HAL%Q(QS6/<0X@ D4.QI5MRV73,1.V&;^'R66Q
M==%(EB:KJ\YLI4HI_84#8@;D#X$1>M;6YO;B.UM(G37$II'&P5)/N *3=$16
M6K;9NFD=K.Y'0>L,5:F^R&&NK>U:*F62)[6@4KO("X6\1CNFD3%7JOX/-9;6
MZV:-<^!>AY$5*J)&W>H)V(J*^XJ@-J@G8BB)5%?<5"J@(5*A%J5"!55 ;>A1
M0HA5 J.I"IO0;IRJV:TLO\G<?]WD7CXS^E/N^]]+T[^O'O\ NEJ^7'_BU\?Z
MQ+_?E>JS]L?8\.3]\_:\C&ES@UHJYQH .M:8;9%RQUY-&V:+ WCHW@%KA#(0
M0=Q!X5Y9XO%'\T/?' 9Y[+98K)Z6U!AKF*TRF/FM;B8TC9*QS"XG:* @+K9F
MLOBL35PR</DLFET3$K69P&8T_,R#,V<MG+(WC8R9KF$M/30@*X\EM_[9JSEP
MWXOW11C#L71Q.A KUHALZ$#9T*B5%>O&XK(YFZ;98NVDNKIVZ*)I>X]&X#W5
MB^^VV*S-(=,>*Z^:6Q67LS6E=0Z>X#F<?/9"3:WMHW,KXP"SCS67_MFKIEX?
M)B_=%&&J5U><JB)J@5/4B@02B(HJ&P(%.E0*^XJ-_P"3Q_\ O#=_L&0_[I*O
M!QO]/WQ][ZOIG]7_ .F[[FEY4TRE[_EY?[\KV6?MA\[)^Z?M6(899Y601,+I
MI'!C&#:2YQH  K,TBK,6S,T>_,Z?S& ?#'F+.6S?.WCB$S7,XFT!J*@=86+,
MEM_[9JZ9<-^.F]%'KET9J>'%^FIL7<,Q= [SIT;Q'0D-'A4IO*Q&>R;MV)VN
ML\+EBW>FV:,#L7=Y"ON(IT50-J(V.#0NK+K&>F;?$W,F,[/MO.6Q/,?9AO&7
M<5*4IM7GGB,<7;LS%7LMX/--N_%LT>##:=S6H;A]IAK&6]N(V\<D<+'/<UH(
M%2&@])6[\MMD5NFCEBP7Y9I;%9>L:)U2<H<(,5<'*!O&;7LW]IP[Z\-*K/GX
M]W>KL=.4R[VYNS51:Z.U+>&\;:XV>1V/(%YPQN/9$@'PJ#9L/2K.>R*5GM2W
MA<MU:1V=K!@KL\I4(""ID;Y7!D0+GNV-:-I)29HL15!#FDM<*$=!WH;4#;_:
M0-FQ V*H544_L]Q$-^[<@?H0-R*;$1-$$"J!TT* J"![Z!L017W%%2-J('9N
M11"I5$J5]Q!.Q%1T[D T"(BON()" @5"!4=2%04*%4T01\"HE0%2J/>0% 0J
ME"H@BON()V(()5*HJH5354% ^! V*@%"H2A4K[B!7W$"ON(%?<5$J"-]0@W+
ME;_SWA_\L?[UR\G%_P!*7T/3_P"O:^X%^-?T1\J_F5_YTL/_ .71_P#;SK]-
MZ7_3G[?P?B_6_P"M'_;_ !EQBB^N_/P^CN5ARC.4>7=@W/;E1<'S=T1#7UX;
M>M"=FZJ_/\7N\Q&]V?\ 5^N]/F_E;MWMK^#+\MIM?/Q67/,&1S\5V5&ONWM<
M_<ZM.%YV?]%<>*C%O1Y?:[\%=GFV[SNSQ<UTURJPV?TI>:OR>3DL;:"YDBD+
M2"P,:YE#01N-3QKZ.7C+K,D61%=CY&'T^S)CG)==3:Q^!Y;8?5.5O78;)O&F
M,:QLEUDIQPDEQ.QK3&UWR3\A=,G%78[8WH_5/<Y8>!LRW3NW?HM[U^^Y786_
MP-YF=$99V4.//^F02 L?P@CB(XXXMU05FWB[K;XMR12K=WI]EUDW8KMZG;[;
M%K3'*^QO-,2:MU3D3C,5OA[/PGN\$NK1K)#NI38M9>+F+]RR*RQ@X"V[%YF2
M=V/;[7MU%RFP^)T7][<=E7WT;R.R(V,<"_@W.C:Y8Q<9==DW)BCKF].LLP^9
M;=5?ON5.DL'IW&ZASV;FM8+^$2-C XW%] :-#(7'Y72LV\9DOOFVVVM/;5J_
MT_%CQQ??=,5CV[F.P7+;35WB!F\SF)+>UN9WQV4,'[:8L:XM!>V.*0BO"3M
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M<X$$?W"\O"VW9<D1/9:]O'76X,,S;VW_ (/E5?IWXDZ$$HB"HTA5E.Y W;T
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M" U_3UKZ/#X(NPW12E7R.+XJ;>(MG>KN_FZ)S#O<7IK1V1U3C*,O-5,A;5@
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M(514@I.] 157O*![ZH((]Y0 .M *HA$3TA10[T5'2A54B'2@W'E;_P ]X?\
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M_P"K5ZGA\?@=$SZV_'\CV<^8?SK#R[_JTZGA\?@=$SZV_'\CV=.8?78>7?\
M5IU/#XG1,^MOQ_(]G3F'UV'EW_5J=4P^)T3/K;\?R/9SYA?.L?+O^K3J>+Q.
MB9];?C^2?9TYA]=AY=_U:=3P^)T3/K;\?R1[.G,/KL/+O^K3J>'Q.B9];?C^
M1[.G,/KL/+O^K3J>'Q.B9];?C^2/9SYA]=CY=_U:=3P^/P.BY];?C^21^7/F
M'UV/EW_5IU/#X_ Z)GUM^/Y'LZ<P_G6'EW_5IU/#X_ Z)GUM^/Y'LZ<P^NP\
MN_ZM.IX?$Z)GUM^/Y(]G3F'UV/EW_5IU/#XG1,^MOQ_(]G3F'UV/EW_5IU/#
MXG1,^MOQ_)/LZ<P^NP\N_P"K3J>'Q.B9];?C^1[.G,/YUAY=_P!6G4\/C\#H
MF?6WX_D>SGS#^=8>7?\ 5IU/#X_ Z)GUM^/Y)]G/F'UV'[P_ZM.IX?$Z)GUM
M^/Y(]G/F'UV&S^L/^K3J>'Q^!T3/K;\?R/9SYAGIL/+O^K3J>'Q^!T3/K;\?
MR/9RYA_.L/WA_P!6G4\/C\#HF?6WX_DCV<N8GSK#]X?]6G4\/C\#HF?6WXS^
M"1^7/F(-[K#R[_JTZGA\?@=$SZV_&?P/9SYA]=AY=_U:=3P^/P.B<1K;\9_
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M>%U]* '"K@XTVGI Z5F;ID:UJC\NN'U/J7(:F?F+BTNKZ0R/9'&32ONB1O\
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M<[>58_\ R.'R-Q]6G+Y-#F<?U)'.[E4/_P BA\C<?5)R^31.9Q:GXW<JC_\
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MY11 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M!3S,YKI^Q]:[C8CAHPVQ]KH#11H%*>XOKOD)0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!Y[E\
MT<#WV[.TF:/ 9NJ@PWI+47JX>,?HJ[%V'I+47JX>,?HIL-AZ2U%ZN'C'Z*;
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MFY)F,N+'LXW?&?Q'Z(38,W4\-:;:5414@(" @(" @(" @(" @(" @(" @("
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MHCIP.I6HIOHH/I"NT;"!TU51I_,QF>ETS.S3K)WY*K> 6P<7GPA6G#MW(L.
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M[J*Z0B" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(/.^>!KRUSV\7S3OJ@O-.W;OZT%2 @(" @(" @(" @(
M" @(" @(" @(""*GJ0*CK0*CK0*A034=:HBHZT"HZT$U'6@>\@("@*@@5" @
M(""*^X@ U02@(%0@5'6@(" @(" @5"!4(" @(""*H%4"J!5!* @(" @BON()
M4! 5! 0$! 0$! 0$! 0*H%4! 0$! 0$! 0$! 00#5!* @(" @(" @(" @("
M@(!V"J".+]"@<7N*AQ=)V!!2'UW4KT;4$=IMI2OO(.<:KYP6. S<FGL9C+K-
M96 %US!8Q]J8P*#P@#4;?<6HM'OTES3PFK,;D+RWBEM[K&1R2W=E. V9C8F\
M1);Q'K"3;0:=;_F"?D.TEQ6DLM?VC'NC;<6]N9(W<!H35KB%=T;KJ3F7B]+Z
M=M<WE+>:.XO*-@QY:!<%Y)\'A)'0"5(BLC'Z.YOXS4^7=@;VPN</ERT.M[:]
M8(G2 UKP@NKU='2DVT'1>TVTI0^ZLB.TJ*@;.CKJ@D25 V;T#M-E2*#=\**U
M>'7>-N-9W6BHF/.2LX6W$SMG  X1$"M:[I6]"M-B/;I;44NH\>^^GQ]QC7LF
M?"+>[88Y2&M:>+A-=AXDD9LOI2HVGHZ5%3Q^YNZD1':;-VT[@@UC2.NL;K&.
M]GQS'B&SN'VSG/H*N8UCJ["?GA68H-HXCU*"#)0TIMI4CW$ /KT=X^\@<9ZJ
M[=E/[:"!+7BH-H- BIX_<[B(U+7>OK+0T&-GO('S#)7,=I&& $M=(]K 34C9
MX2L14;1;73;JUAN6"@F8U[0?UA515WM-M*(@9 #0"NRNQ ,@&VFSKZ$&!DU-
M,S5,>G!C;DPOMS<G(B,^;@A[&\!=U^'7X%>X9WM?<V#>>@*"KCV TW[D#CZQ
M1!2Z2FRE2@T[2?,2QU9FLUA;6W?%/AIG02N?0-<6<-2*$[/"6IB@W+CZ:>#U
M^XLAVGZONH-.R7,2PQNM<=HJ2WD=>9!I=', . 4#3MV_K=2M-E1N!DH#LVA0
M!(3M(H-PKOJ@GC]RA]W8@UAVN+,:X9H<0O-Z^U\[$VS@X:.-*U_5ZE:;*JSU
M_?LL+.>\>TN; PO<UNVH'4HC!:&UM9ZXPCLW90NAA$[K?ADH#Q,:UW03\Y68
MH-E[4"O%L WD]2@=H>D4Z#[Z#5[77-G=:WR&B6PO%YCK>.YEF-. MD;$0 :[
M_P!J.A6FRHSF7RC,1B;_ "LK"Z*PMYKE[1O(A87D#X I TZTYGLR& Q6?Q^(
MN[N#)S^;\$,?&8MI!<^AV#8M45OW:>XLHCM-E:>\>A!C-0YV+3^$O<U/&9(;
M*,RR-;M) (%!NZTC:/)HS5EMK+3UIJ&TB=#!=-#VQR;'>$UKN@GYRLQ0; 7^
MY\/0LB.TWU&[9\*HPNK-2P:4T_>Y^ZC,D-DUCWQLVN(?(V/9NZ7*Q%1>TYGH
M=1X2RS5M&617L;96,=L< X5]U28I(R?:>YMZNFB">TV5<*=_W$ R #B.P=)0
M.TZQT_V%!J6$U_8YO5V7TE#!(RYQ#!)+,X#@<"(SL-?^L"LQL&V]IUBGNG<H
M'&>KWD5':]-*MZ"-U$175!275]SIJ@@$4K7;OITH+B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("#Y8U=E
M,A%S<GMV7#VPB]#1&#LIQ%%?4K!LV;NA$5(" @(" @(" @(" @(" @(" @("
M @\&6S6*P<#;K+7<=G;N=PMDE-&EU*T6K;9GL9F8CM83\2="T_\ /;7Q_P"9
M;\J_1GS;-4_B1H7U]:^.>\GE7Z)YMFI^)&A?7UKXQ[R>3?H>;9J?B1H7U[:^
M,>\GDWZ'FV:I_$?0WKVU\<]Y/*OT7S;-3\1M#^O;7QSWD\J_0\VS4_$70_KV
MU\8]Y/*OT/-LU/Q%T/Z]M?&/>3RK]#S;-3\1=$>O+7QSWD\J_0\VS5/XBZ(]
M>6OCGO)Y5^B>;9JC\1=%>N[7Q_YD\J_0\VS4_$717KJV\?\ F3RK]%\VS5/X
MAZ*]=6OC_P R>5?HGFV:I_$+1?KJV\?^9/*OT/-LU/Q"T7ZZMO'_ )D\J_0\
MVS4_$+1?KJV\?^9/*OT/-LU/Q"T9ZZMO'_F3RK]#S;-4_B!HSUW;>-_,GE7Z
M'FV:I^_^C/7=MXW\R>5?H>;9J??_ $9ZZMO&/>3RK]#S;-3[_P"C/75MXQ[R
M>5?H>;9J??[1O1F;8_\ 3_F3RK]#SK-3[_:/]<6WC_S)Y-^AYUFJ?O[H_P!<
MVWC'O)Y5^AYMFL'W\T?ZYMO&/>3RK]#S;-4_?O1_KBV\;^93RK]#SK-3[]Z0
M]<6WC_S*^5?H>=9J??O2/K>V\?\ F3RK]#SK-3[]Z2];VWC_ ,R>5?H>;9J#
M76DC_P 7MO'_ )D\J_0\VS5/WYTEZWM_'_F3RK]#SK-3[\Z2];V_C?S)Y5^A
MYUFI]^=)^MK?Q_YD\J_0\ZS5(UQI+UO;^-_,GE7Z'G6:I^^^DO6]OXW\R>5?
MH>=9J???2?K>W\;^9/*OT/.LU@^^VD_6]OXW\R>5?H>=9JD:UTH?^+6_C?S)
MY5^AYUFJ?OII7UM;^,GE7Z'G6:GWTTKZVM_&3RK]#SK-8/OGI4_\6M_&3RK]
M#SK-81]\M*^M;?QD\J_0\VS6$_?'2OK6W\9/*OT3S;-8/OCI7UK;^,GE7Z'F
MV:P??#2WK2#QD\J_0\VS6#[WZ6]:0>,IY5VB^=9K"1K#2XW92#QE?*OT/.LU
MA/WPTQZT@\9/*OT3SK-8/O?ICUI!XRGDW:+YUFL'WOTSZT@\97RK]#SK-3[W
MZ:]:0>,IY5^AYUFI][M-^L[?QBKY5VAYUFL'WNTUZS@\93R;M#SK-4_>W3?K
M.#QD\F[0\ZS4^]FF_6<'C)Y5VAYUFI][-.>LH/&5\J_0\ZS4^]FG/64'C?S)
MY5^AYUFJ?O9IWUE!XR>5?HGG6:P?>O3OK*#QD\J[23SK-8/O7IWUE!XR>5=I
M)YUFL'WJT]ZR@\;^9/*NT/.LUA/WJT]ZQA\9/*OT/.LU@^].GO6,/C)Y5^AY
MUFL'WHT_ZQA\9/*OT/.LU@^\^G_6$/C?S)Y5VAYUFJ1J?3_K"'QD\J_1?.LU
MA/WFT_ZPA\93RK]#SK-8/O-@/6$/C)Y5^B>=9K!]Y<!ZPA\97RK]#SK-8/O+
M@/6$7C)Y5^B^=9K"?O+@?6$7=3RK]$\ZS6$'4N"Z+^+QOYD\J[0\ZS6'MM+Z
MTOFF2TF9*T;"6&JQ-LQVNEMT7=CTU66A 0$! 0$! 0$! 0$! 0#M"#S74SK>
MVEGI5T;7/X3TT%>A!KF!U1=96_DM)H6L;0EI;6HH:=)]U686C:7<5*TJHC0]
M=ZPU5IV\LK#3>G79R>[CDE>1+'"Q@C+1OD>P?*ZUJ(KVDM/M.=^?FN(\;=Z/
MNHLK(\-+ X&(-)%3Q"K=U?E*[@VN>WT;H(9'7.4:+&]RK6R79>72.=( Z0L:
MT<>XO.X*;9V#G.@,!J'4AUEK&VMACFZ@M);+&P/+6M+']DTO()J/B.WT6IGN
M59LM$<U.7>CO2%EFK=]OBH774N+X&.9(R&/C(XJ5-0VGQE:Q,H\C]0CF%K[E
M]>7L8;9W,3Y#;@$-XV.N8SOV[VU2E(D;-SD9'C->\N,A:1B.ZFOY8IG-V<4?
M;68 -/<)6;=L2.JZCFE9IN]N&$LD%L7-<.@T!JLJ^>]&Z4UGJ[0<NL+G4MS;
MW]C&\XV!@BX'-MXA*TOJP[R:;UTF8JD-BM]6ZEU;RRQ[VY.'$7C+MUME\D\M
M;6&)T\?@!U:N/ P[ =RE(B1IMUGK+2.J\!'I'6%UG&7]RRVR$%S"6-#9'M95
MKNQC!^,>E:I6-HS6*T@)?S 9FW=D[EOF\45X'CLZO,D=J[LSX/Q1VGZ%)G])
M':L67,G-:>Y27-[YU7)WV6FLX;E[>(QQEMNUS@&C;PB2H3=K(P%]J:VTSC[3
M4>G-97F8U&7,=?8R>SF9 [C:7.X7&W8-C@!\=6E1O&KY\_K'FM@L%B\C-B\5
MD\%'<70C#>-H;/>$D<;3M/9@+,4B!&FK/-X?F+E.65QFKB[P]W9&6&ZD$?;L
M<6QDD4:!ODZDG;%1/Y<=.M@=F,OY]-(8KR:W\V?P]FX".,\1HT&OA]?0E\D/
MH/HK\"YCA',6#.:@YMX72%CE9<;89"SD=<20\!>WL6SRBG$TC;V8"Z1V5#5>
MGKS#R8W 936,F.TK;LD=-=N[)U[*_AC^0UKNKH9TI$C5=':JDQNL<IIO":@F
MSF"EQ\\L4]S$Z)[)&LK4!T<>[AZE9C8*]$Z7U/KK2^6U!?:DNK46,UVW'P0B
M*A=#Q'PN)A-#1JLS077\R]2_AOB<7;W(.H+V]DQGG9;X79QN>_C^;6C:*;L5
M'AYGZ"S&D+?34LF;GRMI=9.V-W'<B,<$S)HZ%G UNP\1K56)J-F[3.<T-8S:
M5M,G+B<#@;.W,C[4-[61[X8CM[0.Z7G<%GL@>:VS6HM#YW4/+R[R+\E:RXF]
MO,;>2AHEC,-M.^IX0!NC'0K2NT8#'Z=U;E^6-QS N]1W4$UL)I+*WC[+LW-B
MN7PGB\ G>%:Q6@]%[::M?H.VYJS:CN79;M()39!L0M^"1S#3XE>D]*FRM!M6
M%U!E,[S.PC)KAS+>_P!.MN9HFTIVSI+8%V[?M*E-AWM:YEZ3;I>XL\3A=2Y+
M(:HRCP+6R/8AK6EX;QN(C  ^-O<-RMLU'JUGD\WR^T]IG1M[F9(+S-@S9+*%
MAEDB:P^$UK8V.K0OIL:=RD17:,5::QL]%:HQ,FDM47FI,9=O,60MKRTEB+"X
M.:' F"+=5I6J5[8*MDQ%GJ'G!J;/W;LY/BL/B;CS:SBM!'M<TN9Q'M&N.WLZ
M_"L[+8%?("TO;/5>M+7(R]O=LNI!--L\-P$6W9[R7]A#Z !  ^;NK[O4N0XO
MK[(9C5?,3&\M<=D'XNREMW7M[=0 &4B(2$ <8<-I:WH72.RJM'GP5]HKG'@H
MLCD9,C801ROM[B<-[7LV-C)#A&!T4Z%JM;49726#U/S>M+_5V3S]SC(6R/9C
M[6S$7"!'L\+C:X[2'*3,1L&+N]>:CGY<9G&7EW_XSIW+VUA)>1@!TD1?-'MW
MC;V-=BM(J-HYOYK*8_E7@+VSN7PW4TEOVDK:5=Q 5K4*6QM)8C4^"S&I^<.-
MQ^/R$F/;+B8?/+F+@,G9'CX@WB!%:<70K$Q$$O3#)GM :PN]"7F3DRV$RN.E
MN+22X#1*Q[. GX@:-_'T*=L5&LX76UWHWDTT8^007N3RDUNRZ+2[LV%MNU[@
MT U(#^I:I61X;_5-IH^VL]0:3UA>9O,AS?/L9<V<T<3@X%SN%QMXQL<&CXR4
MKVP5?2)YA:0@>V&]RL%K=&A,$CB'M)-*$4]Q<J2.,933UYK?GEG8,9EI+'%R
M6%K--=VW 7O88;8 -XP1MXJ[NA=*TA%VRO\ /:7R&L>7>4R#\ICS@[^\L;F4
M-$H_82M(/" -T1Z%*5I*L$S*9#&\MM"^8SNA,V3;'+PTVM+W;-H*O?(SE[9:
MBUAS@S&EX\U/CL0V,R2F 1E_@ND( XFN&]H4[(%.!UAF^7N4UCIZ^O7Y2VPU
MN+FQFG XZEA?1W !\Y*5'D&B=6:AY=WFNKC4%P_*74$\YQY$0MS;L<6$?%K7
MA#C\96L1-!T_D*:<L<+UF*.GN_LHUB_M(='?Q-#B-@ -.XLCYMP&"U-S"UQK
M''RYZXQ^&Q>0E;%YN(^,]K/. /#:[=V:ZSLA'E?J+.'0FO-$YVX-[/AFPN@N
MG !YB-Q;&AX:#?(E-L2K-S>E;C0>D+/TY%@=.OMP<C<@M\X<T".@:UW$30<6
MYJ=XP>G=50:6YC8_$Z<U-<:APM]"[SMEU$8BUX#G&A,4=?B#=7>DQ6!F<)C]
M2<X\EG<M+FY\58X^>6SQMM:".G%'4M+^T:XT\)JD_I%G6FI=;: TEC],YS(-
M9D+ZZ\W&6:WM)1:.,SJ\,?$"11H^+T*Q$3(UX:JM-'9C$7NC]6WFHC<SQP9&
MSNK2:)M)'-9Q-+K>+YQ._H5I7M*O;C=+Y36O-S4\-MDI<39=C#/<R0!AD-8K
M8<(XP[YU?@4K2$[V3M-<:AY:3ZKTKD+LY3T7 )\9=3@<?%,'M;Q<  WL'0E*
MJBUT9K'+://,)^IKF+/SL%Y%:-$7F[6/VM;M83N<.E*Q6@Z#H+FOA,MI*QRV
MHLA;V&0FJV6.0N;Q.;0U;6O6LS;M'0L7F,=FK87F+N67-J=G:,-6_ ?@6.P>
MP@#=O&Y!PW%<S=2W/-"YTM*^/T;%DI[0  U[..X,8_0HKNRJ" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M/DS6/_K%/_OW_P"HHKZS&X(@@(" @(" @(" @(" @(" @(" @("#@_YK/^0K
M3_>Q_>%?0X'^H^;ZC_2E\6K[K\FJ15005#>JBL(BH(JINXH*@HBH(JH*HK&Y
M152(J1574@K""INY!4$)5!!4$%8V()"*J"(J""MNY!4@J&Y!4$%?2@D;T56$
M%005!!(W(+@W!!4@J""H;T%0214.E%5M1$C>HJL(BI45A05#]"*K:@K1!45A
M05!!(Z$54%45C<@K"@D(*PA"0BJT14$%:*D(*AN05#>@K1501%;4%;>E!4$%
M:"H;D%2(J0;-I+5EWIN\;1SGV,KAVT7$0*;J@;5Y<^",D>+W\+Q4X;O!W?%9
M6RS-FR\LGA\;P*@;:'J*^!?9-DTE^JQY+;[:PR W+#HE 0$! 0$! 0$! 0$!
M 04.#7@M<*@BA:=M0@\UOC;&TD=+;0,CD=M>YK6@_H 0>L;4$H+3P2\FIX=Q
MIT4VH/FG6S->9S7]S/FM(Y'-:2QD\@QEC&9&6\A9)PB4CL9&GB:T?)Z=ZZQ2
MB.AV.8U9J_3V6P4.F+O1TT=H?1UT9'L':->VC&TB@IQ;=Q69I$JT\Y?F]/I&
M30=WI>ZFRTL+L=)G)9'OB[-\?8=H2Z(BORJ]I\*M(K47\WRPU%IO#Z5RNE8C
M?9S30<)8&^"^1LCY7.X2"X[#+U'<D70/3!B]:<R=<8/.:BP<N"P6G9.VAAN2
M7/DED=&XTXF1],(Z#O2L1 ZQJR@TUD@-S;=P ]P;%S@?.?+74G,*#EW-I_$:
M;FRD-\)8;'(QR.[.+MH6QT<!$X#AJ'?&"[3$5(['OS_*O5N+T9IRWM[)V7-I
M>&\S6'BV"0R/N)-H''Q4$@;\52+HJ/'G]*ZGSV8T[D,/H+[OXC&7T,D[(HVB
M=[3+&2YP9!$:-#:I$T[QNUQC=4X3G5>:G@P=Q?X7*6T%NVZB#J1\,-L"748Z
MA!B(VJ;*#7[+E7J'*<JY\9-9NML]9Y66_LK>X;3C8&V[J4=38[LZ*[VT77_?
MS(XRRP.+Y=6N-S$?!'=YBYMHG0N:QO"7#BMVC::'XZ;-1NDNF\PSG5ALXVU<
M_#6N#;:2WK(^"$3=K>GAV5 -)&[*]*S78+,>F\V.><FH392^AG6+HVWG"1'Q
M\,  XMWR2I7]*L%RV?JG0$&H[7*Z<N7PQSS7\-T"YD4K2UC>$'LW#Y%:U6KJ
M2.MZ0U(W5FGK//-MC:>=-XO-G/X^ ]5>%M>XL3%)1I&5T]F)N=N S\5I*_#V
MUG.R>[:T]FQSHKAH!=N%2X#X5J)V#4M?:7U&SF4W4EYIR35VG'QN9#8 <;8G
M4 KPF.8#H^2-RU$[!A<1HW6#M>R9Z;2QPV+NL?/%!;VT=61ES7-#7\$<8!)Z
MPDS%!T/E+I[,X3E]F,9E;.6UOY[B^?#!(TM<X2 AI (Z5FZ=HT&/E?JJ\T%'
MYO9OM]18O)RWMK!*TL?)&XN;0$T-*.)Z5K>BH:XN.:&OAIVT?I*ZL;7'7L$N
M0D?QOXW=K&>)H,3-@#37>D4@9^7!ZSY>:SEU3I_#29O%Y>U@CO;*"K98I(X8
MF[FMD)VQ_-"E8F!YK/26L=59S4.NL[BGXV>3%WEEB,8ZKYG&:WG8!M:P_P"$
M ^(E8@9_$:;SEOR$DTW-8RLS1BNVFS<TB2LE]+(W92NUI!4K^I7CN]*:A?R*
M@TZW'S>FFLMPZRX7=I5G!7P:5Z$KM1X<!IG5&)UKA,P<5.Z&RTXVV>>!P'G#
M9+<]F30T/@N[B3,4& TI=:[Q^I[[6&JM$9++YN=W#9E[9&LMX:'P8^*&2FU[
MOBT6IIV#8]>8;5.N8,'K2UTW)!E<'(]IPEZ.,S0R.J=KXV]+1LX"I$Q&P+2/
M6&I=08V/':$M=,X>$N=D;JYM8G.<0UQ 9Q0PG:>$;"FR.\6\?8Z[Y6:FSGH?
M 39[ Y>4W-N;<EABE<7/ <&LEV5D/4FR8$<J;+6.FI]9:HU-A9H;JY=)=QVS
MN)G&/V9HUQ;U _)2Z@ZWHK4HUA@(,Z+8V3I3X5LYW:%AH#OX6UW]2Q,4D:!K
MW3VI\-KO&\Q],8]^5?;PNM+W'1;)'1R"05! >2 7M/Q%J)BE!JL>-U[K/FGB
MM0YS3=QC,$QLD89*'2<+'A@/'6-E*@#>%K9$"_I1G,?E7!D-,PZ:GSV/D>^2
MPN[9SFM:)-OA!L<M*'B^4I-)%B/E-JF;ESGW7$0;JG,WK,LZSV;X^VE9'OVF
MLI;N^!7>BHQ.M8.9NLM'8S33=(W-FW$NB-Q,\N>92QW#X#3$WH(.PE(F(DEL
MFIK#76$YF8W5&!P<^2Q]MC8H;N.,N94-+N)@<&/\*A/0I%)A5=CI[6FM=7W>
MML]B),1:VEA):8RPDJ^4O?P#I;&=M'GXJ5B(HC"VO*O4F3Y4LL7V3H-18W)/
MO;6SN&</:,I 2/"IO[.FY7>BI1Z[G[\9FTLL/AN7=KA[]G"V]R=U;1/B+6@M
M/#QV[!4DM=\939J.K7O*_0^4NW9'*X2SN<@\@RW+[:%SG.!J-KF$_I6(ND<S
MR-AK/1O-G)ZATYIJ;(Z:?96UFR&W!C92.* >!PQO&SLZ4 6XI,4%6*TGK'46
M1U;K?4&,DQUQ=XF\Q^+Q;JOEK)%)PU)##M,I%.!)F(V#$W6A]5/T'HO'-Q<Y
MO+')-FNH0QW%&SC<>(BFP4*M=LJW33^F\Y:\YLWG9[.6+$W$+A#=N:1&X\4A
MI7=TK,SL1A;GEYELYS!UB;RTD@Q&6LF06MZYA[,R&%K=A- :&O2E:0,7%<\V
M,3H6YY>0Z6N)[QC)8(,JQ[A$ZWD=QD"D1!)!>WXZULK4;)I;.9/E=RTT[!E\
M/+)<RR1VMQ"YQA= [LF;2"QU=QZEF8K([#'-VUNV4CA[2/CX:U^,VN]8'S3H
MW4NJM.\PM>S8/!2YVQER,@FA@>6OC<V>YX=T<A-:GHZ%VF*Q!#*6W+W5T^C=
M9YG*V+V:EU 8A;XV,%[Q$V:!QK2AK^RK\59WHJ,;F=#:O@;HS(WF ESV&QUK
MV=[@Z&K9.&+:YA9(*^"=[%8F-HI9I+5&3U]A,_;Z-. P$+3!YK;QCB8."0%\
M@9%%2I/2WJ2NSM&?Q%EK_E9D\]88C3\V<Q.3FFNL=<6SBWLI)*AO&&QR[!1M
M:D*;)'@S'+7F'GM+6N?S+GW^J;6]%]%BKEQG#8&]LT1-+W'>'--.'X$WHJ,D
MQVL]19/&6F*Y?VNG(H9&OR-]<VL3APM(<>#B@BVT!I1R;([QY8+;F#HWFAG]
M18_35SE\/>QQP$1!T8?2.#PFTCDW&,C8KLF!=L>6VIM;NU3J34UH<5?YB'S?
M'V,AXW1]F'%A>3P4VOZ6A3>B!8MK[FOC-'NT S2<]Q?0M%M!EFO<+<PLV-)'
M9$;@WY:NRM1NNE.2^E[+2^/Q>I<=;9/(6P/'+-!%)PDFE 7A^SX5B;IJ.@X7
M!8K3MBW'86TBL[-A);#"QD8J36M& #]"S749)O2!M'6BOEO!_P#KK>__ ,[N
M?^^%!]4(@@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @("#@NH>56I<CS#EU' (_1[KGMA4GBX:D[J**[RT[*=
M(WJHE!!/4BE5*A5 50JBE5$*I52J%"J!7J2I0J@502J@@(" @(" @X/^:S_D
M*T_WL?WA7OX'][YOJ/\ 2?%J^\_)J@BJA^A$5=*"L?V!45!!4U05#8J*@H*A
MN515[ZBJ_P"5!4-J"H405A!4-FQ!4$)5#?1"50*"H?\ L05!%5!$5#<@J""L
M(*@@J05C:4%0WHJH(*@@J""H(*MU$%:"H(*D%0VH*AO15;414-Z"H(*E%5!$
M5A!6WW4555$2J*P@J""0H*@J*QN05A02%14-Z@K"*J1%005(JH(*AN05A!4B
MJ@B*P@K:@K&]!4$%0W(*D14@J0;)I35-UIR]#P[CLW[)8M^SK&Y>;/@C)'B]
MW"\5.&[P=ZQ>6LLM:MN[*021NZ!O'OK\_?9-LTE^LLR6WQ6'M!)/N="PVE 0
M$! 0$! 0$! 0$!! 'NH)011!*"DM!->E!'9M_ME!/ $%(H":;"-]>H(J0!NW
M(B"P$[=^VGO%!XLK8>D\==6'%P"X88^(= /OU08+E_H^/0VG(L!%.ZX8QYD$
MCZ<7A-:VFP ?)5NFLC: 1NW[=W3505F,&E2:CI0' "@IL00!MJ[?^BA10!H%
M-P.Y$1M!&RE.A!/@@@A!Y[VTM[ZWDM+MG:V\P+98ZD5'P$% Q^-L\990V./C
M$%I T,BC;4@-:*#XU2@])C: 2-B"@4^ ;2>LH*@P$;34'>@GLVH'9-0#&TD$
M[QN]PH'9@=)KUH)X&H(,8/\ ;]U!/ /AZT%/9=/$:]?N]:"K@ -1T[3[Z"#&
M#TT0.S;4'I"">#W3OJ@LW5E;WEM+:7+..WF:62,J14'W10H+>-Q5CB+2*PQ\
M0@M(6AL<8)(   WDD[@@]/9MV$;QN*"> ( 8T #?3<@CLQU^^@&,$U[B!V;=
M_3UH'9MJ3U[T$\#2:].ZJ"D1 5VGW/<05%@*".S%0:[MR"> &E>A! C Z>M
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M;D([=]O$_P"()*@D D5%0-BO <;'%8_,BV;8\4X[A)X;)N3,3+,+Z3YX@("
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M! 0$! 0$! 0$! 0$! 0$! 0$! 0$$.KT;?<04@4(-*$[T%: @(" @(" @("
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M"CJ\;7<!%>&F_P!U!LB @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @("#Y,UC_P"L4_\ OP_OBBOK(#IZ]Z(E
M!2=_]I17&=;:)S=QJ2:YQ$#W65^&"<QM=P@ BH--GR05_,O6/1L]_%3=BB=V
M^E:>W@_H?I7JN&WAHMR3&]9V5=&&'-EHR;#6K"Z<8Y\#6@;72F#@W#K*_:\I
MY? SAMC;Y<Q[]VC\ES/F<;&6Z=F_$^[>JYYIN;7VF; X^UP;I8N,OXWMD!J?
M^BOQGI]WJ7!X_+MQ5BOC^#]9QUO <7?OW9:336/Q;1#>:KSN%RUMEL9YK*Z!
M[+<-#JO<]CQ3:T>XOO69N,XG!DMRX]V=V:=ND^#XMV+A.'SX[L=^]%8KV:PI
MT=I>1VD9</F[8L?))(X,D;M%7D@CB"GI/ID\E.+-;2LS]Z^I^H1'%QEQ75I$
M,;I'$:DTW>W^&F@DGP\S7BWGX7<(-"T&E"-NSI7A]*X3BN#OOPS$W8YK2=KV
M>I<3PW%6698F(OBE8>; ::S5K@]16T]J]DMV7FW86N!=5U10$+CP/IV>SA\]
MMULQ-U:?%VXSCL-^?#=%T4MI5M_+W&WF*TW#:7\3H;@/)+'@@TX6CIIU+]%Z
M#P]^#A8LOBDU_A#X'K6>S-Q,W636*?BVF@K5?H'PW/=.X/*6FN<CDKBW>RRE
M'[.4M/"?!<-]*=*_&\!P66SU"_)=;,6SW_%^LX[B\5_ V61,;T=WP=#ZBOV3
M\FE5! 0$! 0$!!P?\UG_ "%:?[V/[PKZ' _U'S/4?Z4OBU?=?E&T\NIX+76N
M&N+F1D,$<Q+Y)'!C .!PVDT 7+-%;)>CAIB,D3+J_P":#+XG+:AQDF*O[>_C
M9 0]]K,R9H->DL)7BX&V8MFL/H^IWVW712:N"C>OI/C-JY=ZBDTQK#%95KN!
MC)V,E/%P#LWGA=4^\2N6:S?LF'HX;)Y=\2^MN8O,72V$T9D<Q@,C8RYW+"(%
MMO<1/F#^SV.<UCB[P6LX5\7#ANNOB)B:0_2<1Q%EN.9MF*R^)JDU<3M.VJ_0
M/R;+Z9DCBSMA+*YK(VR@N>X@- V[R5SOVVRZXII=%7>OS/9S#9B' G$Y&UOC
M&7]IYK-',6_&I4,<ZB^;P-LQ,UA]CU.^VZ+:35\ZA?5?"?0WY>\UB<9IK4L6
M0R-M9R2QSB*.XFCB<^L+ .$/<*[>I?+XRV9NMI#[GIU]MMMU9B&L<F,CC[#F
M=+=WUW#;VI=,1//(R./;,TCPG$!=N)B9QTAYN"NB,U9ELN=UIIW#\[I<Q=]A
MD\)*.SDF8]LL;>*(M!!;Q#8XCI7*W%==AI&R7HOS66\16=L.@C3?)^34L',&
M'/6D+F.;="Q;<6S6&3X]2WBK6N]>7?S;NY1[?+X??\S>CXPX=SGUW::WU.9<
M<P>CK-@A@DK7C )=7JWN7TN%PSCMV]KX_&\1&6_9V0T[2U[#CM387(W!I!9W
M]M<2G]2*9KW?H"]&2*VS'@\F*ZE\3I,/HKFYC=*:TQMGJ>UU/9,EL;>(,Q[9
M87RR$OV[I001Q[N$[E\KAKK[)W=V7W>,MLRQ%\71L8[FYFL/><J<%96>1MKB
M[C[(R6\,\<DC:!M>)K7$A:X:V8RS-&.,R6S@B*PUO\N>3QN+U/EI<G>P643\
M9*QLES*R)I<9H"&@O(J:#<NW&VS-L4U>?TVZVV^:S39^#8^5NI].8_6VK;;(
M7L5L_)SR,LK]TK&, +I/"#W$#IWU7+B,=TV6S$=CT<+ELC)?$SV][:](V&CM
M%:KGR]]K2#*W^3#K>/BFA$<3)'MDJYW;/W=F!T+ADF_)92+:1#T8;<>+)-TW
MQ,RT[2]WB<7SUR>0FR-J,?<SW5PR[,T8AI*):#CXN']*]&2)G!$4VO+BNMMX
MJ9K%&B\Y;RTO]=W]S8SQW-NX1\,L+VR,-& &A:2%ZN%B8QQ5X>.NB[+,PT+J
M7J>!4@J&]!4@KZ4%015005!!4-R"H=2"MJ"H(*AO05@()&]%2$%P(BH(*AU*
M"45<1$CK05BJ"L5Z4$A45A!4$$A05!45C<H*@@J"HK"@D(JM$5#<J*@HJH;D
M%0W(*@@K150WHBL(*P@J""L(*AN05(BH=""I%5A![,;CKO*7;+.SC=)-)L\$
M$T VU-/>6+[XMBLNF+'=DNI#NVDM(V>G;5KJ=I?2 &64@ @[Z#?UKX&?/.2?
M!^KX;A;<,>+9N$>][R\KVI0$! 0$! 0$! 0$! 0$$.^*4'%^;^/SMEJ?3&N\
M382Y&'"=I%>6MNUSY#')(R0D< <?\'\U;MT&,R6I]7<T,B["83%7>+TN^SE9
MD;B^@EC<^;LY"UK>,,%./LQTJTB!CM*\P-1: TN_1M]I?)7.;QE;:PGB@G?!
M(V(=FP\0B( \$4H3O28K(UN;0&=P.D=-13V4\E_=9EMY=0QQ.>8F'B XP 2-
M@&^BU7:.F\\\??7LVCO,;2:Y,66A?,88W2<+!/ :NX0:"@*Q;WC6[J2_TYSC
MOLE=XN\FL<GCO-[>XMX))8P\AIH7-;3Y!Z5>V#O9WD_@;V72VJ<7D+>:S.0N
M+F%G;1NC);,)&U >!7>ET[1K.C]49SE;C\EH[-:;R%Y+$^5V/NK2":2.5L[W
M2[2V-P%.TIO.Y)BNT8"?1.HK?0$N8O,?.S*9G45C>.QS(GODBM^/CXB .+87
M&M6A:K%1M.0TYD<IS1CB?:3BTGT^RW-QV3S&)"VU'#Q4I79UK-=@T[3N,P&C
M["\P&LN7DN5SEL][+2]BLI)FW! X6\3Q&X 5%:U.]:G;WHSF9T1FKO0F+U'B
M=.1X;(V%YYZS!VD3F/,(,[6ES0T.XO":?B=*D3M6BSS&UQF.8'W>LL=I?)VT
M5M?12WTLUO/1I,T1 VQ-V#AWI$4'T?8L<S&6K>']J(8@&.V4=P#N+F/F?44V
M*RS<E!J[0=Y;ZN:7MLK_ !EK)PO):.S<9.Q=3P^*M.A=8\)&0S>#U5!R/P$&
M1L[R[R=EF8[Q]OV<DURVS:)BRK:<6QI:-RE8WAZ\KD\AB-<Z9YF086_O,++C
MS;7%O%;R]O%)PW#*.:&./^$;O 4CLH2QUL,MK_FS=96;"WN-Q&1LW6T$MQ!*
MSP:11@N+V- )#:T5[('ITUJK4'+K2V1T%D--9"\R,(FCQT\$$SXI&3DN));&
MX"G&[=U),5VC)<K-)7^HN66H<'F;*:QNLE/*0R>)S'->\OH>%X:=E5+IVC&<
MA+'(ZFU#/J#-!SFX*%V.M"ZI\(2!X(+O<>[<K?L(?2S* TW;Z#K7(5H" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @((< 1M0?+&
M"_\ 76]__G=R/_ZPHKZH1! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$'R;K%I_&&<TV>??_J**^L 0=@W@
M(BI!%-JBHIL2@FA0*(B*%%30H(H4$T0*'X$"B"*?"A5-$1*H(" @(" @(.#_
M )K/^0K3_>Q_>%?0X'^H^;ZC_2E\6K[K\FK:X@@M-"-Q&]%5NDDD-9'%Q&[B
M)/\ *A4&]5%;:@@C>-R"Z99G#A?(YPZ 22%*+64#]"J*FDC;W%!==)*\#M'N
M?3<'&J$R#<@N,ED8*,<YM=X!(0JEKWM/$UQ#NL&A0JJ+G//$]Q<[K)J4%P33
M!O#VCN'<!Q&E/>2BUD"(J&\4Z-Q071-,1PF1U.JIIW$HM93VDC@&N>YS1T$D
MA!4Q[XS5CBVN^AI5#L5->X.XPXAV^H)K5!7VTQ(<7N+AN))JI1:RJ$L@/&'N
MX_G5->ZJE0N<\\3R7'K.THG:J""I!4$%2"OI05!%5!!4$%802$%8]Q!4$%0W
MH*D%0H$$A%7&HBH(JH*(GH15P(BH;T%8WHJM$2%14$%002%"505%8W(*@H*@
MJ*PH)"*K1%0W*BM150W()&Y!6$%2*JZ416$%805!!6-R"H;D%2(J'0BJ@@]V
M-QMWE;MEG9LXY7GN!8OOBR*RZ8L=V2=V'=M)Z.M-.6P-&RWKZF2;;LJ *"OO
M+X&?/.2?!^KX;A;<,>+9@*'^1>5[52 @(" @(" @(" @(" @((<"6D#>@L.8
MQ[2R1H<#7P7 $4]U!2RWA@_H(F1CY7"T-![BBAM+>23M)((WOWAQ:*UZ>A5%
M3X&2 "2-KP#4%P!H?<02Z%DG#VD;7\!XF\0!H>L5042VMO)1\D+'N&QI+02!
M[A.U%2R&.,$-:UC2=S12M?>1%#[6WFD#IH&//R7.:"=GNH+G81/:&.8UT8I1
MA (%-QVI4/-XN/M!&T/ X>*@XJ=54$/LK:5W%+!&YP^4Y@)[I%45686\(8UH
MX!LX2-E HBR+"U;M;;Q#IJ&-&T? J+M!N.XC=U4ZE!:?902N[66&-\OSBQI(
M[H5%PV[',[-\;7LI3A< 1L]Q!2;.$QB(PQF-NUK"QO"/>"BI9:6[' QPL:YN
MXM:!0=2J(-G;R/XY(&/?\]S6EW=*#7M8X?4N1P[K/1U[!BLBZ0%UQ*QI:6'?
ML[.3;\"L4[Q9Y=Z(BT+@&8D2BYN'/=+<W(%..1Q)KW-B734;<T4-3N&Y055"
M"4 D!!'$.M J-Z"4! 0*]" @((J$$U0*[:("""0-Z!Q-Z^O]""=^Y K1!'$W
MK0 YIZ4"H*!4% J$ D#>@<0Z]^Q J!TH(+VC95!/$.M J#M0 YIW% XANJ@<
M0ZT#B;OJ@ @[D$<;>M!5O0$! 0$! 00=R+#Y8P?_ *ZWO_\ .[K_ +X4'U0B
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(-<NM%:<N\F<M/81OOR_C,Q:WB+NO:*J+5L#!0[MRJ*T! 0$!
M 0$! 0$! 0$! 0$! 0$! 0<'_-9_R%:?[V/[PKZ' _U'S?4?Z4OBU?>?DU04
M55TH*AO516$14@J;N15005J$J@B*AN05="*J05#>@J""L(*@AW*@@K""I%2$
M)2$16$%34%:"KH05A!4$%0WHJH(*@@J""H(*VH*D%0WH*D$A%5#>@N!$5!!5
MT*"KH05!!6 @K&]!6@!45A!4%!(0E4-RHK&Y!6%($A!6$$A%5#<JBL;E!4BJ
M@@J&Y5%2BJT54B*AO07&H*@@K&Y!4-R@J5%0ZT1[L9C+S+7<=G8Q.ED>0#P@
MD"O2?>6+[XLBLNN+%=DNI#NVC](VNG+5KGCBOG@=K(:;*[:#_P!J_/\ $9YR
M3X/UG"\+&*WQ;4-R\SV" @(" @(" @(" @(" @(""';&FB#4=8<P],:&\U&H
MII(77KBVW;%$^8N(Z@P%6(F1K?X\\OR0 [(;=@/H^Y^@M;DE70L1D[?+V%OD
M[3B-K=1LFA[1IB=P/:'"K74(V%8'OV$U;M]Y W[>D=""']'\B#!ZEU3AM(X\
M9/.2N@L^(,XVM,AXC_<JQ%19^^.";E\;@S<.%_EK87UE'P. =;G8#7<$HK8(
MP&DUV=0Z#[JB+G@[M@J@@UZ!4=: *&O7[B""=FRG4@\60R%EB;.;(9"5L5G
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M-8UC=P^:%B>T<@T'C;?F#S2U7G,ZP7=O@98K:SMYJT:YX< X-;X)_H>E;G9
MW3F]HW!Y+163O(K**#)V4;9[2ZB:8GQ.CE8\CP* @@$;:[U+9VC3CS+R<_+;
M3V+Q3G/U=FHV6<#N%IX0QHC=(:U^5P_)*N[M%CD9@QIOF#JK$<1DEAM8C+)M
M<2][F.)V^_1+IV#N>>Q<6>Q-WBI9#'%=1NB=(RO$ X4--H7/O5R?7F)T9RWY
M:2Z?=;,N+B<=A9DQAT\LTLO$"7.=797YW0MVS,RC1[K!9*"PY/Z8RSJQY"=U
MS/;N)+>!GF!8QU0#X(<X+5>T;)SKMK/36H-)YS%P,M;V*=L)D@:&U862BA&X
M[^D*6[1T/[D:7TYFLWKG)$3R78=/<.N&<;(F1![G!H<2-SNKH6:UV#G/+?#6
M^M,YK/+8YKK'2F7:VTM6QC@<9(?-P]X#30 NC<-CEJZ:0,)S6.GM(:9M>7N)
MP[V258V?.2QM[%A=^S,G:=HZ2HIQ'P5;=NT=ZT QD6C</##<"[:RW:.W;4AV
MT[B0#LW+G(V4&O3N4$H" @(""B2E-I04T&\5H-X074! 0$! 0$! 0$!!Y+[*
MXS&-8[)7D%FR1P9&ZXD9$'..R@+R*G:@] FC+.TXAV=.+BZ*4K6O4@\]EE,;
MDHWRXZ\ANXXSPO=;R-E#7=1+":'8@]7$.M XA\(Z$#B;UH(+VC?_ &50>6;+
M8NWN8;*XO8(;RX/#!;R2L9+(>IK203\"#U![2@QWWDT]PW#_ $K9\%H>&[=Y
MQ%2)QKLD/%X)V'>K0>V"ZM[J%MQ;2MFMWBK)8R',<.L.%05!<XVU KM.Y!4@
M(" @(" @(" @MS3PV\;I9Y&Q1-VN>\AK0/=)V(,$->:'/_Y+BO>\^MZ_WZM)
M&3L,SB,JPRXN^M[V(;Y+:5DS>ZPD*#VAP.Y +@!4]"".-O6@\M]E<9C(3<9*
M\AL[<;#+<2-A94BOQGD!!&/S&)RT1GQ5];WT+3PNDM963-!V&A+"17:$H/7Q
MMZT#C;UH(=+&TAKG .=\4$[33J0>%F?P<M\<7%D[5^2&^S;/&9QT[6!W%^A!
M[G2L8TO>>%K=KB=@ '24'CL<WALHZ1N,R%M>OA/#,VVF9,YA'0X,)(W]*#W<
M00.)O6@ @BH02@(" @(/EC5V5R4?-R>VCNI6P"]X1&'D-IQ'91%?4K0=Z(J0
M$! 0$! 0$! 0$! 0$! 0$! 0$!!!%4$4._>>I!-!U(%/@0*()0$!!%/=0*!
MX0@4]Q H@FB"*>Z4"GNE!* @CA]TH'#[I0*>Z4$H" @(" @4"!1!%$$[4! 0
M13W4$H""-O4@G:@(" @40$! 0$! 0-J!M0$! 4!40@G:@(" @(" @(" @("
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M@*BC@=B73V#7-%:JS'*6#):1S>!O;P1RNEL;BVBDEC>'T('[-D@&TGI5F*C
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MJ.**+B$<894UV  ?H1!S&/!#P'];2*CN*"&111U[-C6#I  ;7N*B#;P.=VG
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M&*Q1M8X[-@#3W0JB.P@#N/LF\?SN$5KUU0>AHH $$H" @(" @@[D6'RQ@_\
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MG,+=YJ6,S16C0]T8/"75<&[Z'KZD')_:1Q'J:3R_^:01[2.)]3R>7_S2#?\
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M&AP'Z459RV19B<9<Y-["]MNPO+ :$@;-]#_(B.0._,;B6.+/0\G@DC^GZO\
MY2"!^8_#-%!A9 /\O_FD&YZ#YEV>O9+IEK9.M?-N#BXI..O'Q_J-^:BMZV@
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MB+.1QUOE+.:PNV\=K.WAD;4BNVN_X$&C_@GR_.UV/?7I_;/[Z*?@GR]]7O\
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M'%52W]J][Z9C![-M3M'2N0J H@E 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$!!!- @CB[G6@J0$! 0$! 01Q! KLJ@<00.(=:!4%!*"*A X@@<002@(" @
M(" @(" @5""*CH02@50*H%0@(""*]2":H(J$$H(!02@BH0*A!-4! J@BJ":H
M"!5 01Q"E4 .J@5J:#X4$H" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @@E!'$/A03Q!!'$*H*@:H" @((J@5Z]W6@ U02@(()H@? @E
M 0$! 0":((XMM$$H" @(" @((!J@E 0$! 0$ [$$5%*H =7=M0*[D$H(K[B!
M4(%>GH03O0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!0[:?>Z.
MM!KL&D,+!J2;54<'_B]Q'V,TFRA;4'JKT!6NP6\/H?3N#RF6S6-M&Q9#,/[6
M^EHVKGU>?!(:#MXW),C'CE7H]N)NL*+5PL+RX-Y.RK:F8D&OQ4WI5DH=%8*'
M,V>?9 6Y*Q@\VMW["&Q4IU)5%5KI'"V>J;G5\,1;G+NV\TGEJ*&&L9ZJ_P""
M8E=E!-GH[!V.4R>7AM_]-S3.SR'&&N9(RKB6EI&T>&=ZDRK69.2/+V2_??.Q
MHJY_:&VI&+8N._\ 9\'#1:WY&?U+H+3&JL?;8O*V3/-+0EUHV)K(S#Q$$]GX
M)X:\(K12)F$3A="Z?T]D79?'0O%ZZV99.D>0YSH8PP-&X'_!M29E882]Y-:
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MI!W5ZE\O)CFR:2Y3%&9'N[QL7)E4@(" @(" @(" @(" @(" @(" @(" @("
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M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 006-=3B:#3:*BJ"4! 0$! 0$! 0$!
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MLO<?*'M=3B800YII6A!]]?#R8YLFDO--LPR_3U'H7)%0V ()0$! 0$! 0$!
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M%&5Q^%M-)Z-CPMW/D<=-F6O%Q<P& OXY'DD-+Y*M-?G;4CMD=%YYL:(M#OH
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M;9F,R-CC34@<+()G5 ]YX7:?T[EOC#4[*0P[;">PY<Z.UU9EWG.%NW=N:UK
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MP)2TD_LIF@;MW@ J=TJC3.+U%KS6FJ<5=Y^YL<-8W)$;+?L^,N+GAHJYA-
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MXHYB_P#-;<>;@@;.P@V^$]G5UKK$?I'1L!K;FE?9BUL\SHE]ACI2X371+/
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M:\L=8'0>F[VTLGQ:BTU?27L=C,US'R,(MGEH! .TP4W*[T5&5U#9\P>:WHK
M7VG9L%C;.1LM_=70?PO+&D> ',8-IIUJ12!L&C])9?$\V,YDWV,L6&DA9':W
M+F.#'!KIM@=0 ['!29V"]I#36;L><.I\[=6<L6*N[)D5M=%C@Q[PVTJ XBA^
M([<>A)G8,US<T9D-8Z=9%BS3)V$C;NV8=SW1N;)P_#P44MF@TFXR7-S4]CB=
M+V.&O--S6CHVY#,A\L;7LB8Z,AAX&;"7-=\8[EK9"J,=B=;<I]1YB3#X*?46
M!S,AN81;<7:124X*.X62?-:=P39*,9^'6K\I@M<:HRU@^/.YV!L>.QC&N=*U
M@>*M(I4FC6]"M8V#:]5:7SMYR&=INUL99,UV=FWS0,<9:QW\4KO  XMC03N6
M8G]1+S<Q-+9[*<K-.X6PL9I\G:7-@^XMV,<YS!%;O:XEH%0 3M2)VC3K#*:I
MT]S=S%Q@L7)E1!CHFW]A&7"3@,KV"@#7'8\CY*ULHO>S]OI+5NJ;K5.M<YCG
MV%[>V3[+%8IP<9N"E&U!:#6@;\E2M-@Q;^6&IY>6^FKBWL'?>/!2R2NQTS'-
M=)$^>4%I:0#6DG%N5KM1FK8ZTU#D\3:6&B6Z>A@D:[*7UW$\M<T<->SJR/J=
MTGH4V"G+:=U/B^:EWEF86XR&'R]GYJ;FW:\MCK05?PL<!M9N)2NP8C X35G+
MJ'(:=ET4[4=N9YGXW(Q,>X!KR0SCX8WB@'#LJ.E6:2,CEN7&MM1Z#MI+RW@M
M=1VE\[(VEC"PL#6^%&&.VDUX"I$Q$C$:YFYG:]M,'CCI*[L(<==127TKV2N[
M0\;#Q,'9MH &GK5BD#K<>L9,1J+ :*GQSR^_LF.=>=I01NB8!PEG#[GSESIW
MJV+5&$^\.G[_  Q/#YY!)$']3GL+0:>X2D;$<5Q>0YK:7TJ=#6FF+F>]MB^*
MRS$7:"+@?*Z6I(C.WP@/CK<TF:B)]$<Q=%Y[$:VLV2:BR++;S;,0<3WSR$<8
MJ'#C)-)#T'<D3$[!EL3@=5Z[YCV6ML]AY<%BL1&WS.SN>(RNF:YFT\3&;*<7
MR4F8B*#V\E],9W3^G\W:Y:REM)KBYFDA9(QS"YKH86@CB WEI4NFLC5[7E_J
MJ;EEJC#>CY8\E<Y&[N;>"1KF.DC=+<%O""*FH>*46JQ47),-JW4.<T/DY-/7
M=@S$F:&[9,R3P08I2'&L;: F2FU39%1L_*W3.<PVL-6W^1LI;>TO;D/MI9&.
M:'MXI"2TD '>-RDSL&"MN7^H[]G,.RDM)+<Y=['X^61C@V0Q>;2;"0*U,9&Q
M6O8-;S%IS.RW+8<OX])W,,]A (YKUS9"R9MO%V0$8[,5)VD4<58I6HW3&Z3U
M!#K'E]?R6,S;3&6-U#?2\#@V)[X;QH#CPT;4R-W]:S,[)&4Y3Z<S6$U)KN[R
M5G+;VV1RLL]C)(US!)$ZXN7<0+@*['M-1UI=.R!H;>7F1FTEK2US/#B)[G+Q
M7F+FO3V$;PV&)M0Z3A%#0C8=ZU7; Q?,35&N;[EM'@\EI^6Q@@,;+K+2.<89
MJ-( CJQH)=X6YQJK;$5)?0FA0?NCA&TX3YG%7HZ.I<I67,&:1U"W,\V9_1\W
M8YK%7,&+=V;Z3RO;<\+6&GA$\3=@ZUJO8C-:8TWF[3DP_ 7-G)'E3;3L%JYC
MA)Q.GD<!PD5V@]2DSM5LW*K%Y##\O]/XS)0/MKZVLX8YX) 6.8]K14%K@#52
M[M1J7,;0FI?O5:\P=%-#\S;,;%>VCC3MV-I2E*$_$9LVK5L[*#PYO5/-#5F.
M=I_%Z/N<//=L=!/?W1D$;&2#A<6DQ1]!/RDB(A6(UMROR^#Y3XC3V$LI<MEX
M,K'?7XMV.>]Y=!<<9\ .- ^2E58NVHV>QYGZY9V%L_EMDV-JUCIB^6@!=M-/
M-O=ZU-V-1JV>CUGA.;]QKBPTI?96SN;2V!B@;(.%_80\3>,1/%6EI;N5BE*#
M<+/F=K2YN(K:7EQD[>*1P:ZXD?*0P5WFML/Y5)MC4=3B+Y(V/>PL+FAQ8=X)
MVT^!8%Y 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MW8]IXFN;#&""/= 3?NU'N: T #8!T+")0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MF0J>@[+];N_S(5/0ED/G=W^9"JJ+$VL,@D9Q5ZB?YD2K((" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @U?7.NL-H#%,RV:$IMY).R8(&L<[BI7;QO8/
MTKMBQ3DFD-6VU<\'YHN6Y.R/(4_R4'UZ]/(Y/!ORY2/S0\MNF/(^2@^O3D<G
M@>7(/S0<M_\ %Y&G^2@^O3D<G@>5*?:@Y;?XO(^2@^O3D<G@>7)[3_+?HCR/
MDK?Z].1R>!Y4GM/\N.B/(?#%!]>G(Y/ \N4^T]RW_P 7D*_Y*#Z].1R>!Y<G
MM.\N/\7D/)0?7IR.3P/+E/M.\N/\7D/)0?7IR.3P/+D]ISEQ_B\AY*#Z].1R
M>!Y<I]ISEQ_B\A3_ "4'UZ<CD\$\N3VF^7-?Z/(>2@^O3D<G@OER>TWRY_Q>
M0\E!]>G(Y/ \N4^TURY_Q>0\E!]>IR.3P/+E/M,\N?\ %Y#R4'UZO(Y/ \N3
MVF>7/^+R'DH/KU.1R>!Y<GM,<N?\7D/)0?7J\CD\#RY3[2_+K_%Y#R4'UZ<E
MD\#RY/:7Y=?XO(>2@^O4Y+)X'ER>TMR[_P 7D/)0?7IR63P/+E/M*\N_F7_D
MH/KU>2R>">7)[2O+O_%Y#R4'UZ<ED\%\N3VE>7?^+R'DH/KTY+)X'ERD?F3Y
M>=,=_P"2@^O4Y+)X'ER'\R?+WHCO_)0?7IR63P/+D]I/E]_B[_R4/UZ<ED\$
M\N4^TER^_P 7?^2A^O5Y+)X+Y<GM(\OO\7?^2A^O3DLG@GERGVD.7W^+OO)0
M_7J<ED\#RY3[1_+ZG]'?^2A^O3DLG@OERGVCN7Q^1?>2A^N3DLG@>7*1^8SE
M\?D7WDH?KDY+)X'ER>T7H#_%WWDX?KDY+)X'ERGVBM ?,OO)P_7)R63P/+E/
MM$Z ^9?>2A^N3DLG@GERGVB- ?,OO)P_7)R63P/+D]H?0/S+[R</UR<ED\%\
MN4^T-H+H9?>3A^N3DLG@>7*?:$T%\R^\G#]<G)9/ \N4^T'H.OQ+[R</UR<E
MD\#RY2/S!:#/R+WR</UR<ED\$\N4^T!H3YE[Y.'ZY.2R>"^7*?Q_T+7XE[Y.
M'ZY.3R>">7*?Q]T+\R]\G#]<G)Y/ \N3\?=#?,O?)P_7)R63P/+E/X^:&^9>
M^3A^N4Y/)X+Y<@Y]:'^;>^3A^N5Y/)X)Y<I_'G0_S+WR</UR<ED\#RY5?CQH
MCYEYY.+ZU3D\G@>7)^.^B/FWGDXOK4Y/)X'ERG\==%?-O/)Q?6J\G?X'ER?C
MKHGYMYY.+ZU3DLG@;DI'//17S;SR<7UJ<GD\#<E/XY:+^;>>3B^M3D\G@;DI
M_''1?S+SR<7UJ<GD\#<E(YX:,^;=^3B^M3D\G@>7(.=^C/FW?DXOK4Y/)X&Y
M*?QNT9\V[\G%]:G)Y/ W)3^-FC?FW?B1?6IR=_@>7*?QKT=\VZ\2+ZU.3O\
M W)/QJT=\VZ\2+ZU.3O\#RY3^-&CSN;=^3B^M3D[_ \N6P:;US@M5&5F,D>)
M8J5CE #J.K3XKG=2XY,-UG:S-LPV+B)Z5P95H" @(" @(" @(" @(" @(" @
M(" @(" @(" @@[!U(,?>YG'XTL%_<M@+ZE@<#X0'O!!9BU)AKF1L5O>LDD)H
M&"M3L]T*T&3:]QJ*@D;#3H*@L.R%LRX9:/E#;F0<3&=8_L""_P 9V] J!NZT
M#B>>JO1U('&:GJ']@0.,])H.M(#C(%2:@BH(ZD$AY_MUZ$$!YVUW[@!UA XG
M$'H_EJ@%[JCW=P17C?F+!ESYF;A@O":"(UJ?T(BQ]X\07=FV\C+J@'?7::#H
MZ2E%9)DO&.)IV$5'O'<41(>>G?U(!<ZF_?[FY!/$?AZ*H(+G;:;:;Q3:@5>!
M5Q 0.-U#MV]'OH)XSTH*>-QIT5V#8@JXG="@%QH2-WZ51Y9LE:V\T=O-*UD\
MVV*-U:D;ME$'IXG#90^^HJ.)_=I0T515Q&M.G>H/.^^@CN([620-GFJ8XSO(
M&PT[JHOAQ(KU[=VY!3+,(6ND>ZD;=[NH=)*!',)&-D8X%CMH=T(*PX]/O((+
MZ;D#CZ:T ^-L0 \D;-M-B 'DD[=FX'W4#CV ]: 7.:#TGH]]!8FOH+=\<4\H
M9)*:1M=\IU":"GO(/14[]_\ *@<3J5I[P06H+J.XC$L+P^([ X=**N<3R:#=
MU@51$\9()&RG<4'F9D;5]RZS;,'731Q.BZ0*5K^E4>CB=T[-FP>Z@<3NL>]U
M((#W#?T?RH*P3\&^J"E\G TN)HT"I)]S:?T(+%M?VUZPR6DHE8UW"XM&X_"@
M]/$:$G9[Z"GC)J-Q&^B!Q.Z#4$5!0.,["2 #N03Q.I[O4@%SO<KT@(#7$FE:
MT06G744<C(7O_:OKP-Z3PBI07&O<>[LKU%!'&=AV@>]O06KF\CM(G37,@BB8
M*O>[=3?T=2"Y%,)FB2-W$PCP7=!'6@JXG;^@](Z$%Q 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!'
M$$ .#A4(%0@<0ZT#B" ' H'$.M XAUH!<!L/\B!Q#N[$#B'6@5""4! 0$! 0
M$!!PK\U'_(=I_O@_O"OH\!^]VQ=KXR"^\]"4%0W( WH*D$J"0@JV(@/<5)2H
MJH()02A"0@J"(E02JJI0@&Y5%0JHJ41(14H)""H(""L;E Z5454H@K!V*"I!
M4$%0150W(BH(*P@D*"L>X@K%4%8*"IIJ@K%*(*QO414$54.M$5!!6$%04%0W
M*BI05A$5!%5!!4$%84%0WH*@@K"@J"HK"@J""O\ L]U![\3E+O#7T.0L7\$\
M+@YIZ#3KI18NMBZ*2DQ5](:(UW8:JM6QO<V+),_I(345ITBI-=Z^)FP3CGP>
M>ZVC<N(+S,)0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!1)*R)CI'FC6@N<?<&
MU!C[+/XS(3OM[64NE9O!:1NZJ[T6C(N(X3W$1\Z\_+#$Y+F#H2RS/!Z,N'/C
MN^T<&,X#-$TU)W;%TLG9*3#%<S=$<I--Z7GR^DKJ"WU) Z V$=G<Q2E[W3QM
M=5HXG?%+MQ5MF9G:LMI=S5U+@L;H_"Q8L9+,YG'0$,DJTF;L8*!Q+VT!,FVJ
MF[VB_)J"]',33L6J\!!;ZF?8/EBG:\2F*-KYJ-!9(X=![JE-FP6K;G)K#-39
MMFG--QWAP4]S'?RO?V<8BA<\,(XI&U)$;]RN[$"BVYW:JSF$EU!I_3+9\59;
M,C+*_@+7AU"& R-)WC<"F[$2-CO>;;Y-,Z>R^!Q4F1RFHJLM;4!PCCE'9@A[
MM@;MD;M<X*1;M'EL.:&J[#5.-TSKC QXM^7J+*>WD$HJ&E]"6R2 ; 4I%-@\
M_P"*VL<KK#+Z5TO@(KZ?$7,D4LTKQ$.RC>YM:OE8-O"4W8I49[0',R754.8A
MR]HS'Y7"EQNK=M0.%H)KM<[>"WI4FVBO=RXUO>:ZL;W)R6@MK".Y?#9/;7]I
M&T-(=M)Z"DQ1'BUYS*ETWE;336"L/2VJ+VCHK3:&MCH07.-6@;2W>>E(MKM&
M*Q?-'48S,VD=286/':IDB=)C8FO#H)G-:YW"7B1S=O#3XRN[WJXC@+35.1S>
MK]1# V][E+"X/:W,DS&FU<9' !E917=3IW+I-$3HBPLL7HBVU)F]-V]RVYNX
M([>^<^KY'F:%NUK7U%.*NT)/:D.X9SF==8[(8W2.C\4,EJ*6WAE-LYW!%%&Z
M-A;Q.+F ?';O<N>[7M57A.:F5+,S;:KP4MAE\-#VSH8&NDCF#G",!KFEX)XB
M=SMR3:,+?<V^8&/P[=5W>DXX]*O_ &PF=(.W; 1Q!SHQ+Q#P>MB;L=@SVH>;
MC;&UPT.G[ Y+/9^,RV%@:AH:PNXBXU;0 ,>=ZD6C#7'-C6N*?>X_4&EQ:YB*
M!US9=EQ30O[-I<YI<R1PZ6_*5BV%;-#S1LIN7#M<L8WM&L(\UVT[;M>R#:5K
MM]]3=VT1L^D\K?9W3V/R^0MQ:W-Y!%.Z$5HWM(VOZSU]:DC1,MS2S]WJ:]TO
MH/"MR]WC1_IT\KQ'&T@ D!SGQ@_&;TK6['>*+#G#--IK4EY>X[S+4>FF.=?8
M]U>'^CE<TM\+:*Q.&QR3;M&";SJUH_3[=7LTNPZ5CH)KDNH_:_LRX,,G$?#V
M?%5W8[!L^?YN06UC@V:<L3DL]GVM=C+(U#1Q</QC5H H=Y(68M5RS4^>U!F.
M:ND8=3XKT7D[4<$D3'!\;VNDXP6N#G@['#Y2Z1&Q&Z6O.+5^=R>5Q&F-.,O;
MS$W$S+AY=V<?91$\)JZ1H+CPNV5^!8W8CM&:QG.G#OTKD,[FK<V5_B9#!D<>
M*\0GXG !N\FH;7I4W1ACS@UKC[&VU#G=+-M=)W3P!<M?Q3QL+@VKF"0N&T]+
M%K=@9C.:AP=_S T)+'8QW<N4LYKBQOW$\<,;G1.IL(W\0K4*4V2,'C><FL]1
M/R4&F]-LO7XN5[;F5[^SCX6,:XT+I&U.W<"KNQ Q.M^8N4UCRFR60QE@V&YA
M?);Y:)SN'L !(TEO$[;\4[JJQ%))=.Y3W6<N=%8TYJSCM2V,-MN!P?QP["'&
MCG4-2Y<[J55CM8<R<GC-20Z.TGBQEM0R-$LT;SP1QM=0#B>7, W]:U%O>C'V
M'.*\L(,PW6V'?BLAB8Q+*V,.?$\/<R-H:\%[34R#Y2;N@QK^<&M[7%QZLO-*
MMBT9*1*VY#ZS^;O <UYC$A=M:0?B*[L=@]VK><\F&O\  VN"QXRD>=M^VM0>
M+B+^.1I'QFTIV9WJ1:,>.<VLK?/OT9DM,,;J^0,-C:PR Q.#ZU+W]HYO2WY8
M3=CM*LIA^;>7D?G\5J#$LQ^HL' +J6VC=QQNC>8N$\0>X'9*-SDW1@L;SJUM
ME,$[5./TNV73UF.+(W'%PO'"WC>6M,@) :*[&E7<CL'DUQJ6QU;=\O\ /8_9
M!<WA\ [VN;'=-<#7J<TI$4JK;LUS/SMQJFYTEH7"LR^2L.)MY)*X11L>PN!;
MQ/?&*^ >E3=V;48[\3LKJ33N=Q5OBVVVK\6T&]L'NX6",D>&USG@'XS-SCO5
MW1K'*WF#?Z.Y50Y'-6;76[I#'B#&X/DN9GEK2TM:XD4);T#>ET5DALK^<&K,
M'YCD]::;;C].Y!S60W<3P][3("]O&ULCRVK6N.UH4W8GL&8U+S.RC-2,TEHK
M%LS>89#YS<F1X9&Q@<\?&+V"O@=:1;%*R.?\L,E?Y7GCF+K)6AL<AYFYL]L[
M:&O:V,&AJ:C9LVK5W[1W75V?9I;3][G9('W0M0REM$TO<YTLC8F[!4G:X57.
M-HY;D^;FOM.V%MJ#46E8[;35R64FCD#Y6LD'$"YC97$'A'2U:W8D9/5_-O)8
M/4^)TWA<2,E<Y?'QWULTU#N.1\P()XF@ -BJD6[!=TWS0S$NI[G2FM<2S$9*
M&'SF-T+NT:]H^-X0?(WI;TI,:#"7O-G4VH[',W.FM.B[TK;1RP37[G<,OA,X
M26M+VDT+NAI3=H)_+5(V72^3FX2..]>X-=L(#G/-%;^T9_F3S/R6B<YBL%C,
M:S(76496)KJUXZOV"CFC<Q2+:CR9CFCJ/ 6>.QN5PC':XRLSH[/$Q/$D8:TL
M <Y[)' 5,C?EINB[A^:>;M-10:9UYAVX>^O(NUL98GB2-Y(+@TN:^0#8';*]
M";N@P]MSBU?F,IF<-I?3K+^YQ$\[;ASW<#.QC)#:%TC07'A.P'X$W1F<3SJQ
M%SI/)9[*VYM+_%.[&]QU#Q=L2[A:W?6H%4FW:,0_F]KC&6%MJ//Z5;:Z3N7-
M_P!)C?Q3,C>0 YS!(YP^-TL5W85Z=3<X\E::@Q.$TQBF95V8M([RQXB17M0Q
MS:GC:!L=3:I%NQ&BYK-<Q9><.G79##6\&6$+PRQ9,Q\986.#G<0E<-C:GXRU
M2*#H5US2U1E\Y=:<T/@HLI?8YC3DI99&Q11O(:',:]\C&DAQ(V$[EG=B.T>C
M"<YL?=:?S>1R]J;#*X%KO/L?MXN(\#6 ;3O<\-4FW:.=<RM>ZTS_ "YOKG)Z
M;%GIS(1.=9WC'!T@XF.X"]O&X@%IK4M"W;;%2>QU# :GEP6G]-6,6*N+YM[%
M1UQ "61>$_XVP]2Q,#H[:FCB!4[13H]]9%U 0$! 0$! 0$! 0$! 0$! 0$!
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MK4><67BN-00:=LW?^&Z=MX<?;L;3A#HXF=H13I+R\E=^&M_3O3VW-6- L_\
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M+V\0+-D;@*$$[UC#;MF-ZFU+8\6H<P<[J:RQFDYKC#P8""R>^YQ<$,CNU%#
M[PFF-G"!PMIO7?#9;,W;:MVQ&UT%]OCH&_C&.$Q28D1T% ?/PZ*UVD;*T8\K
MRUG^EX_)CP<_Y?8"SR^FL]J_//N\E%!+6;$VTDC>W<=O$\,<*BIZ05Z<U\Q=
M%L;/%JZ>YT31?F,VF]0W.,TOZ#Q[K4M9<2!W'*1(P$5+17:#T]"\V6N]%;JR
MQ/;VM'N89I^1MCV,9D[.^+I.$5X0!;G;W%Z(G_>EO^9L>K\K;_=G2M];:6M]
M0V#,?#;NN7>%V4[&T<R@8X U:>E<L=L[UT;U-J6QMEX[S,Y:"UTHS+X*UP&
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MP;*=/6@K0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M*O'//+<S.N)G<<SSQ.<>D_ M1%![[_/9;*6ME8W]RZ:UQS.RLHW!H$;* 4%
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MIN%M]D RXRKQ458/V0/434_R+XN?B)OV1V.%UU70Z!>-S$! 0$! 0$! 0$!
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M8^)UL YS:@$#?0D+IWIW-TUCI6XN=-8XZBYCQS8B9T1L(8L<'/#C$XMX0;P
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MM>#TE*8NK@["WW?#5+^T=D6 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MF\$3F/>R@_Z)"D745BL+R)T1@<E;Y6QCF%U;.#X^*:5PJ/<+RKORCSWWY?-
M7]_=9&:"47-W*^>8MED:"^1Q<=@<.DIOR,AIGDKH[2F7@S6*CE%W;\7!QRR.
M;X37,W%Q&YR3?4;EG<#9:BQ5QA\DWCL[EI9(T$@\+@0=U.M9B:*UC,\I=)9W
M$X_#W]L3;XQO!:2->]KV-J30$.&S:=ZN\CRX[DGH?%W5A?6MJX7F/F;/#,Z2
M1SBYCN(5XG'I"N_(C.<DM$9[)292ZMGLN)J&7LY)&AQ&S: X#<$B^1F+CEMI
M:YTP-(NLPW#!H;V37/K5K>'BXJUKLZU-[;562TWIG&Z4QC,3C X6D9/"'N+C
M0[=Y)/2I,U'#K+EW8ZNYK:M9G[.7S(RAUK< OC!\.<['-(KN:NLS2$=APO+K
M3&"PLV"LK1OF-S_K#7ESC)6F\DD] 7*;AK5OR"Y?VQFI9O>R9KF=FZ64M:'@
M@T''[JUOR,M>\I-(W^G;73%Q;N=C;)[I+;PWAS"YSGFA!ZW%3>[U>O#\M=-X
M3+V^;LXG>?6]L+-CWN<ZL0:YNT$D;GE)N1ALSR-T)FLC+DI[1T<LY#I6Q22,
M:X@ 5H' ="L7R,W?\MM+W^)L<*^T$=ACY636S&.<*/C+7 []OQ IO*]FH]%X
M;5.,L\1E8S)9V4K+B!H)%'QQOC&XCH>4B:(\&H.6FFM29NSU!D(7>D[*@BE8
M][:AKB\ @$#>2D7#;(H!'&V(?%8 T==!L"E1K,/+S3EOJQ^LXK8#./:6&6KJ
M#B#@2!6E://0KO;**]3M'8A^J&:N?'7,,@?:B0DT[-_!44K3Y Z$KLHC4[_D
M/H*_OY<@^U?&^9W&^-DL@96M3LXU=^1GY>6^F9+C"7+;81OP#HW8X-+@&&+A
MX2=NWXHWJ;PMW/++35UJIFL7P%F:;7BE8]X#JM+-HK3<>I-[90;3>V%OD;:6
MSO(VS6LS2R2)U:.!%-M%FHY[9<BM!6.19D8[-SGQNXV1.DD,8<>FA<M[\C*Z
MKY6:4UC/'=9:U_TN.H$T3GQN(V4:>$@4%%(NH+V&Y::7P6$N<%86O#:7@(N'
M%SG/<"X.VDDG> F\*QRZTZ-*.T:(B,*YI:8^)U35G =M:[DWMM17?<OM/Y#2
ML6D)XB<1!PF./B<""QQ>-H-=Y4WAR#,\O[//<XX,5D+*5V 98=DV8<;6M[-L
MQ;X0(Z0.E=8FD#K>D>7>F='1S-PUKV<EP"V:9SG/>YM:TJYQZ@N<W3*F-Y;Z
M8Q>FYM*PVH?B)RYTD3RX[7@ D&M:[.M-X83$\C=!XC(,R,-HZ22(UC9))(YK
M36NP%RLWS*,SJ+EKIK4^6LLUDH3Z0L.#L)8W.::,<7@$ @;W%2+J*QNH>3.B
MM27OI"^MG,NG -D?$]["^@ V\+@.A(NHC/XK0VG,-@Y=/6-FUF,FKVT1+G<9
M( J223\D=*DRK3'_ )>^7DK9FR6;W,EXJ,,LI:TNZO#6M^4=-M;..SMX;6'9
M% T,8/U6B@6)5RK/XJYTOS4QNK+.%\F.SH%ADRQI=V9:8^!Y V@4<\E;C;%!
MNUCH? V^;R6I((CZ0R["R[?5U'-<UK30$]31T*3/<BQI_EOIK33<PS%V_9-S
MA>;[PG'B[3M-@J33^D=N2;JCPGE#HYVG&:7?9\6,8\RL:7O#FO<2XD$.KTIO
M2,=!R'T%;PMB;:O>]DL4S)7R2.<UT)J*5<KOR-JQ6B<+B,_<ZDM(RW)75LRS
ME?5Q!BB# T4)_P"K:I49N\LHKZRGL9]L-Q&Z&2FPT>TM.[WU*CE;ORX\NS(^
M403!\CBYW#-*W:XU.YZWOR-KT_RRTSIW#W>#M(728Z\!$T4KWOK44WN)(69N
MJ,9A>2FA\'E&Y:UM"ZX8XOB8^21S&$FNP%Q5F^1;U+R/T5JK,SYW)PR.R$_Q
MY&R/;U_-<.M(OF!Z](<HM*Z*R<F6PK)&W4L#K9W:2/D:8W/8\BCG$;V!)NJ/
M#?\ (K060OWY"2S<Q\C@^2)DDC8W$&NX/3?D>O79&EM#38?3EH[SR>/S+'P0
M-+@'N:0UQ)Z*C;4I&V1EN76EF:-TK98%FU\ )F=OK(=AZN@!2Z:R-L6:@E1!
M-%0X@@5""4! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M_2@D/-:$?#N01VA'QM@WCWO?02'U /7M%4#CZ:4&X%!6@(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MJE=K8N7_ #\DU!J8:3U5AWX7+R"D+>(/:9*M !KPD$@D[E)LV%69QG-B^O\
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M\,K&.^,UIW*S$[NTB8JZ7SKTAA]8ZAQDV ST%IK:UJZ"SDD:QTCCV?9</$
M:MV5=TK-LT68:'?ZGYI<OK['P<R\3!D<3Q-;!<W+Q.\#:&\!@N"!NZ6K5(GL
M2LK?-?(Y6[YL:;R6C[=EQE)3:S8JWE(8QTKG1&)I+G1T\*@VN"6]DU)='Q68
M_,\[(V[<IIC'18]SJ7$K;B$N:RF\ 7[OY%BENIM>/G'HZUU;K"ROM,9V"WUY
M:L:V+'NE:Q[G1$N8&%P K7B^6K;-/L68:;-JWF=H/-8V#FAB(+ZP,K(X+RX?
MVTNW=PNAG<!0 [VJTB>Q*R^M[.YCO+6.ZB_HYFA[?A]]<57VTH@J0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M(R9EM&\R,<6.#B!\0 'A&X)-\4V)1L&I^4V?RG-?'ZNL?-H\!:6\<#HS(1*
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M;D! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MTZNU9T_"E)*GG^- V7</N 2L[Z4DJI-]CJ_ZU![_ &K-W=2DE82,ACQL\Z@
M]R5G?2DE3TAC]O\ I4'N?M6=]*25@](8_<;N"A_ZUF_NI22JYZ2QWVR#RC.^
ME)*GI+'?;(/*,[Z4DJ>DL=]KA\HSOI22IZ2QWVN'RC.^E)*GI+'?:X?*,[Z4
MDJ>DL=]K@\HSOI22IZ2QWVR#RC.^E)*GI/'?;(?*,[Z4DK!Z3QWVR'RC.^E)
M*P>DL=]L@\HSOI22IZ2QWVR#RC.^E)*GI+'?;(/*,[Z4DJ>DL=]L@\HSOI22
MIZ2QWVR#RC.^E)*GI/&_;(/*,[Z4DK!Z3QOVR#RC.^E)*P>DL=]KA\HSOI22
MIZ2QWVR#RC.^E)*GI+'?;(/*,[Z4DJ>DL=]K@\HSOI22L'I+'?:X?*,[Z4DK
M!Z2QWVN'RC.^E)*GI+'?;(/*,[Z4DJ>DL=]L@\HSOI22IZ3QWVR#RC.^E)*G
MI/&_;(/*,[Z4DK!Z2QWVR#RC.^E)*P>DL=]K@\HSOI22L'I+'?:X?*,[Z4DJ
M>DL=]KA\HSOI22IZ2QWVN'RC.^E)*GI+'?:X?*,[Z4DJ>DL=]L@\HSOI22IZ
M3QWVR#RK.^E)*GI/&_;(/*L[Z4DK!Z2QWVR#RC.^E)*GI+'?;(/*,[Z4DJ>D
ML=]L@\HSOI22IZ2QWVN'RC.^E)*GI+'?;(/*,[Z4DJ>D\;]L@\JSOI22IZ2Q
MWVN'RC.^E)*GI+'?:X?*,[Z4DJ>DL=]KA\HSOI22IZ2QWVN'RC.^E)*GI+'?
M;(/*,[Z4DJ>DL=]L@\HSOI22IZ2QWVN'RC.^E)*GI+'?;(/*,[Z4DJ>DL=]L
M@\HSOI22IZ2QWVN'RC.^E)*GI+'?;(/*,[Z4DJ>DL=]L@\HSOI22IZ2QWVR#
MRC.^E)*GI+'?:X/*,[Z4DK!Z2QWVR#RC.^E)*P>DL=]L@\HSOI22IZ2QWVR#
MRC.^E)*GI+'?;(/*,[Z4DJ>DL=]L@\HSOI22IZ3QOVR#RK.^E)*P>DL=]L@\
MHSOI22IZ2QWVN'RC.^E)*GI+'?:X?*,[Z4DJ>DL=]L@\HSOI22IZ2QWVR#RC
M.^E)*GI+'?;(/*,[Z4DJ>D\;]L@\JSOI22IZ3QOVR#RC.^E)*P>D\;]LA\HS
MOI22L'I/'?;(/*,[Z4DJ>DL=]L@\HSOI22IZ2QWVR#RC.^E)*GI+'?:X/*,[
MZ4DJ>DL</]L@\HSOI22IZ3QOVR#RC.^E)*P>DL=]KA\HSOI22IZ2QWVR#RC.
M^E)*GI+'?;(/*,[Z4DJ>DL=]KA\HSOI22IZ2QWVR'RC.^E)*P>D\=]LA\HSO
MI22L'I+'?:X?*,[Z4DJ>DL=]KA\HSOI22IZ2QWVN#RC.^E)*GI+'?;(/*,[Z
M4DJ>DL=]L@\HSOI22IZ2QWVR#RC.^E)*GI+'?:X?*,[Z4DJ>DL=]L@\HSOI2
M2IZ3QWVR'RC.^E)*GI/&_;(?*-[Z4DJ>DL=]KA\HSOI22IZ2QWVN'RC.^E)*
MGI+'?:X?*,[Z4DJ>DL=]L@\HSOI22IZ2QWVR#RC.^E)*GI+'?;(/*,[Z4DJ>
MD\=]L@\HSOI22IZ3QOVR#RK.^E)*GI/&_;(/*L[Z4DJ>DL=]L@\HSOI22IZ2
MQWVR#RC.^E)*GI+'?;(/*,[Z4DJ>DL=]KA\HSOI22IZ3QWVR#RC.^E)*GI/&
M_;(/*L[Z4DK!Z3QOVR#RK.^E)*P>D\;]L@\HSOI22L'I/&_;(?*,[Z4DK!Z3
MQOVR#RC.^E)*P>D\=]L@\HSOI22IZ2QWVR#RC.^E)*GI+'?;(/*,[Z4DJ>DL
M=]KA\HSOI22IZ2QWVR#RC.^E)*GI/&_;(/*L[Z4DK!Z2QWVN'RC.^E)*GI/'
M#_;(/*,[Z4DK!Z3QOVR#RC.^E)*P>DL=]K@\HSOI22L'I+'?;(/*,[Z4DK!Z
M2QWVR#RC.^E)*GI+'?;(/*,[Z4DJ>DL=]L@\HSOI22IZ2QWVR#RC.^E)*GI/
M&_;(/*L[Z4DK!Z3QOVR#RC.^E)*P>D\;]L@\HSOI22L'I+'?;(/*,[Z4DJ>D
ML=]L@\HSOI22IZ2QWVR#RC.^E)*P>DL=]K@\HSOI22L'I+'?;(/*,[Z4DJ>D
ML=]L@\HSOI22IZ2QWVN'RC.^E)*GI+'?;(/*,[Z4DJ>DL=]L@\HSOI22IZ2Q
MWVR#RC.^E)*GI/&_;(?*,[Z4DK!Z2QWVR'RC.^E)*GI+'?:X?*,[Z4DJ>DL=
M]KA\HSOI22IZ2QWVR#RC.^E)*GI+'?;(/*,[Z4DJ>DL=]KA\HSOI22IZ2QWV
MR#RC.^E)*GI+'?;(/*,[Z4DJ>DL=]L@\HSOI22IZ3QOVR#RK.^E)*GI/&_;(
M/*L[Z4DJ>DL=]L@\HSOI22IZ3QOVR#RK.^E)*GI/&_;(/*L[Z4DK!Z3QOVR#
MRK.^E)*P>DL=]KA\HSOI22IZ3QWVN'RC.^E)*I;D+![@QEU$]QW-:]KB>X4I
M)5Z*C?78HKYAYD\J>:^=U=>Y/!92:'&S._8QMNIX@!Q$[FBG2OJ8<^*VVDQM
M?)XCALU]];;J1]K4_P $N>.[TS/^_7/>7;F<.GR>;D^(^KYR?@ESQ]<W'[[<
M]Y.9PZ?(Y/B/J^<GX)<\/7-Q^_77>3F<.GR.3S_7\Y/P1YX'_C-Q^_7/>3F<
M.GR.3S_7\Y/P1YX>N;C]^N>\G,X=/D<GG^OYR?@CSQ]<W'[]<]Y.9PZ?(Y//
M]?SD_!'GCZYN/WVY[R<SAT^1R>?Z_G*?P1YY>N;C]]NN\G,X=/D<GG^OYRC\
M$>>/KFX_?KKO)S.'3Y')Y_K^<GX(\\?7-Q^_77>3F<.GR.3S_7\Y3^"//#US
M<?OUUWDYG#I\CD^(^OYR?@CSP]<W'[]==Y.9PZ?(Y/B/K^<H')'GCZYN/WZY
M[R<SAT^1R>?Z_G)^"//&O_G-Q^_7/>3F<.GR.3S_ %_.3\$>>/KFX_?KKO)S
M.'3Y')Y_K^<AY(\\?7-Q^^W7>3F<.GR.3XCZ_G(.2//$_P#&;C]]NN\G,X=/
MD<GQ'U?.4_@ASQ]<W'[[==Y.9PZ?(Y/B/J^<GX(<\?7-Q^^W7>3F<.GR.3XC
MZOG)^"'/'UQ<?OMUWDYG#I\CD^(^OYRC\$.>/KBX_?;KO)S.'3Y')\1]?SD_
M!'GCZYN/WZY[R<SAT^1R>?Z_G)^"7/'US<?OUSWDYG#I\CD\_P!?SD_!+GCZ
MYN/WZY[R<SAT^1R>?Z_G)^"7/'US<?OUSWDYG#I\CD\_U_.3\$>>/KFX_?;G
MO)S.'3Y')\1]?SD_!'GCZYN/WVY[R<SAT^1R?$?5\Y/P0YX^N;C]^N>\G,X=
M/D<GQ'U_.4_@ASQ]<W'[]<]Y.9PZ?(Y//]?SD_!'GEZYN/WVY[R<SAT^1R>?
MZ_G*/P1YX^N;C]^NN\G,X=/D<GG^OYR?@CSQ]<W'[[==Y.9PZ?(Y//\ 7\Y/
MP1YXC_C-Q^^W/>3F<.GR.3S_ %_.3\$N>/KFX_?KGO)S.'3Y')Y_K^<GX(\\
M?7-Q^_7/>3F<.GR.3XCZ_G)^"//'US<?OUUWDYG#I\CD^(^OYR?@CSP]<W/[
M]==Y.9PZ?(Y/B/K^<GX(\\?7-Q^_77>3F<.GR.3S_7\Y/P1YX^N;C]^NN\G,
MX=/D<GG^OYR?@CSQ]<W'[]<]Y.9PZ?(Y//\ 7\Y/P1YX^N;C]^N>\G,X=/DO
M)\1]?SD')'GCZYN/WVY[R<SAT^2<GQ'U_.3\$>>/KFX_?;GO)S.'3Y')\1]?
MSE/X(<\?7-S^^W7>3F<.GR.3XCZOG)^"'/'US<?OMUWDYG#I\CD^(^KYR'DA
MSQ]<W'[[<]Y.9PZ?(Y//]7SE'X(\\/7-Q^_7/>3F<.GR.3S_ %_.4CDASQZ,
MS<?OUSWDYG#I\CD\_P!?SD_!#GCZYN/WVY[R<SAT^1R>?Z_G*/P1YX^N;C]^
MN>\G,X=/DO)\1]?SE/X(<\NC,W'[]<]Y.9PZ?).3XCZ_G(>2'/+IS-Q^_7/>
M3F<.GR.3XCZ_G*/P0YX^N;C]^N>\G,X=/D<GQ'U_.3\$>>'KFX_?KKO)S.'3
MY')\1]?SD_!'GAZYN/WZY[R<SAT^1R>?Z_G)^"//#US<?OUSWDYG#I\CD\_U
M_.3\$>>/KFX_?KGO)S.'3Y')\1]?SD_!'GCZYN/WZZ[R<SAT^1R?$?7\Y/P1
MYX^N;C]^NN\G,X=/D<GG^OYR?@ESQ]<W'[[<]Y.9PZ?(Y/B/J^<GX(\\?7-Q
M^^W/>3F<.GR.3XCZ_G)^"//#US<?OMSWDYG#I\CD^(^OYRG\$>>'KFX_?KKO
M)S.'3Y')\1]?SD_!'GAZYN/WZY[R<SAT^1R?$?5\Y/P1YX>N;C]^N>\G,X=/
MD<GQ'U?.4?@CSQ]<W'[]==Y.9PZ?(Y//]?SD_!'GCZYN/WZY[R<SAT^1R?$?
M7\Y/P1YX^N;C]^N>\G,X=/D<GQ'U_.3\$.>7KFX_?KKO)S.'3Y')\1]?SD_!
M'GCTYFX_?KGO)S.'3Y')\1]?SD_!'GCZYN/WVZ[R<SAT^1R>?Z_G)^"//'UQ
M<_OMUWDYG#I\CD\_U_.3\$N>/KFX_?KGO)S.'3Y')Y_K^<GX(\\3_P 9N/WZ
MY[R<SAT^1R>?Z_G*?P0YX^N;C]]NN\G,X=/D<GQ'U?.3\$.>7KFX_?;GO)S.
M'3Y')Y_K^<GX(<\?7-Q^^W/>3F<.GR.3S_7\Y/P0YX^N;G]]NN\G,X=/D<GQ
M'U?.4?@ESQ]<W'[[<]Y.9PZ?(Y/B/J^<GX)<\?7-Q^^W/>3F<.GR.3S_ %_.
M3\$N>'KFX_?KKO)S.'3Y')Y_K^<GX(\\/7-S^_77>3F<.GR.3XCZ_G)^"//#
MUS<_OUUWDYG#I\CD^(^OYR?@CSP]<W'[]==Y.9PZ?(Y/B/K^<GX(\\/7-Q^_
M7/>3F<.GR.3S_7\Y/P1YX]&9N/WZZ[R<SAT^1R?$?5\Y/P1YY>N+G]]NN\G,
MX=/D<GQ'U?.4_@ASQ]<W/[[==Y.9PZ?(Y/B/J^<H_!'GCZYN/WVY[R<SAT^1
MR?$?5\Y/P1YX^N;C]]N>\G,X=/D<GQ'U?.4_@ASR]<W'[[<]Y.9PZ?(Y//\
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M'A;#,YU>&E10U^#I7ER8N^'Z#@>.I^B_XNC-<US0X$%KAL/6O(_1*ZHH@("
M@(" @(" @(" @(" @(" @(" @(" @(&Y!2'M.X_"@GB'P=:!Q#9[NY J$"J!
MQ"M.E J.^@CC" 'M.P;^I!/%[Z".-M:=6]!(<"@@O (!Z>E XVG=M0.-NS;0
MGH03Q"A/0$#B'P( -4 N 0.(5H4"H00' H)XA6B!Q#HV^Z@ @DCI""4! 0$%
M/&WO^Y1!(<#N_LJ@E 0030@=:!4;J[4$H" @(" @IXP@J!KM" 33>@IX@4%2
M @(*>(4KM]Y!55!%4$H()H@CC;6GNTKT505(*2X TZ1O]Q!(<#\.Y!* @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(!0?*_YE_\
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M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @C;U("!M0.G>@%
MKU("!M0*T02@((^% V_ @E 0$$502@(" @((/0@^6?S+_P#-^-_W'_ZSU]C@
M?VS]K^:_W9_6L_[?XN*A?2?A9=?_ "]VMI=ZGOFWEO'.QEJ7-9,QL@KQMV^$
M"OG\;,Q;%'['^U[+;LUV]$3L[]K<+3F98W&N_NA+I6TEM'WPL#.R.-Q#7R"/
MC+1!N%:G:N$X)\O>WNY]:WU:V>+\B<,3&]NUI'?_ /2U[F;RV9?\PH,/I:W9
M;F_A%S/&QH;'$&"-A-&T %75.Y=<&>F.MW<^?ZOZ1&3BXLPQ$;T5GW4C^+&C
MDFZY\\AQ>I+.\R%D#V]FSL^)I;6H-)G$'9U+IS5*5M>./[>WMZ+,MLS;VQ[7
M-2TUR_S^J,U/AL?%^TM7N9=2T/9L[-P83Q[MI(*]&3-;9;67R.$]*S<3EG';
M_+.W39XMOS'(K,V./GO\7DH,H^V!=<00M:'#A%2/!D>:TZ*+SV<9;,TF*/L9
M_P"VLMEDW67Q?,=L>TRPNB>5V4UK!?OM+D6T]B0TP21U<7$D$$ES:;1U+KEX
MB,<Q5\_T[T3)QEMTVS2;>Z8_-LMARSO=-ZFQ-O8YJRNLG=/D;V+H8[AL9;&\
MGC9VIZ!TT7&[B(OMFL31]3#Z/=P_$61;?;==/=2M-D]L58C,:'U#J#7MQ@6N
MADOAPNGG@A$$3&GA%>%KB!OZUTLS6VX]YX^)]-S<1QLX]E>^D4B'LDY+7,UI
M>SXC.6V2N; 'SFUA#.)I90NVME>1L/4L\W$3%8HZS_;MUUMTV9+;YM[8C_K+
M!Z7Y;9#4-I=Y2ZNXL7B;(N9/<STIQMK4#B<P;*'I77)Q$6S2(K+Y_!>C7Y[9
MONNBRRWMF?:'IU)RPGPF$&H;'*V^4QE1QRP%NRK@S9PR/Z2ICXC>NW9BDNG&
M>B3AP^=;?%]OA\-99B_P6>_"NVR#IK5^+D= UD++1HN3Q@</[8/+CLW^"N5M
M]OG4VU>[+PV;ID75MFW9_+^KXU_@LP<GIH;6UESN;M<1<7HXH;>?@XB#6E..
M6,[:=2US<5V16CC']NW6VQYN2VR;NR/:8:KK+1F0T9D665_(R=LH<898Z %K
M:;: G?4=*].'-&2*P^+ZCZ;DX._=OF)KV4>WE;#%<:_PD,\;98GRO#XW@.:1
MV+S0@["L<3-,4N_H-L7<=CB=L;?_ &RZ_K7F#9:6U>W 1::M;NW(8>)D<8<>
M-[FD "%VW8OG8<$WV;V\_;>I>K6<+Q48HPVW1/A&M/I8OG!IW#6[,!J"QM([
M.>]N+=DUO&QK 1(QSC4- W<(&Y;X7)=.];,]D/+_ '#P>&V<66VV+9NNMK'V
M_P#1LG,WEC]Z,E8^CY+7%6[&\)<&1LXWNV!H'$RI7+AN(W(FM9?2]:]$YJ^V
M+)MLC[(_)QK+Z!GTGJ6UQ.HKAC<;,0?/*"-CFEM>EU!M/SNA?3MS^9;,VQM?
M@\_I$\)Q%N//=&Y/?V?]/BZS'K?1T>HK#2F!PUG?8V8-CDN8XXG 5/#\F-P-
M/[I?.\F_<FZZ9B7[6/4^$CB+>'Q8[;K9[XI]FCTXS3&"QG-:YM+:UA=;36?;
M.MW,86,<Y\)^+2G3U+-V2Z<-9GO=</ X,7J<Q;;%)MK2D:VM?U/R8O<UG;^[
MLKZUMII:O@Q[6LXRP>X'M(&_Y*[XN,BVV(F)?*]0_MJ_B,]UUM]MLSV6T[OC
M'W.,YC$WF#R,^+OXS'=6[BUP((J.@BO6OJV7Q?%8?S[BN&OX?)..^*3:ZER%
MMK2XRF2==V\5RV.#C:V9C7BH!^<"OG<=,Q$4?L_[1LMNR7[T1.SO][8L#S%L
M\QJPZ;N-,6A@?<NM>V9'&Z@$G '$"'J]U<<G#S;9O;SZW">M6YN+G!.&VF]-
MM=FM/I:=S(T8T\PQ@].6U'7D+)VP1-H&N/&#X+!L%&57JX;-3%O7/SWKGI<7
M>H>5AC]T1.SWZ?8]QY$9CL>%N4MSE. /=8^#Q D;OZ2M*[*\*SS]NFQZ)_M'
M+N[,D;^GM/\ !KVC-#7.6UJS3V5C, @XI+IKFFI:QA<-AIL.Q=<V>+<>]#Y?
MIGI%V7C?)RQ3=[?A]SH&HN8&F-'97[NXC3]K<P6+NQNIGMC#JL/ ?\$ZI\$U
M-5X\?#WY(WING:_4<=ZSPW Y?)QXK;HMV7=GV?3/BU?F9<:%REG9Y73CHH,G
M,1YQ:0,90-HZI/ 13:!O:O1PL9+9F+NQ\;U^_@<N.W)AF(OGMB*?P:=I+#QY
MW4%CC9YFV\$LT8D>\BCF<;00*EN\%>O-?N6S+\YZ9PL<3Q%MDSNQ6.WOBNV.
M[M==YF<NL7%9V3L7<6UC'!&QGFS6QMDE<YQJX4<TGXW45\SA>)FLUVOWWKOH
M>*<=OES;92FRD;?G# 7?)&]LHW3WF9M[>V#"X23-:T.-*EHXI0N\<=$]EKY&
M3^TK[(K=EB(\8_\ V6<I@\S;\O&7;KBTEQ8F=&QL=LP3DMDD;7M0\D@T/0EE
M]LY>^OVG$\)FM].K6V;*S&RW;VSWU_@\&-Y7W=QC;7*9?)08F.[(%O'/PUDX
MZ4IQOC^=U+I=Q41,Q;%7AX?^W+[L=N3+DMQ[W9$]]?MFUYLKHG(:1SUC;W[F
M7%O.0Z&=HHU[2VNZKA^E:MSQDLFCEF]'R<#Q-D7S%T7=D^[WMAYW6MK:9VT9
M:P1P,-LTEL3&L%27;:- 7'@9F;9J^E_=V.VS-9NQ$;/Q<MC^,/?7T9?B;7H9
MO6'IA?'0LNT=B]TE9=H5,4EVM76K,NL+C1M"C<+K>A9=(71O4ETA<&_X$:A<
M'>4=(7 LMPN#>%.YN%QJC<*V[T;7&]*DMJQT*-KO2%%A<"-PK4:A4/BJ.D+H
MW**N*-PK&]&EQA(-1L(W*2U#>M):L,1;CLB\F/P612N=\7HH:_!TKRY,??#[
M_ \;3]%[H;'![0YIJTBH/005Y7WX5(H@(" @(" @(" @(" @(" @(" @(""#
M6FS>@C^1!XW96P;<^:.N6"XW<'$VNWX45[#7H1'#OS =G-+I2QNKN2SQMWE(
M(;V6.8P4AD)#B7@BE!UK=@BTY6<HI)H!:ZJN);MQ!CC;FF/)<W;3A!J5=Z1K
MNI,3@LASC@T[J+*36.GK?&/[-S[SS4=K"(6MJ]Q J=OOI%:#P\PL#HC2>/M\
MEHG5$\FH6S1>;V\.1%R9:O (X(W@_H*U$S/:-KUWJ_5.09HO0V+N)+'.ZBMX
M#F+B,N;- 'QP"0T!:X$=J\_&&Y9B.V1[[[D190XLS8G.Y2+4,3>,7QN97![Q
MMIPAX.[]<J;ZT:7D]:9S,\GM08W*W,C=1X"8V-U<!Y;*XALK:D[' U8:[5JF
MU&S\B-89.%C]"ZLE>,M:01W-C-<//%-!< 3"G'M-!*T;SN4NCO@6=)86+6&L
M>8V R]U=BP%\\,;!.Z)[.&:448=O"*'<$F:1 T[7_+?#:<UWI?3^-O\ )^CL
MM3SH27LCG[7N;L.SJZEJ+JP4;YKG0V,Y?\N<V_ 7=]VLYB+GW-R^9S:.^2=E
M%B)K(T;F%,Z[P'+2VO;^:WM+R*W;>RMG="2US)22Y]?Y5NWO);FWE9R;<X-9
MJV=SR:- SD9))Z*5WK.]<,7SMM;*VR.@,)Z0E@P6RW?.VX+"^%C UKG25 )(
M%:E6SO)4:RT9RMPFG<AD\)JN5N8MHG26)ARK)GNF;3A:&,>'&IV;%(F1TWDW
ME,UE.7^*O<\9'7Q#V<<W%VCHVFC''BV[6BM5F[M55S-R>L[+%P6FB[$W5[?&
M2*>YJ0VU8UH=QNHUV\5 J6I;3O1KW(*?*OTYE&9JY?=Y*WR-U#<2O<7GM&7$
MS7<-2=E1NJK?VC>]/ZRQNI+V^L+*"[BFQYX9GW,#H6.) /@EV_>L3%!B>9^)
MU7G-/-Q6D9C;W=U,QEY<,E[)[(3L<000>D]*U;.HY-KW1L'+*'"9K3^:OVYR
M2ZABEMY;J203\9\(</$#_+N6XFH\/-;-V.2YEXS$:D?DH\5:V;9KNVQ1D\X,
MEQ%&ZG"RFUI:>A+8V$MSY:'EO:P97)Z1R&1=>002"YM,K<DS1@</A=DXU&WA
M%?=4NJ./Z:R&@\OZ2S&N[K4!NKJ]>]D]B^5MK%&_;X;Z\(H3W%N:]R/J?0UO
MA+73MFW3ET^\Q#F%T-Q+*)WN!<XGB>"=H)(7&>U6,YA\Q;3EY!CKF\M9+R*_
ME, $;BUP+2P5 #75KQJQ;4:[C.>$<F6M,=J+3UY@;;($"PO;DOX)7./@C]I#
M$-HJ?C'<KNCUZ@YP''YRXT_I[ W>HLC9BMYYJ7AD9J10F.*;YIWT2+1C).<#
M]0:2S4V,Q%U!J'&_L[O&ESQ-#X7QN+LP[YOR!O3=VJYYI36+[CECC?O5CK^:
M"/)6K(,@V[DA=/))-" >(Q.J&FE1Q%:F-J1V.O:IYI6>E'X["XW'3YK/7<+'
MQ8VV<72-C#&D%Y8R1PV.'R=JQ%M5-+<V[3/SWV-R.,GPN?LHI+AV+NG.#WQQ
ML+JM+V1NH>%P^)T)-M$AK,7Y@IKVUGO<1I.^R%O:/>V]EA?(Z*,1N(KQMMW
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M,Q16UMKPBJB)0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MK&]&EQO2I+4-@TWIZ?,7+2:LM6%I>_=T[AW%PR7[KZ/"<+=EN\'6K:%MO!'
MRO#& T5V[EXJU?K+;=V*+J-" @(" @(" @(" @(" @(" @(" @("""VJ#4I=
M(7$F8]("X:(.,/X:GCWUZJ+55JVL@BI64<1Y]V5MDLCHNPO8^UL[G,6T,T=2
MWB8]Q#A5I!'P%;LD;GC^4/+NPF@O;/"B.[BH]DGG%R:.IU.E(6=Z1SG*Z>Q&
MI?S G&YFV%W9>C+B00N<]@XF=C0UC<T]/6MQ-+1AN86B+'E;JO$ZRQ%DV;3<
MDS(;VSF+IA$7$^$WM"3L\'Y2MLUV#+\QKN##\P-&<R(?VNG[D-CGF:.)L<,H
MM^%U!M%&DGX%+>R8'7LEKG3&.P<F:ER$/FG 71\)XG.)V <(J[?[BQ2:J^;Y
M+6YNN66N-731F*'460\ZMXR*> ?.'UI_TUU[XA&]<P-*7QTGIO7VFQV6<PUC
M9F0LV&:$PL80>NE>GJ68G;0>?\O>=;J;4VL\ZUI9Y[*)G,(H07R/<>Y5+XI!
M#T\W1_\ W6T+3=LI[O[5R6]DJW+GG3\-\ILW=EM_Z:S;VHXWKRUL[S#<K;6_
M:'6<L=LV9KG%HX"R6NT$$=U=+>\EV&/EAR<A>R1EG:"1C@YCO/YS0M-1_AUS
MWI&C\[L?C;W4W+_&EC9<6Z9T08'$M,;1P@<336E/=6K9V2+?-KE5B--65MK?
M2MB(VX=T<M[8.?)+%+$)0"2)'.Z'$[^A+;NX=?T#J#&ZFTMC<MCF,C@DB:'0
ML :&/ HYO".@$46)BDJSU\!YK/3IB?L]T-*B.8\D#3'ZCW?^=Y&O7LO)UNX=
M+MO1O:R^9=CVM?VO9<'$30?&X5@8#7NL\;H+ S9V_:9"T\$,#=[Y#T#:/Y58
MBHYAHO3ESJ_-0ZXYAY&W>]OA8S$]LS@CH:-+F@[]I/QBMS--D#:QK32<W,BZ
MTWE<5#;Y2*-ICR-RR,B9I#J<+R3L%!2M-ZS2:#GUO=XYG.7-Y/3]KYQB;+'N
M.2AMP!'*\/94 &@.PM6NX;=B]6<N]0<NLMEG6%K86[8)V7%BZ-C9>/L": "I
MKMH""I2:JU;EMA^9EYH'''1F1M,= 9KMSFY#M*NC-U.6</9L?N%-ZU=,52%7
M,B+/X:PT8>8EW:W]U'FA)-+:\9A\V$MKL(>UIKL=T*1X#T<]<CB<M@]-8W#/
MCFRLMY!);-AVO9%V$PWC=M(2PEXF9[4FKM7:@LM.9"PTQ;8UQBN9Y6\%Q,&O
M>.+BX)*D4JK2D;1A>6/:^F.83)[WTC,V#ADO*4[1S7P F@:W^16[N(>2"6)W
M([34;7@R,R]H'L!!+:W%OO'NI_,=ST9/%9.;F]V,N:?@Y;JRB\RO &%I AA\
M&KV/ 4KL&:L-.X^RYA/FO=539K4-OC;H%H:SL^S,%R.%SF1,!H2X[TKL&S\G
M+.V'*6^F[)O'-<9 3.H*D-N'@5[JS=VD.:2?^A,53L&89LZ !-:+?\P^G].3
M0S8#&.AD;(TVD XF$$5$3=FQ<9[5<9TOD<19\_\ 54=^]D5W)&XP324 V11$
MBIV#8"ND_M2&N7,FG\GS!UU>W57:8CMS!D980:.D/;MJ*;R"'*]T#PY7&9C2
M&FHL]@-4VV8TLQS71X>^ DD\*3AHUG9#<37:Y7MD;#I?)VMKSG\_U%P0.S&-
ML)\:YXI'%VL)=V;2?B\/&QO]M28_3L%_4DT&5YYQ/PSVRLL\:[TC+%\6AA=0
M$C8?C,4_E5?Y-Q1MY2:L>UH#W-O2X]=+4TKW4N[4:EB]3S8+E+A+2TMX)+Z_
MR5Q%#<7;..*+_2;MW$>H^#0;.E68K(\',NTU)876GV:AU/!EYY+V$LM+2CHH
MP)8]M3$PBOO]"MM"6X9+3F+SNK[ZXT?J9VG]6100"];(>"&1O8P]+HW_ *BS
M6D;5:Y/G\G?\NM68;*MMIKO'7EMQY"S9P1SETC16M&UI3YH5IM1EY<%@\]<:
M?AQV=?I_6D.)MBVYKPQOAX(Z-+BQXWEO<09[E/F<]9Z_RVDLW-:96YBM^V=E
M[1GA.\(CA<_A97XM?B]*EW94;;SCM]*7>G8K/4\S[5DTS1;740),<I:X!VP$
M;/="S;57+;J35.@=28 7^:L]58V[F,4#)&B6YC!:YM:B-E*5KO6]DP-@P!#N
M:/,.V#AV\UO:B*,D O/8;A7WU)[(2%GE;G<5C>2V:BO+ID4S'Y")T3CX?%)&
MT-%-^]P2Z-I#FV <VVTKH#+WWAX*USKWWS2*@-K"ZI'O-<MSVRD=CIO/+-Z=
MOAI*WQ\L4U\Z_BF9V>TB'A>-XW;>A8MAIY>9TK^7.K<3KJR ;;Y6SGAO&,_Q
ML44087#9M<9'42W;%$JW[DAIZ3#:-CNKH?Z;DY'W5P\[7.)<6BOP +-T[1B.
M<8X=:<L.+UN*]7^LV2MO9(UC*Z<M,SJO.9/0>J?0>:C+?25I<D,A?P11BOA1
MNK4<.Y6NS:-KY$:DOLQC\M87\-N)\==/C==VD?9QS$4''T5K2NY2Z!V!E.$4
M6!4@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @("#A'.V[O['6^D+O%V?G^0B,AAM"\Q\9,<P/
MA!KZ;"?DK[7 6Q..^+II'_1\;C[KK<F.;8K-?L[I;7@-9<RK_+6]IF-%C'8Z
M1P;-=B\=+P-) )X3;,K0?K+RY<&&+:VWUG[/S>C#FSW74OQQ;&N]7_\ IAS_
M ".5U#B>>>:GT[B!E[HV<0= 9C!0>'MJ(Y/Y%[K;++N%MWKMW;H\=U^2WB[M
MRW>_3'?37PE8RV;U/S6U%!H74&/BTP;.=MQ+%)+VT\K6$LK&'M@J"'= *U9C
MLX>SS+9WZ^WBS.3)Q-_EWQN4FO;6OV;(9_*6<=]SKT[@+VLN.Q]A)+!&_P"*
MZ1D<P!H=E=M5PLNIPUUT=LS^#TWQ7B;;9[(AV/(V-KD,?<V-W$'VTL3XGQN%
M6\#FEI&WW"OD6W3$Q,/JW1$Q,2^5+61\W*+-8^5Q?:V>7;#;AVW]F[@<1W7%
M?IYV<1;.MK\U;MX:ZV>R+FYZ.O;GE5J6SP]UQ?='48C?93O\"."=U 6U^*:F
M5O5N7CS6QQ%DW1^ZUZ\,\M?%L_LN[/"?:6R\EGMDRNJWM(<QU\2"-H(,<5"O
M/QW[;/L>G@_W7_;_  A;U5MYX:9_R&__ *05P_\ C7?:SE_\FW[&<YZ@?A_<
M?Y>/^1RX\!_5AVX[^C+FW,FZR-CJ30UUBK,7]_'$##:%YB#S1NSB#7T\5?0X
M2VV;,D732'S^,NOMOQS;&].G9_"6]0Z[YLOE8R30#8V.-'.\^>:#K_U0+QSP
M_#]V3Y?_ +/5'$<37;CBG_=_^K5N9U[E;#G'IJ[P]@,CD66TO969D[+CK&X'
MPPQ^X;?BKT\);;/#71=-(JX<9=='$V3;%9I/A^+RZTUYK?4,PT#FL##ILY4<
M+;^YN#+$ZE/!:7QP"OA5^-T+6#A\5D>9;=O4[J?]6,W$9KY\JZV+-[OK7^$.
MXZ2P4>F=-X_ QRF=MC'V392*%VTFNPGK7QLV3S+YNGO?9Q8XQV1;'<PVN]"8
MG5L4-UEGRNCL6N>VV:1V3W&A\,$&NY=>'XB['^WO<\^"W)'ZNYK7Y=FM9H)S
M&"C6WLE -W]#"O3ZE/\ N^[\7E]-BF%UM?+?3$! 0"@^6/S+_P#-^,_W#_ZS
MU]?@?VR_FO\ =G]:S_MG[W%5]-^%;-HO6N3T-?39'%,BDFGC,+A."1PD@[*$
M=2XY<49(I+Z?I_J%_!W3=9$;=6'RN2FRV2NLI<@-N+N1TTC6?%XG&IH.I=+;
M=V*0\?$9IRY)OGME[M,:HRVE,B,IB)."<#A<QU>%S202" 1T@+.3'%\4EVX/
MC,G"W[^-NCN=FH!)<7-KCK"UOKEI;->0Q.;,:UJ>(.KTE>;E+>^9?:G^XLU9
MFVRR)GOB)K][5\)KG4& S$V=L;@B]N7.=.7%W"_B(<:T(KM 7HOPVW6TE\CA
M_4\^#+.6V=MT[6UYKGEK#-V$V.D;!:1S LE?;AS7.!W[>+;LV+A9PEELU?6X
MC^Y>)S63;,1;]E6&TCS)SFC8+RWQL4,PO:&5TX).PDU!!ZRNF3A[<FV7AX'U
MG-PD76V1$[VK$:<U+?:7S4&<L6,?=0EQ8R0$L\)I8:TIN#EUOQQ?;27AX3C+
M^%RQDMB*PS]MS1U':ZFGU1 (8[VX ;+&.+LG-%*5:"#T=:XSPULV;KZ-OK>>
MWB)S12L_#X,Q#SRU1;22FVL;*&.<$RP,8YK'%VPN/A;33^18Y.R>V9>NW^YN
M(MF:66Q7N_BQ>&YJZBPIOV01P7%GD)9)Y+29KG0ATKBXAK>*E-JZ7<-;=3P>
M7!Z[GP[U(BZ+IF:=VWWJ<YS/S>9Q3\(RWML=C7D&2&R8Z,/(<'"HK0[0$LX>
MVV:]L^+'$^M9LV/RJ19;_P"G8L3<Q\Y+I.+2'90LL;=T;V2Q@B4.B%&[:^XM
M1P]N_O.5WK.:>&Y>(BD4[.W9V,Q#SCU ZSM[/(65EDFVP_9R7<;GN%*T.UQV
MBJYSPEM:Q,P]L?W%GFV+;[;+Z:Q^;6M5ZRS&LKN.YRKV\,((AC8"(V!]*@-)
M/S0N^+%;C['Q^/\ 4<O&W1-\[(^'P>+3V;N].9JTS5FQCKFT+G1-DVM/$TMV
M@4Z"MY+(OMF)>?@^*OX;-;EMB*V]E7IU7JB^UAEW9G(L8RY>SLRR,$-H"3N)
M/SE,6*,<4AKU#C[^-R^9?$1-*;&(@F=;3QSMVOB>U[6G=5IJ*A=)BL/#;?-E
MT71W2VW5G,3,ZPO[*_R,4,<MBYKHNR! )!!H:GW%Y\7#VXXF([WV^/\ 6<O&
M7VW7Q$;M.QZ\IS2S65OL;D+NVMB_%!HB8&GA<&MH.+:LV\+;;$Q$]KMG]?S9
M+[+[K;?]ML9_,'JUU*V=F??C?7X1Q;%QY"S67TO\PXF?Y;?A/XL3^,&HOO"-
M1BVMFWG8FWX UW9\/$TUW[_!"Z<I;N[M9>'_ "3B//C-NVUI3YQ^#VQ\]]8M
MMY(>"W<]X([8M>7MJ-P\+HWK/(V5[WHC^[>+BV8I;]NW\7.LCD;S*7LM_>O[
M6YG<7O<234N-:4.W8O?;;%L4A^2SY\F;)-]VV9]NQG='ZUR>C)[B?%QPR/N(
M^S<)@31IJ.@A<<V",E*OI>F^JY.!FZ<<1.]'>P%U</O+JXNY !+<RNF>P;@Y
M[B[8.C>N]L4B(T?(S7SDONOGMNFLQ]J_B\E>8F_AR%A*8;F(ET<K2=FP@[01
MO!HLW6Q=%)=>'SWX<D9+)I,=[HIY[:P=9^;AELV3@#/.0']I6E*UXMZ\7(8Z
M][]7_EW%S92EO9V[?Q[?!SZ3*WTU^<H^5WGW$']J2221[J]NY%*=S\M/%9+L
MGFU_4Z%C^>.KK*UCMGQV]R8P&B:4/=)L% 2>+;[J\5W V3/>_58O[LXNRV(F
M+;OC5IVI-59C55[Y[EI>)^P,B:3V;0.@5)7JQ8K<<4A^?X_U+-QE^]DGW=S$
M1O='*R1KO"80YAZ*M->ZNM'S8NF)B=/X?Q= NN;^I;S#MPUQ%;NMVAC.T(=V
MA#"'-VD^Y1>*.#LBZL/U>3^Y^)OQ>7-MM/>Q&KM=Y;6;;89..*+S<4'9 MW[
M]Y*[8>'MQ5H^9ZIZQEX^+8OB+::*I=?9B?3$6DS'"VRA?VC)6M<V2O$YPVUI
M\I3EK8OWW2?6\UW"QPU(I'?\99:WYM:@BQ]OCYK>UNO-@!!-.QSI&$  $'BW
M[%RG@[:UK+W6?W/Q$8XLFVV[=[)GM>34',;,:E%D<A!!VED[BCE:"'&@<*&I
M.SPEO'PUME:3VO-QGK^;BMR;K8_1/XP\.K-7Y+6%W'>Y*...6*,1CL@6B@J=
MM2>M=,.&,<4AX_4_5<G'7Q=?$131KL?0NSY=KTM^,L/1:O=#5EZ+>Q?^45AV
MA6W>5)=87&[E)=(7(]X]\*2Z0NMZ%'1=;O69=(7!O^!1J%P=Y.]TA6%EN%P;
MPCI"ZU9:A6W>C:X.E9EM6W>/?1M=&]187!O"C<*^M1J%0^*C<+H_M!1N%Q1J
M%0W]:-0V'3>G;C,W(<X.9:-/ARTV&G0.A<<F2+8?1X3A+LT^#K%E906%NRVM
MV\,; &[-A-!2NQ>&9K+]7CQQ9;2'J"CJE 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$!!#A5I"# 9_2F(U+<8^YR<9DEQD[+JV<.'9+&:C>"D2K-@ -X>H;#U#<
MB,$S2&%9J?[W-C(S/8NMNU\'A[.3AXNBNWA'2E>Y7ISV"QFIL7/B<M")[*X
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M[2],+F0N>UL7Q)7L+3T[EO>I ZU@]!Z8T_B+C"8^R:S'W30VZ:X-)E%"/"H
M#O*Q,C6[;D5R[MKQMZW'DR-=QB%W9F,.][@5WY&PZJY>Z6UA!##F;-KO-P6P
MO9P\;!1HHTN::4X112+I@4Z8Y>:6TA;W%OA;3LA=-='-*0TR.:^E07-:W9LZ
MDFZJO3A-&8+ 8>[P..A+,=>B1L[#PDGM6<#MS0-H]Q)F9&/EY6Z.GTXW2T]I
MQXJ.0SQ@\!<U[G/>2#PT&U[NA6+I1BH.1O+VV@[&.P)>'QRME<8S*TQ.#A1W
M!NJ.I-Z1[=0\I-%ZFN&7V4LR;MC&L,T7 UY#&AC:DL=T )O3 ]4/+/2-KIR7
M2\%EV>*F>V25C0P.<]I!JX\-.@="F]-:BQG.5.CL_:6=GD+$N%C&R*VE;P<8
M8P<(;Q%AV4]Q(NF%9#26@=,Z)CE& M!$^;^EF/"7NW;RUK>I)FJ,EG<!B]28
MV7$YBV$]E,:NC< 16A%14$ T*D2-6P/)S0VF\E%D\=9%UY%7LGS<#@TEI:2*
M,;385J;ID>^XY;Z6NM3QZN=;N9FF.:[M6< #C'PTXAPDGXHZ5-Z:45BKODER
M]O<C)D9<=^TFJ7QM$8C+J4K3@WJ[THS%MRZTI::=FTJVR#\+,YSW0R<)HYXH
M7#P0!0'J4WIK56!M.1?+ZSFAN(;%QFBD[6)[NSJTC=\@;%9NE&K<SX<WKO-8
MW0=OIJ];BK6]B=>9Q\,IMNP;(T'A<8PS:T$_'6K=FT=MM+>.TM(;1@#8XF-8
MUHZFBFY<QB\WI7$:@O\ %9+)1N?=8>;SFQ<R@X9.)CZFH/3&W=16)H-?U)RB
MT5JK)/RV5LB+]X:))(BQO'P@-%26.Z K%TP-BT[IC#Z6L6XW"6S;>T!XN%H
MXC0"I( !.Q21G&[MB@E 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MLUBCQ<%CNQXZ71271EX'N$! 04'?\)0?+7YEMFK<9_N('_[KU]?@?VR_FO\
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M% -R @4'4@4'4@4"!0(% @B@ZM^]!-!OZ4! H$"@W(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MCK3SY:CTFR.]N%C86^/MV6ULT,8P ;-E:"E2O/,S/:^QCQVV12'IHHZ)0$!
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MM\AC[N[FC!EX^*WD)> [P6'YU=I.Y=+J=Z,WD.3VH[;0!L(PRZU#D+YM]D.
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M.<2=E&MZU9NJC:E 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M#NH ?4[J>^@J0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M!=B@,$MU"R0$BH\%S@=RE)&89)'(P21N#V.%6N:001[A""I 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$!!R?FIJW5V&S^"P6E+B*WN,KQ@OF8Q[:L;(X_':[H8OI\)AQW6
MW77]SYW%9LEMUMMG\WX*+;'\]A<1FYS%@Z .':-$4-2VNVG[%)NX6FR)]O>L
M6\37;,,7E-4\Q\CS&O=':=R$%K%:6T<Q,L43ZN<'<6UT9/0NMF'#;AB^Z.V7
M*_+ENS39;,12(6\_JSFIR^DLLCJ:YMLEA9YF03MB9'&]O%MV<,8Z >E,>'!F
MK%D3$IERYL-)NI,-JUMS'FQ,..QFG;?SW4>8#396[CPAK:.<YQ-';@QW0O-@
MX6+JS=-+;>UZ<_$;E(MBMUW8P=Y=\[\/9>FKA]I?Q0L\XN,:QL;7AC1QN:'"
M&I- 0NUMO#73NQ6/'VERNGB;8WMD^'M!J?FU<S<M?OAI<B.];((I(W-:[AD#
MJ%OA C<F+@X\[<O[$S<9_L>99VMHY6ZZ9KG3C+NY\#,V](\C!0 MD(/0 !0E
MI7FXOA_)OI'9W._"<1YUD3W][7,'J?7FK(M16N'NH8<E87?8V;Y61A@8&QDU
M\ @_&.\+T9,6+'-LW1LF'.S+DR;T1VQ+6LCJ3G;CM5V&DI<M9&^OV<<3Q#!P
M#:!M_8KTVXN&NQS?2:1[:O+?DXFW)%E8VMHSN:YC:.T1?974-[;W&5$\;;9\
M#(^$1D.XJ@, K4#H7EQX\.7+$6QL>K)DRXL<S=,58_7>NM:V>3TUBM-W45O=
M9B,&1\L<;F\1 ^<QW6NG#\/CF+IOC]KGQ&?)%UMMG\SWMQG/SIS./I_DH?J5
MC>X7Z9]O>WN\3]4/)K/5VO[/6>#T=@[V""[R%N^2:5\43V<;&N=4<3#T!;P8
M<4X[K[H[)8SYLL9;<=M-L2M:ER/.C2&*ESMWD;._M;8UF@;'$QQ::[B(E<5O
M#9;MV(F$RW<1CMWJQ-'4=*9UFIM/6&>C88V7T?:-C.TC:1_:7S,V/R[YMT?0
MQ7QDLBZ.]I>MM7ZO^]-MH[1T+([N1G:7%]/PEC 0RE YKZ_'_0O9@PX]R;[^
MS1Y<V7)OQ99'O6-):TU;::W9H36HBGOKF%UQ:7L'"UKFM;(:%K6-'^"<M9L&
M.<7F8^QG%FOC+Y=_;VQ/M]CK"^8^B(" @@]"*^6?S+_\WXW_ ''_ .J]?8X'
M]LOYG_=O];'_ -O\7%=V]?2?AW9ORYU.JK\MKQ>9FE.OC:OG<=^V'[/^U?Z]
MWV-QL).;XYA@&"<:;]( /?*UO9^:&3PJ;_DU7GGR?+\:/M6=2YSL_P!O>[_I
M[WGU]I#&:UYJ6^(C>V LLS<9%T8\(AAA92@+:FCPM8<DV8JN/J7 X^+X^W'V
M?IF;O_M_%@+K2G*:*YR&)O'W&(O+3BCCN;ASRU[FU&P=H>D+K&7-2)C:^??P
M/IT77675LFWOF9_%K_+WEG!K')Y"1UV&:>QTKF/N@"3( X!NRHW@UWKMGXC<
MB-9?-]+]'MXO)=-?]NR9VZMMBY;<M]66E[!HF_?Z6M6EP:\O=QT'$*<4CMAH
M15<)XC+9/ZXV/KQZ/P'$VW1P]WZH\9_&6.Y9\K<5J5N:M,YQ1WN.D[)CV%U&
MN#G-)H'-KN6^(XB;:3;WO+Z1Z+CXB,EN7]UDT7\?I[EU>ZMQ.'TM<7)ED?(V
MZN&2RQ'A;$]PX"V0D;O<4NOR19,W-XN%X&[B;+,$S6LUFLZ3XL3E])Z=;S"N
ML5F<L;/$P!KGW%U))+(X#AJWB<XNV@]:Z6Y;O+B8C:\>?@,'.S9DOW;8CMNF
M?XRV+%<O>7^K,?E#I\7$,]BU[F7+R]S']F [8#(=X7&[/DLF-[O?1P>D\#Q5
ME_E5B;>_;^+#:+Y<8F\P62U%G>UN;>RD?$RUMP0YW9\522'-^:NN7B)BZ+;7
MA]-]'Q7X;LV6LQ;,[(]HT8_5&&Y<MP/I# 7C[7+ BN-G+G/=X8!VN>ZFRI6\
M5^7>I,;'DX_AN C!OXKMV_Z9GM^,LY>:.M7<J++-17%SYY<26\?8.GE, +P/
M\&7EG3\U<HRSYTP^ADX"V?3+<D3=O3N[-Z:?"M/D]N1Y=:)TA98\ZAANKR:\
M +[B$N8QG%Q=4@ZNI9MXC)?,[NQWR^C\%PEEOFQ-TW=^W\7.]<8K3&,R+&Z5
MOQ?V,@=Q4K^RI3A&TFM:GN+W8+K[H_5%)?D_5N'X;%?'D7;UL_)ZN4W_ *AX
M/_*R?]B]3BOZ4NG]O?\ GX_MG_VR[)KA_-)NLVG3$$S\3^SHZ@[*O:.K6M>B
MG0OEX?)W/U=K][ZG/J4<5'D16S9][Q<ZQ;>;Z:-PUGIOSBW[>@H[AX'\>VGS
MJ+?!U_5I1Y_[EW?]FO[]ZW^+8^96%T9D<KC#JN[=$9"(+6!M1Q.<0VI+7-V;
M0N/#WWVQ.Y#ZGK/#<)ER6<Q=X1'C\8<GUMH_#Z U'C[UI-S@;@MD;$:D[6;J
MDDFNTKZ.'-=ELF.]^']4].P>F\39?VXY[O<VW$<R,_J_6EC;:>B=#AX^$36]
M  &U-:[.H+S7\/;CQS-W:^]P_K6;C.+MMPQ2R.UM-FZP/-ZY%F&AXL1YP6
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M->=HQPZ0Z.(]*X<?%(MB='?@IK-TQK_"$:K_ /6_3748/_U!7#_XMWVIE_\
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M$QL<;>%C!1H V !>-^DB*12%Q&A 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M*BO2@IX7!VP;.OW>M!7PGN&J"6UIMWH)0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M1Z ]3V_DHOH)Y^363I'"?\=O^F/P3^$>@/4UOY*+Z">?DUDZ1PG_ !V_Z8_
M_"/0/J>W\E%]!.8R:R=(X3_CM_TQ^"?PDT#ZFM_)1?03F,FLITCA/^.W_3'X
M'X2Z!'_!K?R47T$YC)K)T?@_^.W_ $Q^!^$N@?4UOY&+Z"<QDUDZ/P?_ !V_
MZ8_!/X3:"]3V_DHOH)S&363H_!_\=O\ IC\#\)]!^I[?R47T$YC)K)T?A/\
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M$C_A%OY*/Z"<SD^J3HG!?\5O^F/P3^&>BO5-OY*/Z*<SDUDZ)P7_ !6_Z8_
M_#310_X3;^2C^BG,9-97HO!_\=O^F/P2.6NC!NQ4'DH_HIS&363HW!_\=O\
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M+HFI#+?EM?&_ERV2,#@-]-PCJ\")2_M(=D6 0$! 0$! 0$! 0$! 0$! 0$!
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M7"OQ>E:W8[!W+!Y2#-XJSR]LVEM>QLGC:34@/V[33:N<[)&50$! 0$! 0$!
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MG4"=]3TH)I4@T_MH*T! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M.X;^GW$$ N&\^X$#B(-*U0"\@50>6ZREG8OB9>3M@,[^SA#S0N?U#NHKV@U
M*(E 0$! 0$! 0$!!0_?[B#DWYB,5>93EW+YE&Z1UE<-NGQM!-6112 [O?6[.
MT;;H34>(S^EK&]QUQ&Z-D($S0]I=&8_!/'0^#NZ5F8I*N/:CNHM4\ZHIL,\7
M5MA;.<7UQ%1\8>Z-HIQ-J!MC=TK<;(1DN1K\=C.7><R=U$'1BXE=/T%S=@I7
MN)?VD-;L\KK/+:)RN0TM98_ Z(?%<EXD?%(Z1AC<7 AS8_"+=RULKM&H1.>[
ME9I@O<'$9>X%1N_I9SL5[R'V?7]'2N ^?,7LUQS6_P!UM_\ NEJND]D$-O\
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M\;C;?&6S+:V: UH +NEQ WE>&ZZL[7ZW%BC';2'LHLNSAOYE=N"QE/\ '/\
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M<50H =^SJ]_>C'>D'W=O6@JH-FW8-PZJ?RJDT"!7]/P[D85@ ;?T="C5(C:
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M0F*_=PWLSS_0@.8W^1U58MK Z);W5K,X&"5KB6\7"' N(IOI59'H[5@%7'A
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MB;&2.@FDRL, >PEI:QS[D["*?-"W2M!T'47*'2.(Y9W&3L;=L6>L81<Q95G
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M@E 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! H@("
M@(" @((*#7M3PY:]M#88QPB=.'1NEZN(4KN/6O;PLV6W;UW<\7%6Y+K=VS95
MA-+\L\7@Y?/KL"ZOW&ID=Q.VGWZ?R+U\5ZE?EC=C9#R<'Z9CP?J[;I[V^-
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M&2N89\5#:MD<(6M\"6A!J[LVNVTZU)C8-KU9IVSU9@+S WVRVNV&,N%:MJ"
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M"*A!265K4[^X@D"@H=J"4! 0$! 0$!!3PUWG=N0"VNSH00&$4J:@;_?05H"
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M6M)WT[BDPDPV8'NJ(502@(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @%!'#1 IU( %$$H" @(" @(" @APX@1UH*!&1TH)
M[/;6NP=U #"#OV=7OJ*=F.OWE4"SW=G1[Z 8P:U._IZ4$EN\UWJ"DQUZJ?VD
MH)+*]*HG@VUKMW('!M)K[R"#'7>:G^V@".GOH!8>OW_>0.SVU!H@<!V[:50.
MS]WX4$&*IV&@_3\""0RA)KMW#WD$"+K.WH/2$$EE:[=A13LQMZ*TW>XB([*N
MPG9U=""0RG3U;D LKO\ >^!!@G:-P9U)'JSL3Z;BC,+)Z_((<*4]YQ5J,Z(Z
M&O3TJ$)X>HT]T(($0!-.G>@<%=I.WIH@&,4ININ0.SKO.T]Q ,9VFNWH0!&=
MFW=T( 93;TH!8>OWD$\&[;M&Y #>LH(X*; >E0.S'3M5 LKO-2-Q008Z[S7J
MJ@JX=E*U]TH([,=:!V8V;=V[WD#LQ4.'QMU>FG4@&,4V':@=GL .X('9^[NV
M5Z4#L]O%7PNL( B -1L]Y!6@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @YOSI_P"6(?\ +C^]*ZX^UF[L?/H7=A5T
M*BI14C<@D;E!5TJ*D()"*J4$A%5!05(H%%2$%84(2%%5!54A9%UJHO!05M07
M6[D%85%UON*"XU470@N#>@N-Z%$7&HKT6UQ-;3-FA<62,VM(0=/TSJB/*L;:
MW)+;U@:T'91VRG1[RQ+,PVAN[=11%2 @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @((=N067RQQ"LKVLZ!Q$ 'NI05B@V_I04
MM>R:O"\.;NJT@[>FM$%,ES;QG@?+&QW4YP!_25:25298VL[0O BZ7$BE/?2@
MM^>V1JX7$7CM[Z;LI6%;)X)36*1LG#T@\5.XE)6HRYMWG@9,QSAL/"X$]P)2
M2J99X8Z=M*QE=W$X#N52(*HCN(97\,4K7D"I#7!WZ!M28(2^XMV.X7RL:\[F
MEP![B4*J^(4XB13?7<%!;9<6TCN!DK'NK\5K@3L^%6DB7S11"LDC6#H+G !*
M5%37QR-XHW-<WH<TU%?@4H56S<V['<!G9Q[N'B -?>JK22JX7,:.(N#6C:2=
M@4*H9-#,:12-D/3PN!IW%:3 2S11?TLC65W%[@%(@5-='(T.8X.:>EIJ"/@0
M5C<@E 0$'-^=/_+$/^7']Z5UQ]K-W8^?0N[#W8JP?E,A!CV/$;YW<(<X$@;"
M>CWDF:0.@3<H)[:807.H+"&=U.&*0ECS7=0';M7+S/!O=:]J;0V6TQ)$;HMF
MMIG-8RYC_HR7"HZ:]"U%U4F$ZGT5>:8AM)YKAER+L$M;$UP+0*5K7WTBZJT:
MT6D&A!'N'9L595-CD/A!CB.L HH :TIMZD57V4@%2QU!TT*@@"NP"I/0$566
M/;3B:1[I%*]U14[^\@RN T_?ZAOH[*R8?"KQ2D'@90$^$?@69FBJ]28&;3>4
M?B[B9L\D;6O,C 0VCQ[J1-1C[:WFNIF00-+I7FC6CK164SFG;[3\\=M>C]M(
MP/+6;0VH!I4$CI6:U&+[.3YAKT"A6E96;$00XJ/)"_BDG<6@V0:\2-XMY)(I
ML]]9'AC8]VUC2?>VJCV6%F^^O;>Q8>S?<2,B:7 T!>X-K^E0934.G)]-W4=I
M<3,G=(SCJP$#HZ_?2)*L6W=M05A476H+C5"5UJHN#>@N-Z%$7 JJMJBO1!+)
M!(V6)W"]A!#NHA$=.TWJ:')QBWN7MCO&"FVH#@/?[ZQ,,S#9:UK^GW%$5#<@
ME 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$ H*=PJ.Y[J".)M>$D<1^35 =6E>GI0<4YZ\P-3:(EP9TX ]U
MU([MX2'N+PT@4'"YN^JW9%>T;AC==VVH^7\^JL3(WSB*"0.;X7@3QBA:X&A&
M\'X5*4D:C@.;=QC>5SM8:AI<W[[N6TMX6\7[20-XF,&UQVT/2M;NV@\]K'SU
MS6/.H67=ACVO:98,6]LQ>YC=P/#,0":=)";!D\-G^8NN--7-M:1QZ=U3C9FP
M74EW'-V,@'$TN9PN)(JPG8X[U)B(D:)=9KG3::ZM-!NS]@;^[B[9EP([D1 5
M<*$&2OR5K92J-PU!J;77+[3UK89J\M,MJO.7(M,4ZW;,V)KW$,)/&^NQTC/E
M!2(B95XH]7<Q=!YK##7=S:7N$S9X'2P-EK;/+2\-/%([;X/0TI2)[!&OM:ZL
M?S!.D=/9['82UM[5MQ/=Y&0LBXW%XX:B1@KX.Y(B*5&RZ9RFJ-/8++Z@U;J#
M'9VQMXC);R8QTCFAPH-I<]X.VHV+,Q$]@TF'4W.6^P#^8D#K08-M;L8IS9>U
M-HP"0N_I@*<->XM4CL&Q:CYOW<NF=//TK!'/J34@C%O _BX(G$/#S\9E*/9P
M[7*1;J&!R?-C!ZFLK'.^:YW#WE1-=6)<3;FAW\4SNDCY*;)@6KK-<U-:ZERV
M.TN8L%BL2X,;<WL4[3.X^#X-'MJ*@G8U*1"K>E^:^HY-,:F9EK%MUJK3Q+8X
MK5LCV2\9BC8:![R:.>2:.W!)MA&(O\YSIPNG!KV^N;+S  7$N&<V9DC(B"_Y
M4U*T%-ZM([!G=4\S\YD(=-X31D<?W@U'!YUQRAY;#$.,DT#F'_ OZ5(MU%>F
MM9ZRTSK*/17,&2WN!?L[2PR5N) '%I:#\=[^F0;P-R3$4V#%_>_F1K[(9>\T
M)+:V6"PSNR8V<2%UP]K0\@4D;MV]05I$=HW7ESS#;J' 7=QJ)T&/R>'F\SRQ
MD=V439(^)CB3(XCXS'?*69B@WVWN;>\A9<VDK+B!X_931/:]C]M-A%05D<2U
M[JGF!/S2M]#Z3R%O8LG@$K7W#92VO T[>![>OJ72V(I48[4>H^;_ "O?9Y?4
MM]89C#2RB&;L&SM+2ZNRCY0?T)$1(V"7FIZ-YD.QN=OXK/31LFW#>TXR[C=V
ME*!I-=PW-4W=BNB8#6VE]4-F=@,I%>]@.*=C>)KF =;'M:[]"S,3".5ZUYVW
M4.H,?@-,6CW6S[^&UO<G)'*V,<4[&.:PG@VT)Z]ZU%FH[=9N,MK!(_X[HV//
M55S:DK P^H-::7TLYC-09.&R?)MCB?QOD<WKX6!Q_0K$2,=-S&TK+IZ^S^*R
MD%U;63>*3A#R6>%3PHZ!X[B4GL5J/+/G%B<UI-^6U-D8;>]CN&Q3,$<W"T2A
MC8Z$AV]Q/2M76TG8CH>8U9I_ XV'+9B^9;8Z?A[*=S7EKNT;Q-^*"=H68BJT
M4:@UEI;2O ,_DXK)\@XHHWESI'-)H"&L#C2H/0D1,HYCB>:YR/-*_P =%D(I
MM%V^/=>-F8)'4+&1$D@&NPN=\A:FW85=8LL[A[_$#.6-Y'-B>!TIN@2&AC!4
MD@@$;NI8F!.$SV)U%9MR6&N6W=DXT$K0YH/2:<0!*3L&I6^H9+76^7M[[/6C
ML790.E=BVLG%Q  &^$YQ\ C;\G;M6J;%>B3F[RYB$3WZA@_:;6D-E( -/C49
MX(V_*4W9&WV=Y:W]O'>6,S)K25M8I6'B:X5Z"/=4'*=2\R+C3?-6UP63O8K/
M3+K5\L[Y..H<(VD4H34[>AJW$;$;YI_7.D]42R0X#*Q7DT+>*6)O&R1H! XN
M&1K33:.A9F)@>/)\S]"8>\?C\EFX(KP.X7Q-#Y QP-"'.C:X#;UE-V1EW:EP
M$>(].R9*!N(H#Y[V@[,@F@%??V44VC"67-?E_D;N.QLL[ Z[E=P1,D;*P$GH
M#GL:#W5=V1@8-<7EMS9SF O[AK=.8[$B^:0'N(D)M!7834?MG;FJTV5&EV/.
MV\RV@\_DHKJ)NH+*Z/FT;63!OF]&4-2>OB^4M;NT;MI3G!H^YPV-9G,[;QYF
M>&,W#").#M'-!(XZ%H(/6Y2;=HW9FJ< _--T\V^C=F7Q]LVTH[B='5P+@ZG"
M1X)W%9H%QJ;!VV:AT_->,;F+AI?%:@.+N$<(J: @?&'2E)&;.S:H.2ZSUKG<
M1S/TQINSD:W&Y&5K;EK@ZI!?$-E' ;G'H6XB)A6W9OF-HK3MV;'+YF&VNPT.
M="T/E>T'<7"-KZ;NE9B)%ZVUQI.[PMQJ&TRL,V'M@7W5U&7'L@!4\3:<0)H?
MD]"4E'@9S7Y>37<=BS4%L9Y2 RHD#"2-@XRWA!^%-V1F,UJK3FG;9EWF\E!:
M6\PK"Y[BXR  $\#6U+MXW#I2(J/%@^86C-23/ML-EX;JZC:7NAH^.6@WD-D:
MTG?T),3 \EUS7Y>V3GMNL]"PQ2.B>T-E<X/8:.#FM83LZU=V1G;'4N R>+&:
ML<E#+B*$F[#PU@X26FO%2FT;BI082RYI\OLE?QXZRST#[N1PCB81(QCWN/"
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M1]$VW^K0_P!PW^0+F+J @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M870*!!* @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(!W(*?>W;R@?R((-:=0]Q!HFM=!'5F=T]F/.NP]"7+;
M@Q_/#7AW4>KK5B:*]^OM$8_7NF[C3]_5K)&M[*<$!T;V/:\':';^$#<ELT1A
M=,<J<;BM G068D-[9%[R^1I -'M#:@\-*T]Q6;MM1J\7);5>/M),-B=7W-OI
MR6K3:.?X? [:YHX8@W]"N] Z)H;0V(T%B!B\2'N<^C[F>5S7/EEIM<[A:T;R
M3NZ5F9J,1><N3=<Q[+7@N^$6D/8^;=9JXU^+^MUJUV4&6UWHBPUYA_1E^]T,
MT9,EI/&0'1S4V.VM=T@'<I$T&F8#D[?Q9JPRVK,Y-F1AQPXV!S@61M((%:QC
MH/05J;AZ-4\HKJ_U')JS2F8FP>9N6F.]<UX$;VDDG8&%U3Q'Y21<,AHSE3B]
M,VF1%[<29'*9ACH\C=3.!XVD[FT8VGQ6[Z[E)NJ-2'(;)1L=A(-27#-'OE[1
M^,XAQ< (\&O9<.X ;EK>&XZJY48/4.F;# 022VDF($8QEW&YHD88VN:.(EC@
M:\9)H!M68NF)&'TYR?NH-0V^HM7YJ;-W]D"+$.<.!NPU)!C!Z>M6;A@#R.UA
M9ZCRFH\-JQ]C=9*5[G.C)#NR<_B:RHCZ*!7>@9N;ECK?)Z6R^G<WJV6_=D@Q
MK)I7%QC:V2-Y&UG3PD?"IO1487$\F^8V"LH\;B=<36EC%L;%&YS6CX.S5WH&
MV:KY6RZJP^)\ZRDK-3XEM(<LUPXB[B)-:L<=Q(68NH&C.54N"S<VJM1927,:
MBD:&1W#W QL:*5V< =\EO2DW*Q.<Y+WLF7OLEI3-S8:VR@ID;9KAPN- T\-(
MSO &\E6+D;'C>73M-Z,DTUIJ_DL\C* ]^2<X&1TQ;M=5K1O-3N4WMHVW!VE[
MCL3:V62NG7U]$");MYJZ0DD@DT&X&BS(U*\Y=.N^95KK\77"+>+L?-NOP6M^
M;[G6M5V4&_;]^\]"R-(M]"&#F#)K@77@O@\W\V\?]7]?K6J[*"6:$+>8EQKK
MSK9+ RW%OU%K8VUW?J=:5V4%S7NBCK,8H"Y[ XN\9=@_.[.2-]-Q^8I$T&V6
M[.P@CB)J(V-87#]44K^A0<ZUORNN-09V#5. RLN&S\+.S=+&X!CF[=M.!Q^4
M[Y2U%RJ=)<IH\1>9'-Y[)S974.3C[&YO"X4$8+/BUC!K2-@VU2;D8;$\C9+;
M3>3TG?YB2XPMT]LM@P$<<,K*4=4QTWM;\E6;ABLCR!SN<QL6*S.J)KNVL>%N
M.B<[P(V,'"*@Q= IN5WRC<M=<KOO+FK75.#R4N(U+:Q]@RZC(#3'5Y((X''=
M([I68NIL&)T;RCGT9JR?7&6S+[^>6VDCNY)#7:_A-11C3\E6;JQ0:A%BL+KK
MGI%E<%(ZYQ=A;.?D)V@AGG%;@ #B:*[71[JJ]EIWOHQI%*'HZ/="YCF]WRL=
M<ZJS^H_/:#-VK[01?,X@W;\7]5:WMBLAIO0!P.@YM&&Z[0SMD8;CYO:- ^:.
MKJ29VU1D.7NCSHG3D6#=/VYC<]_'_=N+NH=:DS61CKK0#KGF/::Z\ZV6T+H?
M-?=+6M^;[G6K7901D.7@ON8,&MG7-(F6WFKK4].P@_)]WK2NR@U2YY)YBPNL
MB-'ZBGP^)R[G/O[$/%#Q\0('#'3<XC;57?U'IO.1.%DT9#IJRNIHLC!<"]CR
M)<WC,U9*U_9TI^T/R>I-[;48O(\B\]GX87ZDU1/?7EE)'+9.<[]DWLWAQ!!B
MXMM.@A7>H-XPV@),9KJZUE+<B0W.,9C7VXK\@6PXAL_ZCKZ5F9V4&HQ<D,C;
M8_-8.VS;_064D[9EL\U+)#0%VQ@'0.A7?&U9?ET[(\N!H,77"6PQP><]?9MI
M\WIIU*;VVHU#FL,%@N6T>B[^Z[3,".-MC"T.+WR&0\)%&T^,%JWMJ-TY1Z8&
MEM#XNSE:1<SPMN9JD$\4X[0UI[KEFZ:R/1S$T#9:^PGHN>:2UG@>V6SN8RT&
M.0/:[I:[YO4I;-!JNC^35WAM11:HU+F)LQDK5@CL^-P+6!O#0FL8.S@;N*U-
MVR@\DW)?-X_+9"?2FH[C%8?*/,EY:!PJ2YH:ZG#'3:&C?5-Y:-=U#RN'+OE_
MKZ>"_?=VV7L^-XE(=)VD39B7$M8P;>T/0K%U9AFBK2O)K)YO3.+M;G45P=)2
M@3NQ7$.+B:XFG]$6TXA5)NVK1N&J^3@R5]A\MI?)2X;*8>%EI;3-<*=C"R-C
M!L834!G6LQ<,;8<D+ZWU3C]69#.RY#*VQ<+J28AW$US'- ;2-I^4-Y5W]E!N
MN@]#.T6<P\W';^E+DW5/F;7NIN'SEF9J,!C.3>.CPV:P>6F=<VN8N'78X" Z
M,DM(()9386]2N\,%%R,S=PVSQ.;U-<WFF+*5DD>/:]H<6L(\$ET7#0@4W+6\
M,SJ3D_+=9>VSVD\M+A,M#"RV,C'#A='&UK0#1A-? ;T]"SO#T:8Y/V>.9F+C
M4=[-F,MG&&&_N9' U80[XO@ UJ]QVU2;AK<O(S/-M9<!:ZJN(=)&1SF6'$.)
MK7.+N$4BX=A<>A:WQUW3N L=-XJVPV,8Z.TM6EL;7D.=0G?5H K\"YS(YYJ#
ME'E9=57>K-(9Z;!W^08V.^#7>"]K P"G#&3O;7:5N+MFT>'!\C#A<MDLHW+2
M74N5Q]Q97CIR'.,EQ')'Q@MC;L'&T[:[DF^I1N.D=!G2VCY-+NNNU+Q(.V_R
MCB?FC=7J4F:R-=;R5L)>7N/T=>7+_/L9X5GD(B ^-_&UU=K"-M*?%5W]M1@C
MR(SE_EL5ELYJ67(7&)EB= )#5HBB(\$5CWT:WI3?6CNT3.SC9'OX6AM?>%%A
M%2 @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(""';O[ @PFH-+8?4\<$.8@,T=O()8@'%M'M! .SWUVQY;L>VUSO
MQVW]KWW]A9Y.SEQ]_$V:SG;P2Q/'$'-.WI7*VZ;9K#=T1,4EB]-Z0T_I*QDQ
M>#M>PLI'%SX22]I)).X]'A%=<N:_)-;IVN6+#9BMW;8I#!7G)_0=U<277H]U
MJ^4UECM)7V\;C[K(RT&OO+O;QF6(I7XN4\'BF:T^&QLNG],X/2]GYC@[*.SM
MS0O$;0"X@;W$"I)ZRO/DRW9)K=-7?'BMQQ2V*+.5TGA,WDK++Y"#M;_'$FUD
M#BWA)#FG=[CRK9ENLMF([)2[%;=,3,;892]L;3(VDUE?PLN+2=KHY89&AS7-
M<"T@@UKL*YVW3;-8=)MB8I+3L=RCT)C;V*^@QW:20$NA9/(Z:-A-1X+'DM&_
MH"]5W&9;HI,O+;PF*V:T974N@],:LDBFS5DV2ZAKV5S'^SG;6FZ1M'?)'2N>
M+B+\?[9=,N"S)^Z.Q5IK1&F]*"4X6R;#-.")YW^',\$C8Z1U7$;!O*F7/?D_
M=*XL-F/]L,5DN4NA<KD),C<XT-GG=QSLB>Z**4DDGM(V4:ZM=O$%UMXS+;%(
MERNX3%=-9C\VPSZ;P<^&] 2V$+L1P=F+0QM$0'N-I0':O/&6^+MZNUZ)QVS;
MNTV:-?Q/*?0^'O8LC:8_M+B#;;^<O=,R,_J-D+@WX%Z+^,RW129<+.$QVS6(
M>;*\F]"Y?+3YJ]M)O2-SP]M+'<2QU#6M:!X+AT-"U9QN6VV+8G9]C%_!8KKI
MNF-L^,K]CRHT=CH+JVMX+CLKV,PW#9+J9]6.!!'A./6LW<7DNF)FFSP;MX7'
M;$Q%=OC+&Q<BN7MNWLH+2YCC&T,CNYVBI]YW2NL^H9I[9CX0Y6\!AMC9$Q[Y
M;)]PM,.T_P#=F>S%QB0>)K)WF5X=L\(/?4@[.@KS<Q?O[\3M>GR+-W=F-CS8
M'EGHW3EZ,CCK#BO6@-CFG>Z=[!L-&&0DMW#<M9.*R7Q29V,X^&QV36(VKFHN
M76DM3WK,AE;(&^8W@%S XP2EE2:.='0D>$=YZ4Q<3DQQ2)V&3A\=\UF-K*Z?
MTUAM,60L,):LM;<;7!H'$YQ)-7.WDU)VE<LF6[)-;IJZ8\=MD4MBD,P-RY.B
M4! 0<WYT_P#+$/\ EQ_>E=<?:S=V/GYNY=V$]*HJ*@"B2JM02BI"BI05*">A
M15005(H%%5()'0H*@BJE%5!07&JB\%%5-51=:HJX%471O4%P;U1=""X$%QJB
M+@W(JMOZ>D]"#9],Z:ERLHN)P6V+""ZH/A#?3]"DRE74+:"*VC;#"P1L:-C6
M[!1897T! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!!2_XIKN0>*\O;7'VTE[>2MAMHF\<LCS1K6@5
MVHK0QSSY<F[%IZ5:'EW#QDQ\%??XUK=E&SY766!P^/LLI>W3189&:*WM)F%I
M;(^=I<RA)&\!2@SS'M>QKV"K' %M=U#MWJ*P=MJS#7NH+G35M.'9:U =/"2-
M@/%3I)^2>A6@SHVG;NZ!T%1$NV'^=0*;-^SKZU0%":U!'1M0*@;Z>]OH@G8=
MH_EV((-.FE.H((&T@TK3<:[?@05'A_L*"DT/O;]Z"*[*UV=808G(ZCP^(O;/
M&WUPV.^OBX6L!(!<&@N.RHV>"5:"WCM687*Y>_P=G/QY'&D-NXJCP2:]1)Z.
MI)@9LFF_=U**PC]4XB/446EGS#TS-&Z>. D'P&-#B=]=QZDIWC-C9[M>GH1#
M;TGWD$C?MW>Z@@NV_#L04.I&UTK]C6@EQW;!TH,=A<]B\_;2W6+G;<0P3OMI
M)&4/[6, N'@D[:."4HK*AS>$'H1%N=[8HWRO-&1M+W$[ &@5/Z$5B,#JC$ZC
MCGFQ$_;16LCH)C4>"]CBT_%)Z6E681F^(4VT%=U"H'3T^_\ SH!(IMI3K043
M0QS1.BF8)(7BCHW-#FD=((.Q!C,-IK3VG6RMP>,ML<)B3)YM%'#Q$TJ7<#14
M[$F9D939Q#<2@JZ:[O=ILH@I=0;=PZR@D [A\'5W4&$Q>K<)F,KD,/83]I?8
MR3LKQG@^"[B>WH)/R'*T&;KU;1[G0H,7E]18C!S6,&1N&PRY&9MO:L)%9)'N
M:P 5(Z7!(@9(N!VM\($ U&_;NJ@J)V]!W;*H+5[=PV-K)=W+N&WB'%([J&[I
MH@Q^F]28K5>)CS6'E[:PF)#'[-[:5W$CIZTF*#*UV[=O6-^Q!A\CI;3F8O;?
M)9;&6M[?VP M[BXACDD90DCA<YI(VDI$R,NU@CHUH :T !@V- &X (+R @(,
M?D<=89>RN,;DK>.[LKAICFMYFM?&]KME'!P(07[&UM[*UCM+6%D%O".&.&-H
M8QHZ@!0(/2@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @((X?=0*!!' *H'".^@!H"
M":;:]*!2J!PA X1TH'"$$<(^%!/"$ "G35 H#O01PC>@GAVU0*>Z@<(0.$('
M"$$H" @(.=\XX)[C3<++>)TK^W!X6-+C3A/4NF/M9EP48K*;_,I]O_5/[R]%
M88HJ&*RGV*?R3^\E86B?164^Q3^2?WE*E$C%9/[%/Y)_>2I15Z+R?V*?R;^\
ME5HGT7D_L4_DG]Y2HD8K)_8I_)O[R55/HO)_8Y_)O[RE15Z+R7V.?R3^\E0]
M%Y+['/Y)_>4JJL8O)_8Y_)O[R55/HS)?8Y_)O[RE1(Q>2^QS^3?WE*JGT9DO
ML<_DW]Y*BH8S)?8Y_)N[RE5HD8S)?8Y_)N[R5%7HS)?8YO)N[R555Z,R7V.;
MR;N\H+C<;D?LDWDW=Y*BZ,=D.FTF\F[O(JMN.R _V2;R;N\B+K<=?_99O)N[
MR"L8^_\ LLWB.[R"Z,??_9I?)N[R5%;;"^^RR^([O(+HL;W[-+XCN\@K%C??
M9I?$=WD%QMC>_9I?$=WD%UMC>?9Y?$=WD&PZ9TO<9*X$UVPQ6L=2X.V$D;M^
MU9F29=1MK>&WA;%"WAC8 UH'N"BRPO  ;D$H" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(""E_Q2@X
M3STGN,EJ+1^BW2F'&9FY#KPM.TL$C8R*CW'E=+=1T>;E]I6XTZ[3OH^..T?$
M6!P%7@['!W%OK45WK%9''.;.E)- \N<'BL;<27Y@SUK)9MGH>$]G+1E0&[-@
M"Z6S6261R>I.:&@Y<#E,[>VU[B<E-%;R64;2#$) 0*$'W!UJ1$2,S#J_*CF/
MJW%M[,6V.LI)[=S6 /#V13N!+MYVM"E-D*UC :EYPZIT?)JVSO[>UM+4/[.)
MS:ON R0M)WFE-O5N6IB*HRM_SJRPT%IS(6T,,>HM12/LVOD=P0LDB[)CGDN<
M  #,#M<IN[1XY>8NK]$9'%S9[.8_/XO)N$=Q%9O:Z2W<YI<!X)V[J;BE(D>C
M-:]U?FM<9C3.*S-GIZ'%.<RV;> M\Y+7O:*.=X(KPCJ2D4J,I-S0U1ISEY+F
MM2V<+<TVX\QLY&/:^*=[S*6NJQ[@!PLZPINQ4:[>Z\YA:4M+34>2U!C,M9OD
MC%]BH)8W21,>X TX7U-.([J[EJD2.]X?)Q9G#V67MSPPWT$<[!\T2-#J? N0
MXK%J'FAJK7&J-,Z=O8;+'XB[D9'=2MKL:*M:*'IIU=*Z4B('OTOS-U?-C]1X
M6_Q\=]J[3Q8&,8X,9,U[G#C)<X#<&_*Z5)M@8+,ZGYHZ;POWJR6H<<]T3HWW
M& :]ADX7RM86BCC6G%78[H5B(D>G4W,?65]F]+8_3$D=O)J"UC)$@JV.281>
M%M(W%Y2+85K&M\-KZ#F/I.VRV<@N,I)&XV]PQA#(P&SD@@CJ#NZM12C+=,'K
MW)X;/:Z=F.RN8=-0B1[F,#3(^-KN,D@5VD56*=C3R8[+\Z<_@QK;&SVPM7NX
MX,'0!TD0?V9\)S@!TNVN5G=C8C.8[5N<O.:.GL/D+>.U%YB775W;\+2^.<VT
M<A:'BIH'$C>I38-1TCJSF]KJPR5[C+Z"TM\4Z0<<C=L[HSQ<._J/N;E9B(&S
M8;FAJS.:(O9K#'1S:OQ]P<==1%X9$QXXHS*2]X%.)I.QRDV[1KF?UOS%T*W'
MY?)Y['Y:&YD:RZQ<+FE\)>":;'5-/<JM1$2,OF]9Z^RG,,:1TO/%!#=6K)^U
ME'@P@E_$[>": 5Z=RE(I54XK4VOH\YJ'E[GKZ&7*1V8N++)L::4+8WD$?W+R
MW<DQ':0TGE[F]6:+Y;ZEU1!=1W5K%D);:.U+'>#<O:QKIC2AX1Q-._H6IBLL
MMJP^K>9$3\5E[3,6&IK&_<T76.@>R.:!K@226O<QVPMX>G>LS$*[M>2NCLKF
M1C=K(Y'BM" 0TE<U<#BYHYW#Z#SN>B@BEO8,I)90$,HQC"^X=Q.#*$_T8"Z[
MNU'OT_JGF)#D\1<,R]AJC$Y!U+J.W>QDEL*TVM>YCNFNXJ3$#M-[D(L?82Y"
MY'#% T22=- :;-E>M<QQ#"ZAYO:_Q%QK'3]S;X[&M<X6>,< 73-8&N.TNV5#
MJ;2-RZ3$0/3F.9FN;DX+2&.L(K'5V3;6]?(0]L+6%K"X<+R-I>';RD6QVB[#
MK+7>A-5V&G=<3PY*PS,<GFE_$.$LE8Q[N&E>M@WMZ5*1,;!A\9JCFIJV^U5%
MALC!966 O)XA+*VKGCM) Q@^!FW8K2('EPNN^:^K=+7VH[&[M;&/!ES+AA:2
MZX<PU--I \%WN;E:1$CUYOFWJ^YTIHS)X.-C<KEY7VEW$1X#YHVVXKM.[BD=
MTJ1;%1[;W5W,?EWE\0[5]U;Y3"99P8\QM+70/<'. V&OR>H[TI$]@QVF=01:
M6UGS3S\K0\6$LMQP'<XQ/O'ANSKHD[8@66:\YB7N"=K://8N& DR1:?=+'VO
M9-?V?SZU('%O2D=@P_,//Y?74W+K4.-NF6;;Z]BCA@+21#=]M;'B.S:T%[>X
MM1%*I+;\[KK5AU-#R[QN7LK&]L;=DV3SETX,C)>QDC0T.(Z)6C8#N6:12JKF
MFN:V6Q&<R>F-5W=KDW6MM+>VN2M'<;)1!'(\@\!=2O9]0WI-H\$.5YM:NTQ=
M:OMY[9N&G[3L,1PU<Z..0Q5J7;ZLKOZ4I$2-I_+ALY78VO\ C9:=QJE_:D.M
M]F/>Z5A4EH(IT( 8 @J0$#?L04"-HV='4@J#0-W3O02@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @((< : H(I3X=Z"1L
M0$#8@>#[B"?>0$$()0$! 017K0*BM.E!*"$$H(0 :H)0$ H(H51*@%!%"@F@
M0$!!3P[-U?<05#<@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @AXJT@(./<Z-)YK(2X36&GX#=
M9+3TXF\T:TN=+&TAY H#TL W+=LCPW'/FTFPS[6RP>3^]#XS%'9=F !*?!XB
MX'B-!X7Q.A7<&L:KQVMI= Z<N=5237.4N]0V5RVV=QN=!$]DKN$\>W9Q4.P;
ME8I4;9SPM;BXP.FFP1.D+;^U<X,%2 -]:+-HP\-G=?BKKF7LG]E)CI0R3A\%
MQ[&XV#WU>Z%9SEG;SQ<C;>"2-S9VPW0<P@AU3=2D#N*7?N2'*KG1^1R/+71V
M8=C9+VUP5[=2Y''M:>-]O,;9SJ#A<*\,+MX6Z[9*,I9,T%F<GC+#2&B)[J]>
MX&]DNF1116_""2:MBDKM'3PJ;8[9&6Y@WNDKO4V1LM?:6N+>6,DV.9Q[(W23
M-#G4\)S(R"=_QCO2VO<-9AT7K'4?+2^C[.[GQEID&7V*L[TR23/@B;-&6CBK
M\\[E:Q$BYYQRZO;>RL\)H:ZNM13/C9+:2Q1,CC)< 2YPC>2!M^2-RFW4?3N!
MM?,L+860MVVCH8(V^;,^)$0T>"*!NP>\%RD<"P7,2WT1S(UXW(X^ZGQT^1E+
M)[5@?21H^*:\(V[.E=9MK$#%>::XO,5K37^$L[JQGS#X8K*%K7MN/-F<=7@M
M .TL9NZTV;(&JYJ#2N2TG*S#XS-9/4Q8QTUU??M60%DK7.))+W?%!ZMJU%:C
M>,99W;M8\MY1"_LX[.$/=0^"6^;UJ?@6>Z5;!SCEEQ/,+2.HI[6>7%VK'QS3
M0LX@'/;.P [AO>WI4MVQ*,+CL/>:LS?-"WL8GL;G;?\ T%SVD<0F8YS=U=M#
MT*UI0>C!<U\GIW1L.DHL)>#6MI_H]K"80Z(ETO%Q&HK0-)/Q%)MVU&0PL6H)
M^<>F;_4##Z1DPTC[Z1C.!C)Y+6(N;T4HZH2>P:;RIYF6^D\%FL3D,;=SF::8
MV4ULP/8^1PH&$DBFWWUJZVI")\-KC#:!O\[!!=6;-0Y)U[D(+7M&745F][I-
M[>$_$E=U;DK%1JNK+'3N0P]E+I;$Y6ZO8)(I,CDKX<8:#1I%1QFO$1O<K$R2
M['IFWG/.:.Y#'>;NQ; ):>"21+TK$]BKUS:7+^>.6F9$XQ/Q8:R0 \)/8PB@
M2OZ4:CHG4#L+HK5&F+C 39/)PY&:ZN,;,P".6UE#&/X0YKZN C=\A68VC5\G
M!@KVXL9^5N-RV(U7),TW-O&.QMXV<+@\'L2#\?@WM6OM'UO>M(QMV!M=V,@]
MVO >ZN"OGO3<F0Q.@]22G >FXW9>7M\?(VI,!DN"7 .CDZ>'HZ5UG;(U>.WP
MMYJ7"7'*RPRN+R+KEKLG;T[*V9%QMJ"V$T^+Q;PKMIM1]0YC&3933T^+>[AG
MN(6QO?2OA["3[NT+E4<'T1S%NN6^D9=&9G"WOWELG/99-CCK'+QAK6GPJ'?Q
M?).Y=)MK(M9!^ML'G].\TM18Y]X]\3XLE!:QEKX8I'1N;4<- 0R.AW;4V=@]
M6<R=QSCUC@#AL;=6^!P7;7-S>7+.$&1T4@X1PU'S/E=*G9 S7*NTN(8^8O:Q
M.9VF2F=%Q CB!EGVCK2[N&'Y4V=U#RKU=#+"]DLDTI8QP()\ #95+NTAI5U=
M7F!T;R]O#:22SVV2NI?-6BDCN$VAH!0[31:[Y&WZLU#+SAR>!P6G<9=PPVLC
M9[^[N8J,BX&N!;X)=UMWD*1%!YV:5R&H<US7Q4$3V37KYO,W$&CWUO T;-X)
M<$K2@UG&?</%:?CQ6:T9=W&M;:L,ELV&-L<K@\\+N(L+@"RA^(5=NHV;6F.N
M,)A>7>6.#?CK+'9".\OK*V;QF"-LEJ\U 9& ZC';P-RD;:C&ZEQ>#AU])K;4
M&%N<GHK/6\?92MB:^6&6..*/P@^K=\3_ )21V4&5TUI[ :OO<O;Z2TI)C,8Z
MSGAM\S<M:R1TDL4C6@-9%N-16DG2DS0>C3'-"ZT7H_[EWF"OG:FQIDAMXFQ
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MY$4QVEK"XNAMXV.=\IK6M)[B"9+2TG-988Y2-Q>QKOY0@N"-C&\#&M:T"@
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MO[2VO8@>RN8V3,K2O#(T.%?@*B/13;NH=_N(.;:UYRZ>T1FVX#(6MQ/?N8)
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MCE;6">?%32'A$UJZ,/HT.WT+9-Q*LQ7:-,N;NX_!S3^%BD,=OE<_);W3@?\
M!%H:6_#Q?H6N\?3^$T]B<=I^+#VMJQE@^ -?$T4:0\>%7WZU7%:O/I70^G]%
M^?-P$;XH[^7SB:-S^)H>2YPX0 *#PRDS5'*,UM_,7A>OS/;LI\J3H6X_:,AS
MT'G6HN7N)EJ;&[R3G31G<_@GM* C_I%+>\>'GVR/%6^D\I:1]G>6=PR.![=C
M@PL<V@IT;4L%[.:&YH7?,S(:KP-S;6%N;?S6TNY&,N#P-=)3P2YE*AVTI$Q0
M9SEEKC5-_J;+:$UHQAS^+A\Z\YB 8R2$F(@AH&S9,SY14F([8&%YH9"[UIK?
M$<ML=(?1[7"YS1C/'Q,:>/@-*4_HW#:>E+=D5'CUWC+/\3-":2$?_@-KV1CM
M'?%HRK ".NCBK$[)'LYSQ0X;6NA<U9,+,A/=RV\SV["Z,&$ ;/<>Y2W;$C/Y
MK%Q\OH;_ %/I+3]UFLYGGL%Y&POE<QI#GUHV*0\-0!NZE*U5R_0#,3/R?UQ#
M?7IL<A/---?6[P(_-R66P8WLRYI\)S0VNRM:+<_NA&OY34N>ON5UCIJYTU<6
MF!8YK!J%T4AA[,-<WM #$UHV>%7M5JFU'6M4ZKN?06"T+HV?SS,YBW8'W$!!
M[*U%2]YX>*G$V.1N\+G$=\M,+R0P<6G.8&K\-$XO\T,,<DAWOD =Q.._>:E6
MZ=D(N<]N7V/;A<SKB[NIKK(-N+#S")Q/96[9+RWB<&BIK4.=U;TMGN)=3[#.
M3Z$Q\6G+EMKEGV%OYO-(P2-:>Q;M+2YO\JQWC/8*'*08FVBS<S;G*-:?.)V,
M$;7.J:4:"X#93I4'SYK_ %'8Z5Y^V.7R,5Q-;16C>)EK$9Y=L;-S NL16T>;
MF=JV+FU%CL!I+ 9%]\VX;(;VZM9(A&UM:CXI_ONE+8IVDKN3PFH\ASFBQ&%R
M3L3<^CV,N[R(%SVL!D#N$A[.CBZ4KL&UZ*R>J\#S&RF@LYFILW9BV;-;74_$
M)&N>V-VP.?(=G&1\92=L#6.:/+VQT]F<#J&6]FR.5OLQ!6:8D"-GG,/@M!<[
MYYZ5;9J/HFP'^@VU-G[*,CI^2%R'#N;>KLUC=<V& DSEQIG3,T >[)P-=1TK
M@:@NXX@*$-^7TKI;%8$X)NJ\K@=1XY^J69C &$.QF8@N&2W0\)E>)C)'N'A%
MPVOZ$FE5<]TK<:@TQRA9F\9F[J,W.2@A;;L<YC8P7PAU*.^4'4.Q:G;+,.H<
MX=3Y_!\ML/E<5?SVF0F%J9;B)[FO=QPESJD&NTK%L5E94ZDS>J=9<S?N)IW,
MS8/&6-N7W]U "][IFNE/R71D \+!\96(B(J-+T[A-2V_.C,XB\RDEQECBIF6
MV4VQRFK(>%Q\,FH%/E+4]B-NTYS.OX>5&7O\M=/DU'B9GX_CE=24RR&)C75.
MVH,U5F;=JNA<LH\ZW1N,N<_=2WN2O(8[J669Q<X=M&UX;M).RI6;NT<XR&K-
M11<P]9XR+(SML+#'22V< D<&1R-$9#FBM =I6J;(5KNG8N9VI-!7FLWZON[6
M2S;(;*W9QN$G9-J>-PE;O\'>U6:1*.Q<IM3WVJ]&V>5R3N*]/&R9X^46/<VO
M1T!8NC:5<HY@6&;RG/3%V. OCC;N>U(=>M;5\<3F1\1 XF^$ ?G+=O82R^&S
MVJ]$<R+G26<SL^<Q4E@;N*6[JU[)*!WRWR;-AZ5)BL5&FV&O\AJ]F4S5_P P
M1IQ\4CQB<4R5H#F@%S>/]O%6IX6_$5I3N*MLTYK[6FK^6E[)A[Z!FH,?=LM;
MC*S2,CC[ OD/:!SJ"M&M'QE)B(DAK>H=39G1]SBKS%\Q_O!=/N88;W&F=LC2
MV21C#PM%Q+LHX_)5B*]PV['0SY7GAJ*.&X?9W%SIR-S9X@>)CG''N) !;_*I
M/[1S# X:_@Y3:KR+LI-/ V\= +)]>R,C6QGM#X1%3Q#HZ%N9VG<SYL>86F>5
MMEKBSU7<,-M#$YF*:US;<0EG@C^E()^+\A39,T&Z7&LM06&LM*9FXNYONQJ*
MW="^T<\B!MUQ2BH!\&NUG0LTB@R>+U#F]4<W+VSL+V6/36"B:RX@C<3"^9[6
M'PJ$"M6OWJ=D#;N8<VI8=-7/W6DAMLB7, N[B1L4<+#*P.=5U!\7B&\;5F/%
M7"-3:KS>BFXW)8WF*<_?NN(H[_%=LV1E""7T N)=@(X?BKI$5[D;A?YS5^O]
M=NTKI[,RX/%XZRBN;^YMJN>99 X[2UT=*DL%*J4B(J-:PMEJ+"<X\W%G+]U]
MD+?%M$%^X<,CXF "-SO"<>+AI7PE>XAO/*K4F<S'+?-Y/)W\US?V[;HPW$CR
MZ1O9L<6T)-=E%FZ-HY5?9[,:AY<8B\S-W+>W+<]"QLLSBYW#VK-@K5;[)&:^
M[N3GYXV\$><N8I'V#)Q.WBJ&5#>SV/&RNW>I7])WNY<Q<E<XG16;OK0EMS%9
M7)A?6A!$#S7WP0N<1M&I\@L+8VV@K+.,C!RF5=<R7ES2KWTNI& $^X& +5\[
M1L>0T'IR'+7VL(('PYEUM+&Y\3J,> UQ)<T#?M6:CA?*_36L,W8:BGQ&I+C!
MV%K<2OCCMFN)DD#GGPBV6/9\9=;I(9!W,?5MSRKDO)LA*S.V&3AL9+V)Q8]\
M?:0M-2-NWB=7:I2*CV9;-:[S&O\ $:9PV>GQ\%YBK6>>0%SP'216Y<X,XV[2
MY^^J4B(J/?C=2ZHT!K[(Z4SV:FSN-9CSD8;BY)[1O#',^GA.D.WLQTJ4B8J-
M3LM=9+5HR&9ON8C--R&:1EABV3,8UK(WE@+QV\6\ 'XJU2G<5>YW.#5>4Y:P
MW\,[X;UE\++*9:W':&* &!QE'"!3^D(^,/?4W=HS>BLOJ"74V-EPFN(]38&<
M-])P7ES&V>)I<VI:QTTIW<2D]@UUG,6^UGF\I<7NNAI/&6LCH+&SCE:US^$!
MP<[]M#4'BINZ%=V@Z)R5UW?:E],8+(7PRK\+/V,&58X.$\/%(&/)!=O:T'XQ
M6;H*NQ+ (" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @((=N0<?Y^,9)B<.QXXF.OHP0=Q' ]?5]/_=/V/F\=%;8
M^UKH=/R=U?+AY'$Z,S\<LD/#X0@F=&]H:2ZI_P &P;^E=]G%8][^>UPBO#9-
MW^2[Y2U&YENQR;U,^R<:/R%QVA;3^C+KFJ]=L1S-E=(_@\.69Y/)3_U?Q?1^
MC(;"+2^-BQP:+7L6\/#6E2:NW^ZOSV>9WYJ_1XJ19%%VTN-.-S%U;V1A&9IQ
M708TAYK7:XTZU+HOW8KV$3;6D=KFG-+_ -1]%C]9_P#V5POH\)_1O]M'SN*_
MK8_M_A+U\_>+[M8UKMD+LC;B0='9E[:U^!9]._?/V2WZA7<C[8^]5SL#!RS/
M"!4>;=GXS%. _K?%>._HRQ(Y80:PN\'FKO-OMKB&PC8ZSB-) ',:'&K2"*\/
M6NO-SCBZV+>]B>$C)=;=,[8@TOZ6T'S.;HOTC)D,'?6XF@;-1SXWNH3X3JN^
M2?E=*9=W-@\RE)B4Q;V+-N5K;,?![>9\LNJ=8Z=T# \BU=,R^RK=S76[7MJR
MHV[0'A8X2/+QW9)^R&N*KDOMQQ]L_8\W.2S@L6:0QT+ S'PY"!AC&QH CF"U
MP-U=^>^GX)QL4W([M[^$LCS_ .%ND+)T5/.6Y&Q\WV;:FZAW+'IO]2?LG[I3
MU.:8HIV[UO\ [H;7-CKN;$MGTQ)9VFJ);>(3W4P#C3LVU#@&O.\-^2O)%T;W
MZZ[KWS$T_33><ATA>#3.1UKA];1>>Z@=:R7-[>0FC)8.RD- !P4^*[Y(7UL]
MOF6V78]EM7RL%WEW7VY-MU*S/AM8G&8#F/?\O+V7 75O:Z1N9))[;'2@&X[*
M21SMCNS=O)!VR+K?DPQFC>BMT=[C9CS3AG<F(MGLCO92YYA8HZ#T]I3 R/Q<
M-^WL+B64%_8VW$2_:.,U(X@*+E'#7>;=?=MI][KS-OE6VV[*_*'ETODM'X/F
MM;18V^8_',LXH1<!DG[28MAXB0X5VN#BMYK,E_#S6-M?Q9Q7X[>(I$]WX.K<
MT-+X*;3F:U!-9,DR\=GV3+IQ<XM9VE:!I/"/CNVTKM7R^%RW1?%M=E7TN)QV
MS9-U-M&2Y5T_#?2=-_HBQ/\ _31K/&?U[_\ NG[V?3__ !L?_9;]T-R&Y>-[
MDH" @YMSI_Y9AK_CQ_>E=<?:S=V/GZE*+T,*VCHWJ"L**J455PF@)&PHJKJ4
M%3>I%5TIO&WJ*BI454%"%845<;O15]FY!=:@OMWA07V*B^S<B+S=Z*OM4%UO
MNH,QA,5=Y.Y:RVJWAVF3=3;3^VI,CKUM&8H61N=QEH +NNBPPO(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @((X1N0>%V$Q;KKSUUN#<UKQU=O'N5I^A%J]SALKU=2
M(XUS;P^3R&L=$7-E;NFAM;Z.2X>VE&-$K3U]2W;V2*>=W+J\S^-9JG38[/4V
M,A$;>'8Z6%[N%S=O@_%D?O"6W4V2-6T_RXS6J.2MMB)8_,]06E\_(6HEV4E$
M= /!KO)_0M3-)&<LN;&L,;BO0N2TC>2YV%AACN(70]BYU*-<:R [CU+.[ V;
ME-I_5.-MLEFM77!=D,U,VXCLZU%LQQD?P[*#_" ;.I2Z8D:]EL)EI.?6(RS+
M9SL?':\,EP*<+7<4FS?7I5K^D9GG+I;+9FUPNH,'&+C(Z;N77S8":&1@=%*Y
MHKLV]C1+9&EY.347-[+8#&282?$X[%O$V1GNC&0Y[6%H#.S<XTJ0K&P9W-:B
MUYH/6^0O[RRGSVEK\$V4-J(&N@/&XAIXN F@(Z2D1$P*^66$U%?ZRSG,K-VI
MQXR=H;.SL7D%X8TPBKN&H_P'7TI=.R@GE?@\G)S!UAJ3-6KFODG,-A(^GQ&R
M2$D<)Z0]2Z=D#U<W=,9H9/"Z^TW;B[R&"F8^6T!\.2,!Y-.+9OX4MGN&O ZB
MYLZUPF2N<1-B-/X%SIW>=EA<Z5X!H.S<X[V-5[(&0?K'7FA-19>WU%C;G4.%
MNW]IB'V;;>,Q-KQ<)KV9(HZFVNY2D2-9PW+;5.:TGK+*W5NS'Y'4)C?9XTGY
M-M/!<[>&H'%V;F[UK>B)%>1U5J;,Z);R\BTA<1Y@0MLGW!,(M0&L[/C%'U]W
M<E(K4;+9\@<5=6F,N<CD+B'+VUJVVD= ^1NYSWD A[?GE9WAK_+GE;-B^9F<
MN)Y;IEGCKB-UC<.D<>W#23X7AFN[Y55J;M@Z-SNQM]E.7&2L\?";BZ?-8%D3
M* D,O[=SMY V $K%NR1FY,O+IG1-I?NL9;V:TLK</M(>$2$B$5 XB!LIUJ4K
M*LU@\F_,8JVR3K:2S=<-+C;3</:,HXMH>$D=%=ZG>CD&;T_?WG/RPRDECVV)
M;:\+Y7AKHZAC *@]Y=(G]([-#C<?;.[2"TAAD^='&UAW=8 7,<KL\1D6<\KG
M*.MG#'&R+!<&G#7]K[M>E;KL64QXC)#GI=Y8V[ACW64;&W&SAX@R$4WUZ$_E
M1?YT8K(9,:8\PMW3]ADX))@VG@L$\!)VD= *6CIEF',L[=E/VC8F M]T ;%B
M1R;F9?9;'YR Y+3C=1Z1FB+7,B;&+ACS4&CG%CAO;N<MVC5^7>D,I<Y_4&=P
MV)EP6F+RU$%GBIY3*_M:PU=M?)O,;S\;I5F1K^'T_J;(\KK[2#<3-!EL/=QW
MP,A9P3!IB<6MHX[?V72M3,5%6O\ .:KUQHO':<M-+W=K)BQ V\FF=%PN=#&8
M_ X7DT/NJ1$1)+<]3X[.\O\ F6=>XW'29;$9& LOK> M$S9G.E%0'EHIX3.E
M9B:Q0>#0,FI,_P Y[K5>2Q$N-QMS82QVXE+"0 (FBO"YVT\*U/8=[6M2:3OA
MS;=HRT?_ .#9R49:XB&X.C<]^WI'^K-Z58G94?4D$3+>&."-H;$QK6,:-@HT
M4&P+B."9' 9B3F1K:^9:/-K=8V2.VD\&CWD1B@V^X5TKLA89[0.&R=IR8O,9
M<VKX[YT<X; :<1)8T#IHI,[49CD?C+[%Z&MK/(0&"Y;)*3&ZE:&1QKL)ZU+I
MVD,-DL+E'\^,;EF6SCC66DC3<;.$.=&P;JUWJQ.P>;4NF\ADN=,5R+=SL9)C
M>P?<5HT/+2.NN]6)_2-)P6/EY<09'36>T4<_==J\XG(0B(L((+!QE[FNI4-.
MY69KWCWZETWKBZY:Q3^BXK1LE_'<7>(L0V&5UNWMF@%S WK:?C)$Q4:QJ;$>
MG+#'G26A[C$065U!+>W%Q*)974E8:-+II#0<)5B?$EU?2V+R3.<V2R\MLYEA
M-I^*!DSJ<)E#;"K=AK\AW<6)G8.>65AJ"RT-JG1$^%N!D)+LW<5P#&8W-(8*
M#PJU\#J6^^HWO4N%RLW(=F*BMG.R'F<#?-A3BXFL%>FBS$_J)>37N"N6\GL1
M?.;V&5P!CNX@X^$TLEXG 4J-H:D3M&=Y"X6XM=,S:@OQ_P"(Y^7SF9Q^,6\3
MW-'5N?T*7SM%SGOB=0Y;2;(\%&^:&&:-]_:PN#))(A+&:!U13=T$);0<5U9B
M#GL!:V^D]#W&+\TEBEOKNXE$LCS&QP(:732&A))*W'C(W^ZM=0\MM:-UE88J
M3*X?,6,,%[;P%O:LF8"*?M'-&\,.PK,;85Y-,LU1K'FGD]09/$RXNQO;#S>U
M[4L/"T4#>+A<>BE59I$(\&G,EJ_0N S>A/NY<7=]=NF%M>1NB['@E9MKQ/!W
M$]"32=HQ%II34C.6^+L9;!XO8\U%-+%5O@L;(TD[U:[1NF=AS&FN;F,U([$S
MWN-FQT=L7P%G@N+B=O$X=2S'8.TYS$PYS#WN)O!^SO8);=Q-?!$K"RNSJKT+
M%2'%-+9[5W*&*;265P-QE\3 ^23&W=D8OB3O,O">T<P["YRW-)VC(8&'7&N-
M3W6K,G!)A\%;6SX;+%O<TOE>0ZE> D;:@;7)LB![.2N&R>,T[J*"_MW02S7$
MQB8ZE7 NEI2A/6ETCF[=*ZA'+?*V/H^3SJ3-QS,CJVIC$L)+M_N*UBHW3%8'
M+1\U\-D)+5[;*/#6L4DQI1KVQVH(W]!:5*[!>U9I;(YKG(]_F[FXRZPYM'71
MIP-?)#.S;0UWN'0I$[!J&%M)N7D=YIK4&A_3L\4TC["_B$1:]DCR\!Q>]KJ<
M)"U6O>-K;;:VQ.@X[U^!LG2R7':Y'"Q11 OM3V3:"K0WBV.._HWJ5BJM5QV"
M;J;7.GLAI32EUIN*RN8[C-2S2U9+$V1I>UK&RO&ZO0%:[$56&"FY8Y7*8K.Z
M2&H\;=RNNK"[@$;G-XPU@:3(YAI^SK\*5J.I\J+7+.@O\K?X>WPMI?2!]C9Q
M,8V5L-7\(D+!M(!;\HK%RNG+*" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @("""@T#FAH_*ZMLL=;XL-X[6Z;/)
MQ%H\$-<#\8CK7MX7-;CF9G1Y.)Q3DB(C5E>8&C;76^FKK"SM G>T.MI=E62,
M>UX(KU\-%SX?/.*^+H;XC!&:R;9:ARZY77F&T1?:4U0!+YX]X<6EKJM<Y^W8
M7"M'+U<5Q<7Y8OL[GEX3A)QXMR_:Q^,TKS=T?;28+ 7%MD<."[S6>XH)(A)O
M XIAN/4%TNR\/EG>NB8GV\&;,6?%&[;,3'MXMEY=<OK[3<U_G-077GNH\H[C
MGE'Q6!Q+BT;7&@)^<O-Q/$1?2VV*6P]'#X)LK==-;I1K;167SVKM.YJR#3:8
MLN-Q4M'QHYF[ 7 [WC<K@SVV8[K9[_R3-@F_);='\OX2SVN=(Q:RT_<X>5_9
M2O:YUO,*>!+PGA/=HN&#-.*^+G;/BC+9-LN:SZ"YG:IAL<#JJXMXL#9O#I)8
MJ.DE#*\(-)7>YT="^A'$8<=;K(FLO#.#-DI;?,4^_P";,:IY=ZDL]46NL-"S
M1LOHHA;SV<U!&^.,-#/EL&[B7+#Q-DV39D['3+P]\9(R8YVO5HW06H#JF?7&
MM98Y,R^(06]M#3LXFMX0"/#?O .X]*SGXBSR_+Q]C6'!=O\ F7]KUXG167M^
M9F3U=>\)L)H!#:;6EP\*0G9Q$C8X="S?GMG#%D=M6[,,QFF^>R8I][*\P]&'
M6>!-A%)V-_!(VXLIMAX9F-<T5W;*./2N7#YO*OKW=[>?#YEM._N:(-"<Q=69
M#$LUQ-!'B<2\2\,'"73/80X%U)7]+!T+V\QAQQ/E]MSR>1ER3'F3%+?F]V9T
M)K/":LGU5H6:*0WL38;JQN*!E&MC%15[!_@QW5BSB,=^/<R=W>W?@R6Y-_'/
M;VP8#E9EKV;-YK65RQ^;S4#[1S80.".)S'M%/"?7XYZ4R<7;$6VV=ENTQ\+,
MS==?^ZZ*>[VEB;;1/-O"XB;2&)N;:3!5<VVO9*=JR(N) IVP.S=N76<_#WW;
M]T37V\'*,.>RW<MF*:^TMWTSRLTUA<!9XG(64&2FMAMGGC:YQ)ZEXLO%WWWS
M=$T>S%PUEED6S%:, SE+;0\R#J&'&VT>GVPM;'"UK !*!'MX:UWM=T+T<Y,X
M=VLU<(X2(S;](I1O>LL/=YS2^3Q-G3SJZA[.($@"O$#TD#H7APWQ9?$SW/9F
MLWK)B.]&B,-=Z?TA@L+>T\\QUA;6L]*$=I!"QAV@D':%KB,D7Y+KH[)F9<^&
MQ3CQ6V3VVQ$?"&PA>=Z1 0$'-N=/_+,-?\>/[TKKC[6;NQ\_C;1>AAL.CM/_
M 'BS,5BYP;%\:2I ):/?6+II"PW?7?+X0Y*S;AVQPVLQAM61DL#C)(_@!(J/
MG#H7.VYJ88:[Y79^QCFFNGQ110BO$][ '"E=E7[5=^"BO*XK)Q:-LKM]E:MM
M'LB[.YB8.W=4MI5P<2:UZDB=JO-:<OLM-;VUQ<S06;KMH=;QW$L<;WAVT4:]
M[2=W4DW$+=OIN\PFJ<?C,O!3M9(W . +7L<_A]T'<5*UA64YHV%GCL^V&R@9
M;Q< \&,!H^*WJ4M&C]2TJL*$*@HJXW>HJ^Q47FH+S4%]B"^S<B+S=Z*OMWJ#
M+X3#767NF0PM=V1<!++38T=.U29'6L7BH,5:MMX&[0/"=L!<3M6)9J]XK7:B
M)0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!#MQ06Z[NK>3U40"!7?LZO@0*"E2
M-_2>BJ"DM) KOI\&]%5 "M*"IW$*".$'?O\ T]Q5*IV]=#4;>NG0@BE#[^]
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M3O[J1AA$HEDV,K$VC>(N^6=E$ILVC3])NE=R[YDPS0-M2)X@ZUC(<R.LEK4
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M@4* &H'#_.4#A_2@FAW[B@4Z3O0 *"B"4$402@((H@E 0$$4ZD "GO()0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M^] 0$! 0$! 0$! 0$! 0$! 0$! 010=2!0=2!0=2"4! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
50$! 0$! 0$! 0$! 0$! 0$! 0?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
